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1. Solid Phase Synthesis of Tariquidar-Related Modulators of ABC 
Transporters Preferring Breast Cancer Resistance Protein (ABCG2)i 
 
Aiming at structural optimization of potent and selective ABCG2 inhibitors, such as UR-ME22-
1, from our laboratory, an efficient solid phase synthesis was developed to get convenient access 
to this class of compounds. 7-Carboxyisatoic anhydride was attached to Wang resin to give 
resin bound 2-aminoterephthalic acid. Acylation with quinoline-2- or -6-carbonyl chlorides, 
coupling with tetrahydroisoquinolinylethylphenylamine derivatives, cleavage of the carboxylic 
acids from solid support and treatment with trimethylsilydiazomethane gave the corresponding 
methyl esters. Among these esters highly potent and selective ABCG2 modulators were 
identified (inhibition of ABCB1 and ABCG2 determined in the calcein-AM and the Hoechst 
33342 microplate assay, respectively)ii. Interestingly, compounds bearing triethyleneglycol ether 
groups at the tetrahydroisoquinoline moiety (UR-COP77, UR-COP78) were comparable to UR-
ME22-1 in potency but considerably more efficient (max inhibition 83% and 88% vs 60%, rel. 
to fumitremorgin C, 100%) These results support the hypothesis that solubility of the new 
ABCG2 modulators and of the reference compounds tariquidar and elacridar in aqueous media 
is the efficacy limiting factor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________ 
i Puentes C. O., Höcherl, P., Kühnle M., Bauer S. Bürger K., Bernhardt G., Buschauer A., König B. Bioorg. Med. 
Chem. Lett. 2011, 21, 3654-3657. 
ii The flow cytometric calcein-AM efflux assay and the Hoechst 33342 microplate assay were carried out by Peter 
Höcherl, Stefanie Bauer and Kira Bürger at the Institute of Pharmacy, University of Regensburg. 
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1.1 Introduction 
 
Whereas numerous inhibitors of p-glycoprotein (ABCB1) are reported in the literature,1–9 the 
number of available modulators of the breast cancer resistance protein (ABCG2) is very 
limited.10–15 The multidrug resistance (MDR) modulators tariquidar16 and elacridar17 (Figure 1) 
are among the most potent inhibitors of ABC transporters. They are known to inhibit both p-
glycoprotein (ABCB1) and the breast cancer resistance protein (ABCG2) with a preference for 
ABCB1 in case of tariquidar. Recently, we synthesized a series of tariquidar analogues in 
which, at the benzamide core, the hetarylcarboxamido residue was shifted to the meta-position 
and the two methoxy groups were replaced with a carboxylic acid methyl ester. Surprisingly, 
compounds such as UR-ME22-1 (Figure 1) turned out to be potent and highly selective 
modulators of ABCG2.18 It is noteworthy that compared to the considerably less potent but 
more efficient reference compound fumitremorgin C the maximum inhibitory effect was by 40–
60% lower18 (cf. concentration response curve of UR-ME22-1 in Figure 2), presumably due to 
limited water solubility. Regardless of the lack of drug-like properties, UR-ME22-1 and 
analogues are considered of potential value as  PET-ligands19 and as pharmacological tools in 
proof-of-concept studies, for example, to overcome the blood-brain barrier by analogy with the 
modulation of ABCB1.20 Although the synthesis of the new ABCG2 inhibitors reported before18 
is relatively simple, only moderate to low yields were obtained due to solubility and purification 
problems. 
 
 
Figure 1. Structures of tariquidar (ABCB1 preferring), elacridar (combined ABCB1 and 
ABCG2 modulator) and the selective ABCG2 modulator UR-ME22-1. 
 
With respect to structural optimization of the lead compound UR-ME22-1 and solving the 
aforementioned problems, we developed a solid phase synthesis (SPS) (Scheme 1) to get more 
convenient chemical access to a broader variety of analogues including more soluble ABCG2 
modulators. 
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1.2 Results and Discussion 
 
Wang resin was selected as polymer support, and 7-carboxyisatoic anhydride21 as a ‘‘key’’ 
building block, because it can be easily linked to the resin giving a solid phase bound 
aminoterephthalic derivative, which is the central core structure of the target compounds. The 
best conditions to attach 7-carboxyisatoic anhydride 1 to the solid support were found when the 
resin, previously swollen in DMF, was heated overnight at 98 oC with 5 equiv of 7-
carboxyisatoic anhydride and 3 equiv of DMAP. 
 
 
Scheme 1. SPS of tariquidar analogues 9a–f and 10a–f. Reagents and conditions: (i) 7-
carboxyisatoic anhydride 1, DMAP, DMF, 98 oC, overnight; (ii) quinolinecarbonyl chlorides 
3a,b, DIPEA, DCM, rt, 12 h (twice); (iii) tetrahydroisoquinolinylethylphenylamines 5–7, 
HBTU, DIPEA, DMF, rt, 24 h; (iv) TFA/DCM/TES (1:1:0.05), rt, 30 min (twice); (v) 
TMSCHN2, PhH/MeOH (1:1), rt, 1 h. 
 
The second combinatorial step involved acylation of the resin bound aminoterephthalic 
derivative 2 with quinoline-2- or quinoline-6-carboxylic acids. Although different peptide 
coupling conditions were tested to link the heterocyclic carboxylic acids (HBTU,  DIPEA; 
HOBt, EDC, DMAP; HOAt, DCC), only a mixture of 40% the desired amide and 60% of 2-
aminoterephthalic acid was obtained as detected by 1H NMR spectra of products released for 
analysis from solid support. However, acylation was successfully achieved, when a mixture of 
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the resin, freshly prepared acid chloride (3a,b) and DIPEA was shaken in DCM during 12 h at 
room temperature (this procedure was repeated once). 
In the next synthetic step the tetrahydroisoquinolinylethylphenylamine derivatives 5–7 were 
linked to the carboxylic acids 4a,b. Aiming at more hydrophilic analogues of UR-ME22-1, we 
attached a triethyleneglycol chain to the tetrahydroisoquinoline motif (building blocks 6 and 7 
cf. Scheme 2). The synthesis of the resin bound tariquidar analogues 8a–f was accomplished 
when 4a,b were reacted with 5–7, HBTU, and DIPEA in DMF for 24 h (Scheme 1). Cleavage 
of the resin with a ‘‘cocktail’’ of TFA/DCM/TES (1:1:0.05) gave the carboxylic acids 9a–f, 
which were transformed into the methyl esters 10a–f using trimethylsilyldiazomethane 
(TMSCHN2). 
For the synthesis of the building blocks 5–7, the required tetrahydroisoquinolines 17 and 18 
(Scheme 2) were prepared from methoxytetrahydroisoquinolinols 11 and 12 according to the 
procedure described by Bobbitt et al.22 and were N-protected using di-tert-butyl dicarbonate 
((BOC)2O). The N-Boc protected tetrahydroisoquinolines 13 and 14 were allowed to react with 
2-[2-(2-methoxyethoxy)ethoxy]ethyl 4-methylbenzenesulfonate23 to give 15 and 16 which were 
deprotected with HCl in anhydrous ether yielding 17 and 18. Finally, compounds 6 and 7 as 
well as the dimethoxy-substituted analogue 524 were obtained by refluxing 17–19 with 4-
nitrophenethyl bromide and reduction of the nitro group by catalytic hydrogenation. 
 
 
Scheme 2. Synthesis of tetrahydroisoquinolinylethylphenylamine derivatives 5–7. Reagents and 
conditions: (i) (BOC)2O, TEA, DCM, rt, overnight; (ii) 2-[2-(2-methoxyethoxy)ethoxy]ethyl 4-
methylbenzenesulfonate, KOH, THF, reflux, 6 h; (iii) HCl/Et2O, DCM, overnight; (iv) 4-
nitrophenethyl bromide, K2CO3, CH3CN, reflux, 18 h; (v) EtOH, Pd/C, H2, 5 bar, rt, 24 h. 
 
As shown in Table 1, a set of 12 tariquidar analogues was obtained in moderate to high yields. 
Compounds 10a and 10b were obtained in significantly better yields compared to the previously 
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described route,18,19 illustrating that the SPS methodology is superior to the synthesis in 
solution. 
Table 1. Tariquidar analogues synthesized on solid phase Wang resin 
 
Compound R R1 R2 Het. Yield (%) 
9a H OCH3 OCH3 2-Quinol. 81a 
9b H OCH3 OCH3 6-Quinol. 97a 
9c H O(CH2CH2O)3CH3 OCH3 2-Quinol. 73a 
9d H O(CH2CH2O)3CH3 OCH3 6-Quinol. 87a 
9e H OCH3 O(CH2CH2O)3CH3 2-Quinol. 65a 
9f H OCH3 O(CH2CH2O)3CH3 6-Quinol. 95a 
10a (UR-ME22-1) CH3 OCH3 OCH3 2-Quinol. 75 (10)b (53)c 
10b (UR-ME19-2) CH3 OCH3 OCH3 6-Quinol. 95 (14)b (86)c 
10c (UR-COP77) CH3 O(CH2CH2O)3CH3 OCH3 2-Quinol. 90 
10d  CH3 O(CH2CH2O)3CH3 OCH3 6-Quinol. 53 
10e (UR-COP78) CH3 OCH3 O(CH2CH2O)3CH3 2-Quinol. 95 
10f (UR-COP134) CH3 OCH3 O(CH2CH2O)3CH3 6-Quinol. 50 
a Overall yield based on the loading of the resin. b Kühnle et al.18 c Wang et al.19 
 
The synthesized modulators and the reference compounds tariquidar and elacridar were 
investigated for inhibition of ABCB1 and ABCG2 in a calcein-AM (ABCB1)25 and a Hoechst 
33342 (ABCG2) microplate assay26 using ABCB1-overexpressing Kb-V1 and ABCG2-
overexpressing MCF-7/Topo cells. The data are summarized in Table 2. 
 
Tariquidar and elacridar show IC50 values in the high nanomolar range and are almost 
equipotent at ABCB1, whereas elacridar is approximately four times more potent as an ABCG2 
inhibitor. The carboxylic acids 9a–f are inactive at both transporters, confirming preliminary 
results on such compounds as potential cleavage products of modulators such as 10a.18 By 
contrast, the methyl esters 10b18 and 10c,e selectively modulate ABCG2 with IC50 values 
comparable to that of elacridar, being two to three fold less potent than the reference compound, 
UR-ME22-1 (10a). Interestingly, the regioisomeric triethylene glycol ethers 10c and 10e, 
bearing a quinoline-2-carboxamido substituent at the benzamide core, are superior to 10a with 
respect to the maximal inhibitory effect: 83% and 88% versus 61% (Figure 2). This strongly 
1. Solid Phase Synthesis of Tariquidar-Related Modulators of ABC Transporters Preferring Breast Cancer 
Resistance Protein (ABCG2) 
 
 
6 
supports the hypothesis that limited water solubility is the major reason for submaximal efficacy 
of UR-ME22-1 (10a) and related potent ABCG2 modulators. 
 
Table 2. Inhibition of ABC transporters by reference compounds and the tariquidar analogues 
9a-f, 10a-f determined in the calcein-AM (ABCB1) and Hoechst 33342 (ABCG2) microplate 
assay unless otherwise indicated. 
Compd ABCB1 
IC50 [nM] 
ABCG2 
IC50 [nM] 
Compd ABCB1 
IC50 [nM] 
ABCG2 
IC50 [nM] 
Tariquidar 223±8 a 526±85 b 9f >50000 >50000 
Elacridar 193±18 a 127±41 b 10a c >29000 a 59 ± 11 b 
9a >50000 >5000 10b d >10000 a 172 ± 45b,e 
9b >1000 >100000 10c f >50000 183 ± 32 
9c >100000 >50000 10d >100000 390 ± 57g 
9d >50000 >50000 10e h >50000 130 ± 29 
9e >100000 6200 10f  i >50000 508 ± 191j 
 
a ref. 18: data from flow cytometric calcein-AM assay. b ref. 18: data from 
flow cytometric mitoxantron assay (% maximal inhibitory effect, relative to 
fumitremorgin C): IC50 values (% max. effect), Tariquidar: 916 ± 197 nM 
(39%), Elacridar 250 ± 45 nM (46%), 10a: 60 ± 10 nM (56%); 10b: 179 ± 35 
nM (25%). c UR-ME22-1. d UR-ME19-2. e 55% maximal inhibitory effect. f 
UR-COP77. g 41% maximal inhibitory effect. h UR-COP78. i UR-COP134. gj 
61% maximal inhibitory effect. 
 
 
Figure 2. Concentration dependent inhibition of the ABCG2 transporter in MCF-7/Topo cells 
(Hoechst 33342 assay) by tariquidar (open circles) and the tariquidar analogues 10a (UR-ME22-
1; open squares), 10c (filled squares), 10e (UR-COP78; filled circles) and 10f (filled triangles). 
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The maximal inhibition is expressed as % relative to the maximum inhibition of ABCG2 by 
fumitremorgin C (at a concentration of 10 µM). 
 
1.3 Conclusion 
 
The solid phase synthesis presented in this contribution proved to be a convenient method for 
the preparation of small libraries of this class of ABCG2 inhibitors due to high conversion 
efficiency in all reaction steps resulting in good to high yields. In particular, intrinsic difficulties 
in solution chemistry, due to low solubility of intermediates and target molecules, were 
circumvented. Compounds 10c,e are among the most potent and selective ABCG2 modulators 
reported so far. The increased solubility and ABCG2 inhibitory efficacy of these compounds is 
very promising with respect to the development of pharmacological tools for in vivo proof-of-
concept studies, provided that the drug-like properties can be further improved. Thereby, 
automated parallel solid phase synthesis resulting in larger substance libraries should be helpful 
to optimize the lead structures. 
 
1.4 Experimental section 
 
General. Wang resin was purchased from Fluka (100-200 mesh, 1.1 mmol/g, 1% 
divinylbenzene cross-linking). All other chemical reagents were obtained from either Aldrich, 
Acros, Merck, or Fluka and used without further purification. Manual solid-phase organic 
syntheses were carried out at 25 °C in polypropylene syringes equipped with a porous 
polypropylene disk at the bottom (purchased from Roland Vetter Laborbedarf OHG). Solid 
phase reaction at higher temperature was carried out in an eppendorf tube with a microcentifuge 
tube holder. Flash column chromatograph was performed with silica gel (Merck silica gel 60M 
40-63 μm); products were detected by TLC on alumina plates coated with silica gel (Merck 
silica gel 60 F254, thickness 0.2 mm) and visualized by UV light (λ ) 254 nm). Melting points 
were determined with an OptiMelt MPA100 and are uncorrected. NMR spectra were measured 
at 298 K on a Bruker Avance 300 or Bruker Avance 600 instruments. Chemical shifts are 
reported in δ (ppm) relative to external standards and coupling constants J are given in Hz. 
Abbreviations for the characterization of the signals: s ) singlet, d ) doublet, t ) triplet, m ) 
multiplet, bs ) broad singlet, dd ) double doublet. The relative numbers of protons is determined 
by integration. Mass spectra were recorded with Finnigan MAT TSQ 7000 (ESI) and Finnigan 
MAT 90 (HRMS), IR spectra with a Bio- Rad FT-IR-FTS 155 spectrometer. 
 
General procedure for the preparation of 13 and 14. Compound 11 (0.5 g, 2.31 mmol) and 
triethylamine (0.8 mL, 5.77 mmol) were dissolved in 10 mL of dry DCM, the mixture was 
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cooled in an ice bath and di-tert-butyl dicarbonate (0.5 g, 2.31 mmol) was added slowly. The 
mixture was stirred at room temperature overnight, and then washed with water and brine, dried 
over magnesium sulphate, filtered and the solvent evaporated. The compound was purified by 
flash chromatography (ethyl acetate: petroleum ether 1:1). 
 
tert-Butyl 6-hydroxy-7-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 13. Yield 85%, 
white solid, Rf= 0.55, mp. 119.4-120.2 oC. 1H-NMR (CDCl3, 300 MHz): δ= 6.65 (s, 1H, ArH), 
6.53 (s, 1H, ArH), 4.45 (s, 2H, NCH2), 3.80 (s, 3H, OCH3), 3.57 (m, 2H, NCH2CH2), 2.67 (m, 
2H, NCH2CH2), 1.46 (s, 9H, C(CH3)3). 13C-NMR (CDCl3, 75 MHz): δ= 154.9, 145.3, 144.1, 
127.3, 125.0, 114.3, 108.5, 79.7, 56.0, 45.7, 40.7, 28.5, 28.2. IR (KBr) [cm-1]: ν = 3024, 2906, 
1622. 
 
tert-Butyl 7-hydroxy-6-methoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 14. Yield 80%, 
white solid, Rf= 0.55, mp. 123.6-124.2 oC. 1H-NMR (CDCl3, 300 MHz): δ= 6.85 (s, 1H, ArH), 
6.70 (s, 1H, ArH), 4.47 (s, 2H, NCH2), 3.81 (s, 3H, OCH3), 3.60-3.61 (m, 2H, NCH2CH2), 2.75 
(t, 3J=5.6, 2H, NCH2CH2), 1.48 (s, 9H, C(CH3)3). 13C-NMR (CDCl3, 75 MHz) : δ= 154.8, 
151.7, 149.5, 138.5, 133.1, 120.1, 112.5, 83.4, 56.0, 45.1, 40.4, 28.9, 28.4. IR (KBr) [cm-1]: ν = 
3024, 2976, 1685. 
 
General procedure for the preparation of 15 and 16. A mixture of 13 (50 mg, 0.17 mmol), 2-
[2-(2-methoxyethoxy)ethoxy]ethyl 4-methylbenzenesulfonate (60 mg, 0.19 mmol) and KOH 
(10 mg, 0.19 mmol) was refluxed in THF under N2 atmosphere during 6 h, the solvent was 
evaporated and the residue was dissolved in DCM and washed with water. The organic phase 
was dried over magnesium sulphate, filtered and the solvent evaporated.  
 
tert-Butyl 7-methoxy-6-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinoline-
2(1H)-carboxylate 15. Yield 70%, colorless oil. 1H-NMR (CDCl3, 300 MHz): δ= 6.65 (s, 1H, 
ArH), 6.56 (s, 1H, ArH), 4.41 (s, 2H, NCH2), 4.14 (t, 3J=5.4 Hz, 2H, CH2), 3.85 (t, 3J=5.4 Hz, 
2H, CH2), 3.80 (s, 3H, OCH3), 3.72 (m, 2H, CH2), 3.62 (m, 6H, 3 CH2), 3.52 (m, 2H, 
NCH2CH2), 3.36 (s, 3H, OCH3), 2.71 (t, 3J=5.4 Hz, 2H, NCH2CH2), 1.47 (s, 9H, C(CH3)3). 13C-
NMR (CDCl3, 75 MHz): δ= 153.8, 147.2, 145.7, 113.1, 108.6, 78.6, 70.9, 69.7, 69.6, 69.5, 68.6, 
67.6, 58.0, 55.0, 27.4, 27.3. MS (ESI; DCM/MeOH + 10 mmol/L NH4Ac): m/z (%)= 426.1 
(100) [MH+]. IR (KBr) [cm-1]: ν = 2918, 2873, 1689.  
 
tert-Butyl 6-methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinoline-
2(1H)-carboxylate 16. Yield 72%, colorless oil. 1H-NMR (CDCl3, 300 MHz): δ= 6.47 (s, 1H, 
ArH), 6.44 (s, 1H, ArH), 4.28 (s, 2H, CH2), 3.93 (t, 3J=3.9 Hz, 2H, CH2), 3.69-3.62 (m 5H, CH2, 
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OCH3), 3.56-3.52 (m, 2H, CH2), 3.49-3.44 (m, 6H, 3 CH2), 3.36-3.33 (m, 2H, CH2), 3.17 (s, 3H, 
OCH3), 2.53 (t, 3J=5.6 Hz 2H, CH2), 1.30 (s, 9H, C(CH3)3). 13C-NMR (CDCl3, 75 MHz): δ= 
154.6, 148.0, 146.7, 111.9, 111.6, 79.4, 71.7, 70.5, 70.4, 70.3, 69.4, 68.5, 58.7, 55.7, 28.3, 27.7. 
MS (ESI; DCM/MeOH + 10 mmol/L NH4Ac): m/z (%)= 426.1 (100) [MH+]. IR (KBr) [cm-1]: ν 
= 2920, 2875, 1670. 
 
General procedure for the preparation of 17 and 18. A mixture of 15 (0.2 g, 0.47 mmol) 
dissolved in 10 mL of dry DCM and 0.3 mL of HCl/Et2O were stirred at room temperature 
overnight. The solvent was evaporated and the product was dried under vacuum.  
 
7-Methoxy-6-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-1,2,3,4-tetrahydroisoquinoline 
hydrochloride 17. Yield 98%, sticky white solid. 1H-NMR (DMSO d6, 300 MHz) δ= 6.81 (s, 
1H, ArH), 6.79 (s, 1H, ArH), 4.12 (s, 2H, CH2), 4.03 (m, 2H, CH2), 3.71 (m, 5H, CH2, OCH3), 
3.56 (m, 2H, CH2), 3.51 (m, 4H, 2 CH2), 3.46 (s, 2H, CH2), 3.42 (m, 2H, CH2), 3.22 (s, 3H, 
OCH3). 13C-NMR (DMSO d6, 75 MHz): δ= 147.6, 147.1, 123.6, 120.3, 112.9, 109.6, 71.1, 
69.8, 69.6, 69.4, 68.7, 67.7, 55.9, 55.4, 42.9, 40.3, 23.9. MS (ESI; DCM/MeOH + 10 mmol/L 
NH4Ac): m/z (%)= 326 (100) [MH+]. IR (KBr) [cm-1]: ν = 3334, 2927, 2879, 1516. 
 
6-Methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-1,2,3,4-tetrahydroisoquinoline 
hydrochloride 18. Yield 98%, sticky light yellow solid. 1H-NMR (CDCl3, 300MHz): δ= 6.79 
(s, 1H, ArH), 6.77 (s, 1H, ArH), 4.25 (s, 2H, CH2), 4.09-4.08 (m, 2H, CH2), 3.82-3.80 (m, 5H, 
CH2, OCH3), 3.69-3.62 (m, 6H, 3 CH2), 3.53-3.45 (m, 4H, 2 CH2), 3.34 (s, 3H, OCH3), 3.06-
3.02 (m, 2H, CH2). 13C-NMR (CDCl3,75 MHz): δ= 150.9, 148.9, 125.4, 121.0, 113.3, 113.0, 
72.9, 71.7, 71.5, 71.3, 70.8, 70.0, 59.1, 56.0, 45.1, 43.0, 25.7. HRMS (EI) calcd. for C17H27NO5 
[M•+]: 325.1889; found: 325.1881. IR (KBr) [cm-1]: ν = 3330, 2939, 2879, 1517. 
 
General procedure for the preparation of 21 and 22. A mixture of the 
tretrahydroisoquinoline derivative 17 (0.17 g, 0.47 mmol,), 4-nitrophenethyl bromide (0.11 g, 
0.5 mmol) and potassium carbonate (0.2 g, 1.5 mmol) was refluxed during 18 h in CH3CN, the 
solvent was evaporated, the residue taken up in 30 mL water and extracted with DCM (3X15 
mL). The solution was dried over MgSO4, filtered and concentrated to give the crude product 
which was purified by flash chromatography on silica gel (5% MeOH/CHCl3).  
 
7-Methoxy-6-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-2-(4-nitrophenethyl)-1,2,3,4-
tetrahydroisoquinoline 21. Yield 58.1%, brown oil, Rf= 0.47. 1H-NMR (CDCl3, 600 MHz): δ= 
8.14 (d, 3J=8.8 Hz, 2H, AA´BB´ ArH), 7.39 (d, 3J=8.8 Hz, 2H, AA´BB´ ArH), 6.65 (s, 1H, 
ArH), 6.52 (s, 1H, ArH), 4.14 (m, 2H, CH2), 3.86 (t, 3J=5.0, 2H, CH2), 3.80 (s, 3H, OCH3), 
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3.74-3.72 (m, 2H, CH2), 3.68-3.64 (m, 4H, 2 CH2), 3.63 (s, 2H, CH2), 3.55-3.53 (m, 2H, CH2), 
3.37 (s, 3H, OCH3), 3.01-2.98 (m, 2H, CH2), 2.81-2.77 (m, 6H, 3 CH2). 13C-NMR (CDCl3, 151 
MHz): δ= 148.3, 147.9, 146.8, 146.5, 129.7, 126.9, 126.0, 123.6, 114.1, 110.8, 71.9, 70.7, 70.6, 
70.5, 69.6, 68.6, 59.1, 59.0, 56.0, 55.6, 50.9, 33.8, 28.5. HRMS (EI) calcd. for C25H34N2O7 
[M•+]: 474.2366; found: 474.2363. IR (KBr) [cm-1]: ν = 2881, 1672, 1517, 1195.  
 
6-Methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-2-(4-nitrophenethyl)-1,2,3,4-
tetrahydroisoquinoline 22. Yield 54%, brown oil, Rf= 0.44. 1H-NMR (CDCl3, 600 MHz): δ= 
8.13 (d, 3J=8.7 Hz, 2H, AA´BB´ ArH), 7.38 (d, 3J=8.7 Hz, 2H, AA´BB´ ArH), 6.59 (s, 1H, ArH), 
6.57 (s, 1H, ArH), 4.13-4.11 (m, 2H, CH2), 3.86-3.84 (m, 2H, CH2), 3.80 (s, 3H, OCH3), 3.73-
3.72 (m, 2H, CH2), 3.67-3.63 (m, 4H, 2 CH2), 3.61 (s, 2H, CH2), 3.54-3.53 (m, 2H, CH2), 3.36 
(s, 3H, OCH3), 3.01-2.98 (m, 2H, CH2), 2.82-2.76 (m, 6H, 3 CH2). 13C-NMR (CDCl3, 151 
MHz): δ= 148.3, 148.2, 146.4, 146.4, 129.5, 126.7, 126.2, 123.6, 112.2, 111.9, 71.8, 70.7, 70.5, 
70.4, 69.6, 68.7, 59.0, 58.9, 55.9, 55.5, 50.9, 33.8, 28.6. HRMS (EI) calcd. for C25H34N2O7 
[M•+]: 474.2366; found: 474.2360. IR (KBr) [cm-1]: ν = 2895, 1610, 1521, 1261, 1222. 
 
General procedure for the preparation of 6 and 7. Nitro compound 21 was dissolved in 
ethanol, palladium on activated charcoal (10% m/m) was added, and the solution was stirred 
under 5 bar H2 atmosphere during 1 d. The catalyst was filtered off, the solvent removed and the 
amines were purified by flash chromatography on silica gel (5% MeOH/CHCl3).  
 
4-(2-(7-Methoxy-6-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)ethyl)aniline 6. Yield 83%, yellow solid, mp. 43.5-44.5 oC, Rf= 0.31. 1H-NMR (CDCl3, 600 
MHz): δ= 7.01 (d, 3J=8.4 Hz, 2H, AA´BB´ ArH), 6.64 (s, 1H, ArH), 6.62 (d, 3J=8.3 Hz, 2H, 
AA´BB´ ArH), 6.52 (s, 1H, ArH), 4.14 (t, 3J=5.5, 2H, CH2), 3.86 (t, 3J=5.5, 2H, CH2), 3.80 (s, 
3H, OCH3), 3.74-3.72 (m, 2H, CH2), 3.68-3.66 (m, 2H, CH2), 3.66-3.64 (m, 2H, CH2), 3.62 (s, 
2H, CH2), 3.55-3.53 (m, 2H, CH2), 3.37 (s, 3H, OCH3), 2.81-2.78 (m, 4H, 2 CH2), 2.77-2.75 (m, 
2H, CH2), 2.71-2.68 (m, 2H, CH2). 13C-NMR (CDCl3, 151 MHz) δ= 147.8, 146.7, 144.4, 130.3, 
129.4, 127.3, 126.0, 115.2, 114.1, 110.1, 71.9, 70.7, 70.6, 70.5, 69.6, 68.6, 60.6, 59.0, 56.0, 
55.7, 51.0, 33.1, 28.5. HRMS (EI) calcd. for C25H37N2O7 [MH•+]: 445.2702; found: 445.2696. 
IR (KBr) [cm-1]: ν = 2920, 1645, 1516. 
 
4-(2-(6-Methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)ethyl)aniline 7. Yield 87%, brown sticky oil, Rf= 0.33. 1H-NMR (CDCl3, 300 MHz): δ= 6.89 
(d, 3J=7.6 Hz, 2H, AA´BB´ ArH), 6.53-6.49 (m, 3H, 3 ArH), 4.04-4.01 (m, 2H, CH2), 3.78-3.75 
(m, 2H, CH2), 3.71 (s, 3H, OCH3), 3.69 (s, 2H, CH2), 3.64-3.62 (m, 2H, CH2), 3.59-3.54 (m, 
4H, 2 CH2), 3.47-3.44 (m, 2H, CH2), 3.28 (s, 3H, OCH3), 2.84-2.78 (m, 8H, 4 CH2). 13C-NMR 
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(CDCl3, 75 MHz): δ= 147.4, 146.8, 145.6, 128.4, 127.6, 124.8, 123.2, 114.2, 111.0, 110.8, 70.8, 
69.6, 69.5, 69.4, 68.5, 67.6, 58.3, 57.9, 54.9, 53.5, 49.4, 31.0, 26.3. MS (ESI; DCM/MeOH + 10 
mmol/L NH4Ac): m/z (%)= 445.0 (100) [MH+]. IR (KBr) [cm-1]: ν = 3300, 2929, 1693, 1516. 
 
General procedure for SPS of tariquidar analogues 9. A polypropylene 2.0-ml fritted syringe 
was charged with 50 mg of Wang resin (1.1 mmol/g loading) and the resin was swollen in 1 ml 
of DMF during 1 h. The resin was transferred to an eppendorf tube and a mixture of 7-
carboxyisatoic anhydride (57 mg, 0.27 mmol, 5 equiv) and DMAP (19 mg, 0.16 mmol, 3 equiv) 
in 1 mL of DMF was added. The resin was heated at 98 oC overnight, then transferred to a 
polypropylene 2.0-ml syringe and washed three times with 5% AcOH/DCM, DCM, MeOH, 
DMF and DCM. The syringe was fritted and a solution of DIPEA (47 µL, 0.27 mmol, 5 equiv) 
in DCM was added and the resin was shaken during 5 min, after that, quinoline-2(6)-carbonyl 
chloride (freshly prepared, 52 mg, 0.27 mmol, 5 equiv) was added and the resin was shaken at 
room temperature during 12 h, washed three times with DCM, MeOH, DMF, MeOH and DMF 
(this coupling was repeated once more). The resin was cooled down and a solution of DIPEA 
(95 µL, 0.55 mmol, 10 equiv) and HBTU (102 mg, 0.27 mmol, 5 equiv) in 1 mL of DMF was 
added, the resin was shaken for two minutes and compound 5 (0.27 mmol, 5 equiv) was added. 
The resin was shaken at room temperature for 24 h and then washed three times with DCM, 
MeOH and DMF. 
 
Cleavage. The resin was dried under vacuum and a mixture of TFA/DCM/TES 1/1/0.05 was 
added (1 ml). The resin was shaken for 1 h, the cleavage cocktail was collected and the content 
of the syringe was washed two times with fresh 50% TFA in DCM (this procedure was repeated 
once more). Combined washes were evaporated and residual oil was washed with fresh diethyl 
ether, the precipitated solid was filtered and dried. 
 
N-{4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2-[(quinoline-2-
carbonyl)-amino]-terephthalamic acid .TFA 9a.  
 
Yield 80.6%, yellow solid, mp. 242.7 oC dec. 1H-NMR (DMSO d6, 600 MHz): δ= 13.48 (s, 1H, 
NHCO), 10.54 (s, 1H, NHCO), 10.21 (bs, 1H, COOH), 9.42 (d, 4J=1.0 Hz, 1H, ArH), 8.67 (d, 
3J=8.6 Hz, 1H, ArH), 8.30 (d, 3J=8.3 Hz, 1H, ArH), 8.20 (d, 3J=8.2 Hz, 1H, ArH), 8.15-8.14 (m, 
2H, ArH), 7.92 (dt, 3J=8.2 Hz, 4J=1.0 Hz, 1H, ArH), 7.80-7.74 (m, 4H, ArH), 7.31 (d, 3J=7.3 
Hz, 2H, ArH), 6.82 (s, 1H, ArH), 6.79 (s, 1H, ArH), 4.52 (bs, 1H, CHH), 4.30 (bs, 1H, CHH), 
3.76-3.73 (m, 7H, 2 OCH3, CH´H), 3.46 (bs, 2H, CH2), 3.36 (bs, 1H, CHH´), 3.10-3.07 (m, 3H, 
CH2, CH´´H), 3.00 (bs, 1H, CHH´´). 13C-NMR (DMSO-d6, 151 MHz): δ= 168.6, 164.6, 162.9, 
158,2 (TFA), 158,0 (TFA), 149.3, 148.4, 147.7, 145.8, 140.2, 140.1, 138.5, 137.7, 132.2, 131.5, 
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130.9, 129.1, 129.0, 128.6, 128.3, 123.1, 121.7, 120.7, 119.8, 119.3, 119.1, 118.5, 111.4, 109.6, 
55.7, 55.4, 55.4, 51.6, 49.1, 29.1, 24.4. HRMS (LSI) calcd. for C37H35N4O6 [MH+]: 631.2557; 
found: 631.2549. IR (KBr) [cm-1]: ν = 2926, 1672, 1612, 1570, 1512. 
 
N-{4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2-[(quinoline-6-
carbonyl)-amino]-terephthalamic acid .TFA 9b.  
 
Yield 97%, yellow solid, mp. 227 oC dec. 1H-NMR (DMSO d6, 600 MHz): δ= 12.32 (s, 1H, 
NHCO), 10.53 (s, 1H, NHCO), 10.11 (bs, 1H, COOH), 9.16 (d, 4J=1.5 Hz, 1H, ArH), 9.04 (dd, 
3J=4.1 Hz 4J=1.5 Hz, 1H, ArH), 8.66 (d, 4J=1.5 Hz, 1H, ArH), 8.57 (d, 3J=7.7 Hz, 1H, ArH), 
8.26 (dd, 3J=8.8 Hz 4J=1.9 Hz, 1H, ArH), 8.21 (d, 3J=8.7 Hz, 1H, ArH), 8.18 (d, 3J=8.1 Hz, 1H, 
ArH), 7.78 (d, 3J=8.4 Hz, 2H, ArH), 7.75 (dd, 3J=8.2 Hz, 4J=1.6 Hz, 1H, ArH), 7.66 (dd, 3J=8.2 
Hz, 4J=4.2 Hz, 1H, ArH), 7.31 (d, 3J=8.5 Hz, 2H, ArH), 6.83 (s, 1H, ArH), 6.79 (s, 1H, ArH), 
4.52 (d, 2J=14.0 Hz, 1H, CHH), 4.28 (d, 2J=12.1 Hz, 1H, CHH), 3.76-3.73 (m, 7H, 2 OCH3, 
CH´H), 3.45 (bs, 2H, CH2), 3,34 (bs, 1H, CHH´), 3.09-3.06 (m, 3H, 1 CH2, CH´´H), 2.99 (bs, 
1H, CHH´´). 13C-NMR (DMSO-d6, 151 MHz) δ 169.4, 164.8, 164.4, 158.3, 158.1, 157.9, 
152.6, 148.8, 148.4, 147.7, 140.6, 139.96, 137.7, 137.4, 132.2, 132.1, 131.3, 129.8, 129.0, 
128.3, 127.3, 127.0, 123.1, 122.5, 121.9, 120.7, 119.8, 119.8, 111.4, 109.6, 55.8, 55.6, 55.5, 
51.7, 49.2, 29.2, 24.5. HRMS (LSI) calcd. for C37H36N4O6 [MH+]: 632.2635; found: 631.2619. 
IR (KBr) [cm-1]: ν = 3104, 1670, 1612, 1579, 1517. 
 
N-{4-[2-(7-Methoxy-6-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-3,4-dihydro-1H-
isoquinolin-2-yl)-ethyl]-phenyl}-2-[(quinoline-2-carbonyl)-amino]-terephthalamic acid 
.TFA 9c.  
 
Yield 72.9%, yellow-brown solid, mp. 239.3 oC dec. 1H-NMR (MeOD d4, 600 MHz): δ= 9.34 
(s, 1H, ArH), 8.39 (d, 3J=8.2 Hz, 1H, ArH), 8.19-8.15 (m, 3H, ArH), 7.93 (d, 3J=7.9 Hz, 1H, 
ArH), 7.77 (t, 3J=7.6 Hz, 1H, ArH), 7.70 (d, 3J=5.4 Hz, 1H, ArH), 7.63 (t, 3J=7.5 Hz, 1H, ArH), 
7.60 (d, 3J=7.4 Hz, 1H, ArH), 7.29 (d, 3J=5.1 Hz, 1H, ArH), 6.68 (s, 1H, ArH), 6.64 (s, 1H, 
ArH), 4.51 (bs, 1H, CHH), 4.25 (bs, 1H, CHH), 3.98 (t, 3J=4.4 Hz, 2H, CH2), 3.76-3.73 (m, 6H, 
OCH3, CH2, CH´H), 3.65-3.64 (m, 2H, CH2), 3.60-3.58 (m, 4H, 2 CH2), 3.50-3.49 (m, 4H, 2 
CH2), 3.39 (bs, 1H, CHH´), 3.31 (s, 3H, OCH3), 3.13 (bs, 3H, CH2, CH´´H), 3.00 (bs, 1H, 
CHH´´). 13C-NMR (MeOD d4, 151 MHz) δ 169.7, 167.7, 165.1, 162.3 (TFA), 162.1 (TFA), 
150.6, 150.2, 149.8, 147.8, 141.8, 141.2, 139.0, 138.96 133.7, 133.1, 131.5, 131.0, 130.8, 130.3, 
129.6, 128.9, 124.1, 122.7, 122.6, 120.9, 120.8, 120.3, 119.5, 114.3, 110.9, 72.9, 71.7, 71.5, 
71.3, 70.6, 69.7, 59.0, 58.2, 56.4, 54.0, 51.5, 31.0, 26.6. HRMS (LSI) calcd. for C43H47N4O9 
[MH+]: 763.3343; found: 763.3326. IR (KBr) [cm-1]: ν = 3219, 1672, 1602, 1570, 1517. 
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N-{4-[2-(7-Methoxy-6-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-3,4-dihydro-1H-
isoquinolin-2-yl)-ethyl]-phenyl}-2-[(quinoline-6-carbonyl)-amino]-terephthalamic acid 
.TFA 9d.  
 
Yield 87%, yellow-orange solid, mp. 217 oC dec. 1H-NMR (DMSO d6, 600 MHz): δ=12.31 (s, 
1H, NHCO), 10.53 (s, 1H, NHCO), 10.06 (bs, 1H, COOH), 9.15 (s, 1H, ArH), 9.04 (s, 1H, 
ArH), 8.65 (s, 1H), 8.56 (d, 3J=8.1 Hz, 1H, ArH), 8.26 (d, 3J=8.6 Hz, 1H, ArH), 8.20 (d, 3J=8.5 
Hz, 1H, ArH), 8.20 (d, 3J=8.2 Hz, 1H, ArH), 7.78-7.75 (m, 3H, ArH), 7.66 (dd, 3J=7.9 Hz, 
4J=3.7 Hz, 1H, ArH), 7.31 (d, 3J=8.0 Hz, 2H, ArH), 6.85 (s, 1H, ArH), 6.80 (s, 1H, ArH), 4.52 
(d, 2J=12.7 Hz, 1H, CHH), 4.26 (d, 2J=11.8 Hz, 1H, CHH), 4.05 (s, 2H, CH2), 3.74-3.70 (m, 6H, 
OCH3, CH2, CH´H), 3.57 (m, 2H, CH2), 3.52-3.50 (m, 6H, 3 CH2), 3.42-3.41 (m, 2H, CH2), 
3.34 (bs, 1H, CHH´), 3,22 (s, 3H, OCH3), 3.08-3.06 (m, 3H, CH2, CH´´H), 2.97 (bs, 1H, 
CHH´´). 13C NMR (DMSO-d6, 151 MHz) δ 169.4, 164.8, 164.4, 158.1, 157.9, 152.6, 148.8, 
147.9, 147.6, 140.6, 139.9, 137.7, 137.4, 132.2, 131.3, 129.8, 129.0, 128.3, 127.3, 127.0, 123.1, 
122.5, 122.0, 120.7, 120.1, 119.8, 119.8, 112.8, 109.8, 71.2, 69.9, 69.7, 69.5, 68.8, 67.9, 58.0, 
55.8, 55.6, 51.7, 49.2, 29.2, 24.5. HRMS (LSI) calcd. for C43H47N4O9 [MH+]: 763.3343; found: 
763.3329. IR (KBr) [cm-1]: ν = 2914, 1672, 1598, 1581, 1517. 
 
N-{4-[2-(6-Methoxy-7-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-3,4-dihydro-1H-
isoquinolin-2-yl)-ethyl]-phenyl}-2-[(quinoline-2-carbonyl)-amino]-terephthalamic acid 
.TFA 9e.  
 
Yield 64.5%, yellow-brown solid, mp. 250 oC dec. 1H-NMR (DMSO d6, 600 MHz): δ= 13.53 
(s, 1H, NHCO), 10.53 (s, 1H, NHCO), 9.40 (d, 4J=1.5 Hz,, 1H, ArH), 8.66 (d, 3J=8.4 Hz, 1H, 
ArH), 8.30 (d, 3J=8.4 Hz, 1H, ArH), 8.14-8.13 (m, 2H, ArH), 7.91 (dt, 3J=8.2 Hz, 4J=1.2 Hz, 
1H, ArH), 7.78-7.76 (m, 3H, ArH), 7.73 (dd, 3J=8.1 Hz, 4J=1.5 Hz, 1H, ArH), 7.31 (d, 3J=8.4 
Hz, 2H, ArH), 6.83 (s, 1H, ArH), 6.80 (s, 1H, ArH), 4.38 (bs, 2H, CH2), 4.02 (t, 3J=4.9 Hz, 2H, 
CH2), 3.74 (s, 3H, OCH3), 3.72 (t, 3J=4.6 Hz, 2H, CH2), 3.58-3.56 (m, 2H, CH2), 3.53-3.50 (m, 
6H, CH2), 3.44 (bs, 2H, CH2), 3.44-3.40 (m, 2H, CH2), 3.51 (s, 3H, OCH3), 3.06 (m, 2H, CH2), 
3.02 (bs, 2H, CH2). 13C-NMR (DMSO d6, 151 MHz): δ= 168.6, 165.0, 162.9, 158.0 (TFA), 
157.8 (TFA), 149.3, 148.6, 146.8, 145.8, 140.2, 140.0, 138.5, 137.7, 137.5, 132.3, 131.5, 130.9, 
130.5, 129.1, 129.1, 129.0, 128.6, 128.2, 123.5, 121.7, 120.7, 119.1, 118.5, 111.7, 111.0, 71.2, 
69.9, 69.7, 69.5, 68.8, 68.0, 58.0, 55.96, 55.5, 51.8, 49.2, 29.3, 24.6. HRMS (LSI) calcd. for 
C43H47N4O9 [MH+]: 763.3343; found: 763.3346. IR (KBr) [cm-1]: ν = 3296, 2875, 1689, 1654, 
1570, 1514. 
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N-{4-[2-(6-Methoxy-7-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-3,4-dihydro-1H-
isoquinolin-2-yl)-ethyl]-phenyl}-2-[(quinoline-6-carbonyl)-amino]-terephthalamic acid 
.TFA 9f.  
 
Yield 95.4%, yellow solid, mp. 218 oC dec. 1H-NMR (DMSO d6, 600 MHz): δ= 12.31 (s, 1H, 
NHCO), 10.53 (s, 1H, NHCO), 10.17 (bs, 1H, COOH), 9.16 (d, 4J=1.5 Hz, 1H, ArH), 9.04 (dd, 
3J=4.2 Hz, 4J=1.5 Hz, 1H, ArH), 8.66 (d, 4J=1.9 Hz, 1H, ArH), 8.58 (d, 3J=8.4 Hz, 1H, ArH), 
8.26 (dd, 3J=8.8 Hz, 4J=2.0 Hz, 1H, ArH), 8.21 (d, 3J=8.8 Hz, 1H, ArH), 8.17 (d, 3J=8.1 Hz, 1H, 
ArH), 7.79-7.75 (m, 3H, ArH), 7.67 (dd, 3J=8.2 Hz, 4J=4.2 Hz, 1H, ArH), 7.31 (d, 3J=8.4 Hz, 
2H, ArH), 6.84 (s, 1H, ArH), 6.81 (s, 1H, ArH), 4.50 (d, 2J=14.6 Hz, 1H, CHH), 4.27 (d, 
2J=14.3 Hz, 1H, CHH), 4.04-4.02 (m, 2H, CH2), 3.77-3.72 (m, 6H, OCH3, CH2, CH´H), 3.58-
3.57 (m, 2H, CH2), 3.53-3.50 (m, 4H, 2 CH2), 3.46 (m, 2H, CH2), 3.42-3.41 (m, 2H, CH2), 3.33 
(bs, 1H, CHH´), 3,22 (s, 3H, OCH3), 3.06 (m, 3H, CH2, CH´´H), 2.97 (d, 2J=15.6 Hz 1H, 
CHH´´). 13C NMR (DMSO-d6, 151 MHz) δ: 169.4, 164.8, 164.4, 158.3 (TFA), 158.1 (TFA), 
152.5, 148.7, 148.6, 146.8, 140.6, 139.9, 137.7, 137.6, 132.2, 131.3, 129.6, 129.0, 128.3, 127.3, 
127.1, 123.4, 122.5, 122.0, 120.7, 119.8, 119.8, 119.7, 111.7, 111.0, 71.2, 69.9, 69.7, 69.5, 68.8, 
68.0, 58.0, 55.8, 55.5, 51.7, 49.1, 29.2, 24.5. HRMS (LSI) calcd. for C43H47N4O9 [MH+]: 
763.3343; found: 763.3334. IR (KBr) [cm-1]: ν = 2902, 1670, 1600, 1579, 1517. 
 
General procedure for the esterification of compounds 9. The carboxylic acid derivative (1 
equiv) was dissolved in 3 mL of a mixture PhH/MeOH 2/1 and trimethylsilyldiazomethane 
solution (2 M in diethyl ether) was added dropwise until no evolution of N2 was observed. The 
reaction was stirred during 1 h at room temperature. The solvent was evaporated and the solid 
was purified by flash chromatography (CHCl3:MeOH 5% or 10%). 
 
N-{4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2-[(quinoline-2-
carbonyl)-amino]-terephthalamic acid methyl ester 10a.  
 
Yield 75%, yellow solid, mp. 174 oC (decomposition), Rf= 0.35 (CHCl3:MeOH 5%). 1H-NMR 
(CD2Cl2, 300 MHz): δ= 13.19 (s, 1H, NHCO), 9.41 (d, 4J=0.70 Hz, 1H, ArH), 8.33 (d, 3J=8.4 
Hz, 1H, ArH), 8.28-8.20 (m, 3H, ArH), 8.13 (d, 3J=8.2 Hz, 1H, ArH), 7.89 (d, 3J=8.0 Hz, 1H, 
ArH), 7.77 (t, 3J=7.3 Hz, 1H, ArH), 7.67-7.58 (m, 4H, ArH), 7.23 (d, 3J=8.2 Hz, 1H, ArH), 6.55 
(s, 1H, ArH), 6.50 (s, 1H, ArH), 4.03 (s, 3H, OCH3), 3.74 (s, 6H, 2 OCH3), 3.58 (s, 2H, CH2), 
2.88-2.71 (m, 8H, 4 CH2). 13C-NMR (CD2Cl2, 75 MHz) δ: 167.7, 165.0, 164.1, 150.1, 148.0, 
147.7, 146.9, 141.3, 140.6, 138.2, 136.4, 132.1, 130.8, 130.3, 129.6, 128.7, 128.2, 126.6, 122.1, 
122.1, 122.0, 121.0, 119.2, 119.1, 118.7, 112.0, 110.1, 60.3, 56.2, 56.1, 55.9, 51.4, 33.6, 29.0. 
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HRMS (LSI) calcd. for C38H37N4O6 [M•+]: 645.2713; found: 645.2709. IR (KBr) [cm-1]: ν = 
3296, 2949, 1691, 1654, 1570, 1517. 
 
N-{4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}-2-[(quinoline-6-
carbonyl)-amino]-terephthalamic acid methyl ester 10b. Yield 95%, yellow solid, mp. 199 
oC (decomposition), Rf= 0.26 (CHCl3:MeOH 5%). 1H-NMR (CDCl3, 600 MHz): δ= 12.30 (s, 
1H, NHCO), 9.38 (s, 1H, ArH), 9.01 (d, 4J=1.9 Hz, 1H, ArH), 8.52 (s, 1H, ArH), 8.41 (s, 1H, 
NHCO), 8.31 (d, 3J=8.1 Hz, 1H, ArH), 8.28 (d, 3J=8.7 Hz, 1H, ArH), 8.22 (d, 3J=8.5 Hz, 1H, 
ArH), 8.17 (d, 3J=8.5 Hz, 1H, ArH), 7.72 (d, 3J=7.7 Hz, 1H, ArH), 7.63 (d, 3J=7.6 Hz, 2H, 
ArH), 7.50-7.48 (m, 1H, ArH), 7.23 (d, 3J=8.4 Hz, 1H, ArH), 6.59 (s, 1H, ArH), 6.53 (s, 1H, 
ArH), 4.01 (s, 3H, OCH3), 3.83 (s, 6H, 2 OCH3), 3.66 (s, 2H, CH2), 2.92-2.89 (m, 2H, CH2), 
2.85-2.84 (m, 2H, CH2), 2.81-2.77 (m, 4H, 2 CH2). 13C-NMR (CDCl3, 151 MHz): δ= 168.5, 
168.5, 165.2, 164.5, 164.5, 152.4, 149.6, 147.5, 147.2, 141.6, 140.6, 137.3, 136.9, 135.8, 132.1, 
131.6, 130.4, 129.2, 128.5, 127.6, 127.0, 126.9, 126.0, 122.5, 122.0, 120.7, 117.7, 117.3, 111.3, 
109.4, 77.2, 77.0, 76.7, 60.0, 55.9, 55.8, 55.6, 52.9, 50.9, 33.4, 28.5, 28.5, 20.4. HRMS (LSI) 
calcd. for C38H37N4O6 [MH+]: 645.2713; found: 645.2805. IR (KBr) [cm-1]: ν = 3273, 2941, 
1678, 1645, 1577, 1517. 
 
N-{4-[2-(7-Methoxy-6-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-3,4-dihydro-1H-
isoquinolin-2-yl)-ethyl]-phenyl}-2-[(quinoline-2-carbonyl)-amino]-terephthalamic acid 
methyl ester 10c.  
 
Yield 90%, yellow solid, mp. 103.2 oC (decomposition), Rf= 0.46 (CHCl3:MeOH 10%). 1H-
NMR (CDCl3, 600 MHz): δ=13.24 (s, 1H, NHCO), 9.38 (d, 4J=0.6 Hz, 1H, ArH), 8.54 (s, 1H, 
NHCO), 8.30 (d, 3J=8.4 Hz, 1H, ArH), 8.25 (d, 3J=8.3 Hz, 1H, ArH), 8.11 (d, 3J=8.2 Hz, 1H, 
ArH), 7.86 (d, 3J=8.0 Hz, 1H, ArH), 7.77 (t, 3J=7.3 Hz, 1H, ArH), 7.65-7.61 (m, 4H, ArH), 7.22 
(d, 3J=8.1 Hz, 2H, ArH), 6.63 (s, 1H, ArH), 6.52 (s, 1H, ArH), 4.12 (t, 3J=5.2 Hz, 2H, CH2), 
4.05 (s, 3H, OCH3), 3.84 (t, 3J=5.1 Hz, 2H, CH2), 3.79 (s, 3H, OCH3), 3.73-3.71 (m, 2H, CH2), 
3.67-3.63 (m, 6H, 3 CH2), 3.54-3.53 (m, 2H, CH2), 3.36 (s, 3H, OCH3), 2.91-2.88 (m, 2H, CH2), 
2.82-2.75 (m, 6H, 3 CH2). 13C-NMR (CDCl3, 151 MHz): δ= 167.2, 164.8, 163.7, 149.4, 147.7, 
146.7, 146.4, 140.6, 140.1, 137.6, 136.6, 136.0, 131.7, 130.2, 130.1, 129.3, 129.1, 128.3, 127.6, 
126.0, 122.5, 120.7, 118.6, 118.6, 117.8, 113.9, 110.0, 71.8, 70.7, 70.5, 70.4, 69.5, 68.5, 60.0, 
58.9, 55.9, 55.5, 52.6, 50.9, 33.3, 28.4. HRMS (LSI) calcd. for C44H49N4O9 [MH+]: 777.3500; 
found: 777.3501. IR (KBr) [cm-1]: ν = 3292, 2926, 1685, 1654, 1570, 1516. 
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N-{4-[2-(7-Methoxy-6-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-3,4-dihydro-1H-
isoquinolin-2-yl)-ethyl]-phenyl}-2-[(quinoline-6-carbonyl)-amino]-terephthalamic acid 
methyl ester 10d.  
 
Yield 53%, yellow solid, mp. 131.4 oC (decomposition), Rf= 0.37 (CHCl3:MeOH 10%). 1H-
NMR (CDCl3, 300 MHz): δ=12.30 (s, 1H, NHCO), 9.39 (d, 4J=1.3 Hz, 1H, ArH), 9.00 (dd, 
3J=4.2 Hz, 4J=1.5 Hz, 1H, ArH), 8.51 (d, 4J=1.4 Hz, 1H, ArH), 8.33-8.21 (m, 4H, NHCO, 3 
ArH), 8.15 (d, 3J=8.3 Hz, 1H, ArH), 7.70 (dd, 3J=8.4 Hz, 4J=1.5 Hz 1H, ArH), 7.62 (d, 3J=8.3 
Hz, 2H, ArH), 7.47 (dd, 3J=8.2 Hz, 3J=4.2 Hz 1H, ArH), 7.22 (m, 2H, ArH), 6.64 (s, 1H, ArH), 
6.53 (s, 1H, ArH), 4.12 (t, 3J=5.4 Hz, 2H, CH2), 4.01 (s, 3H, OCH3), 3.84 (t, 3J=4.8 Hz, 2H, 
CH2), 3.80 (s, 3H, OCH3), 3.74-3.71 (m, 2H, CH2), 3.68-3.63 (m, 6H, 3 CH2), 3.55-3.52 (m, 2H, 
CH2), 3.37 (s, 3H, OCH3), 2.94-2.89 (m, 2H, CH2), 2.83-2.76 (m, 6H, 3 CH2). 13C NMR 
(CDCl3, 75 MHz): δ= 167.5, 164.2, 163.5, 151.4, 148.5, 146.9, 145.8, 140.7, 139.5, 136.4, 
135.7, 134.8, 131.1, 130.6, 129.3, 128.2, 127.5, 126.6, 126.6, 125.9, 124.9, 121.5, 121.0, 119.6, 
116.6, 116.3, 113.0, 109.0, 76.4, 76.0, 75.5, 70.9, 69.7, 69.6, 69.5, 68.6, 67.5, 58.7, 58.0, 55.0, 
54.3, 51.9, 49.7, 32.1, 27.1. HRMS (LSI) calcd. for C44H49N4O9 [MH+]: 777.3500; found: 
777.3523. IR (KBr) [cm-1]: ν = 3290, 2900, 1674, 1577, 1514. 
 
N-{4-[2-(6-Methoxy-7-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-3,4-dihydro-1H-
isoquinolin-2-yl)-ethyl]-phenyl}-2-[(quinoline-2-carbonyl)-amino]-terephthalamic acid 
methyl ester 10e.  
 
Yield 95.5%, yellow-brown solid, mp. 123.3 oC (decomposition), Rf= 0.43 (CHCl3:MeOH 
10%). 1H-NMR (CDCl3, 600 MHz): δ=13.24 (s, 1H, NHCO), 9.38 (s, 1H, ArH), 8.55 (s, 1H, 
NHCO), 8.30 (d, 3J=8.4 Hz, 1H, ArH), 8.25 (d, 3J=8.4 Hz, 1H, ArH), 8.12 (d, 3J=8.2 Hz, 1H, 
ArH), 7.86 (d, 3J=8.1 Hz, 1H, ArH), 7.76 (t, 3J=8.0 Hz, 1H, ArH), 7.66-7.61 (m, 4H, ArH), 7.22 
(d, 3J=8.2 Hz, 2H, ArH), 6.58 (s, 2H, ArH), 4.11 (t, 3J=5.2 Hz, 2H, CH2), 4.05 (s, 3H, OCH3), 
3.84 (t, 3J=5.1 Hz, 2H, CH2), 3.80 (s, 3H, OCH3), 3.73-3.71 (m, 2H, CH2), 3.67-3.62 (m, 6H, 3 
CH2), 3.54-3.53 (m, 2H, CH2), 3.36 (s, 3H, OCH3), 2.90-2.88 (m, 2H, CH2), 2.83-2.82 (m, 2H, 
CH2), 2.79-2.74 (m, 4H, 2 CH2). 13C-NMR (CDCl3,151 MHz): δ= 167.2, 164.7, 163.7, 149.4, 
148.1, 146.4, 146.3, 140.6, 140.1, 137.6, 136.7, 135.9, 131.7, 130.2, 130.1, 129.3, 128.3, 127.6, 
126.8, 126.4, 120.6, 118.6, 117.8, 112.2, 111.9, 71.8, 70.7, 70.5, 70.4, 69.5, 68.6, 60.0, 58.97, 
55.9, 55.5, 52.6, 50.9, 33.4, 28.6. HRMS (LSI) calcd. for C44H49N4O9 [MH+]: 777.3500; found: 
777.3485. IR (KBr) [cm-1]: ν = 3284, 2906, 1693, 1654, 1570, 1516. 
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N-{4-[2-(7-Methoxy-6-{2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy}-3,4-dihydro-1H-
isoquinolin-2-yl)-ethyl]-phenyl}-2-[(quinoline-6-carbonyl)-amino]-terephthalamic acid 
methyl ester 10f.  
 
Yield 50%, yellow solid, mp. 136.8 oC (decomposition), Rf= 0.37 (CHCl3:MeOH 10%). 1H-
NMR (CD2Cl2, 300 MHz): δ=12.16 (s, 1H, NHCO), 9.30 (s, 1H, ArH), 8.93 (d, 3J=4.2 Hz, 1H, 
ArH), 8.55 (s, 1H, NHCO), 8.44 (d, 4J=1.7 Hz, 1H, ArH), 8.28-8.07 (m, 4H, ArH), 7.62-7.59 
(m, 3H, ArH), 7.42 (dd, 3J=8.2 Hz, 3J=4.2 Hz 1H, ArH), 7.21 (d, 3J=8.3 Hz, 2H, ArH), 6.56 (s, 
1H, ArH), 6.51 (s, 1H, ArH), 4.04-4.01 (m, 2H, CH2), 4.05 (s, 3H, OCH3), 3.95 (s, 2H, CH2), 
3.75 (s, 6H, 2 OCH3), 3.62-3.61 (m, 2H, CH2), 3.59-3.53 (m, 6H, 3 CH2), 3.48-3.45 (m, 2H, 
CH2), 3.29 (s, 3H, OCH3), 2.87-2.82 (m, 2H, CH2), 2.76-2.69 (m, 6H, 3 CH2), 2.79-2.74 (m, 4H, 
2 CH2). 13C NMR (CD2Cl2, 75 MHz): δ= 167.7, 164.1, 163.9, 151.6, 148.8, 147.1, 145.5, 140.9, 
139.9, 136.4, 136.3, 135.3, 131.4, 130.6, 129.4, 128.4, 127.6, 126.8, 126.6, 126.3, 125.9, 121.3, 
120.9, 119.8, 117.4, 116.5, 111.0, 110.8, 71.1, 69.9, 69.7, 69.6, 68.9, 67.6, 59.1, 57.8, 54.9, 
54.7, 52.0, 50.2, 32.4, 27.9. HRMS (LSI) calcd. for C44H49N4O9 [MH+]: 777.3500; found: 
777.3523. IR (KBr) [cm-1]: ν = 3290, 2900, 1674, 1577, 1514. 
 
ABCB1 assay.25 ABCB1-overexpressing Kb-V1 cells18 were seeded into flat-bottomed 96-well 
plates (Greiner, Frickenhausen, Germany) at a density of 20,000 cells per well (total volume: 
100µL). On the following day, cells were washed with loading buffer (120 mM NaCl, 5 mM 
KCl, 2 mM MgCl2 · 6 H2O, 1.5 mM CaCl2 · 2 H2O, 25 mM HEPES, 10 mM glucose, pH 7.4) in 
order to remove unspecific serum esterases. Afterwards, cells were incubated with loading 
suspension (loading buffer, 5 mg/mL BSA, 1.25 μL/mL pluronic F127 (20 % in DMSO)) 
containing 0.5 μM calcein-AM and the test compound at increasing concentrations for 10 min 
(37 °C/5 % CO2). Subsequently, the loading suspension was discarded and cells were fixed with 
4 % paraformaldehyde (PFA) solution in PBS for 20 min under light protection. After three 
washing circles with loading buffer, fixed cells were overlaid with 100 µL loading buffer and 
relative fluorescence intensities were determined at 535/25 nm at a GENios Pro microplate 
reader (Tecan Deutschland GmbH, Crailsheim, Germany) after excitation at 485/20 nm. The 
obtained mean fluorescence intensities were related to the controls and plotted against the 
various concentrations of test compounds. 
 
TECAN instrument settings were as follows: Measurement mode: fluorescence top; excitation 
filter (Calcein-AM): 485/20; emission filter (Calcein-AM): 535/25; number of reads: 10; 
integration time: 40 μs; lag time: 0 μs; mirror selection: Dichroic 3 (e.g.Fl); plate definition file 
GRE96ft.pdf; multiple reads per well (Circle): 3x3; time between move and flash: 100 ms. 
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ABCG2 assay. The standard protocol for the performance of Hoechst 33342 was as follows: 3-
5 days after passaging (70-90 % confluency), MCF-7/Topo cells were seeded into 96-well plates 
at a density of 20000 cells/well (total volume 100µL). The cells were incubated over night in a 
water saturated atmosphere (95 % air, 5 % carbondioxide) at 37 °C. The next day, pre-mixtures 
of the test compounds at increasing concentrations were prepared in 1.5 mL reaction vessels: 
800 µL of pre-heated (37 °C) EMEM (Eagle’s Minimum Essential Medium, Sigma, Munich, 
Germany) containing L-glutamine, 2.2 g/L NaHCO3 (Merck, Darmstadt, Germany) and 110 
mg/L sodium pyruvate (Serva, Heidelberg, Germany) supplemented with 10 % FCS, were 
transferred into the cups. Subsequently, 8 µL of a 0.8 mM Hoechst 33342 dye solution and 8 µL 
of the test compound stock solutions in different conctentrations were added to the mixture. The 
samples were immediatley vortexed. The incubation medium of the microplate was removed 
and replaced by 100 µL per well of the pre-mixtures by means of a multichannel pipette, 
achieving a final concentration of 10 µM fumitremorgin C (positive control) and 8 µM Hoechst 
33342. The microplates were incubated (37 °C, 5 % carbondioxide) for 120 min. The 
supernatants were drained, and the cells were fixed for 30 min under light protection using 100 
µL per well of a 4 % paraformaldehyde solution. Finally, MCF-7/Topo cells were washed three 
times with 250 µL PBS for each well in order to get rid of residual dye. Afterwards cells were 
overlaid with 100 µL PBS and the relative fluorescence intensities were determined using a 
GENios Pro microplate reader (TECAN Deutschland GmbH, Crailsheim, Germany). The 
obtained mean fluorescence intensities were related to the controls and plotted against the 
various concentrations of test compounds. 
 
TECAN instrument settings were as follows: Measurement mode: fluorescence top; excitation 
filter (Hoechst 33342): 340/35; emission filter (Hoechst 33342): 485/20; number of reads: 10; 
integration time: 40 μs; lag time: 0 μs; mirror selection: user defined mirror 1; plate definition 
file GRE96ft.pdf; multiple reads per well (Circle): 3x3; time between move and flash: 50 ms. 
 
On each plate, the optimal gain was calculated by determination of the fluorescence intensity in 
the presence of the control substance, fumitremorgin C. After measurements, the microtiter 
plates were stored at 4 °C for the following cell quantification procedures. As a loss of cells and 
unspecific toxic effects of the test compounds during the incubation phase are to be considered, 
the obtained fluorescence values had to be normalized to the cell number of each well. 
Therefore, the microplates were processed with a 0.02 % aqueous crystal violet solution (100 
μL / well) for 20 min. Excess dye was removed by rinsing the trays with water for 20 min. 
Crystal violet bound by the cells was re-dissolved in 70 % ethanol (180 μL / well) while shaking 
the microplates for 2-4 h. Subsequently, the absorbance as a parameter proportional to cell mass 
was measured at the TECAN plate reader. For normalization of the fluorescence intensities to 
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the cell mass, detected fluorescence values were divided through the obtained absorbance data 
of each well. All values were corrected to the unspecific uptake of the dye (DMSO control 
value) and the data were referred to the maximal signal caused by 10 μM of the reference 
compound fumitremorgin C. Addition of increasing concentrations of the modulators led to 
sigmoidal concentration response curves. IC50 values were calculated using SIGMA PLOT 9.0, 
“Four parameter logistic curve” fitting. Errors were expressed as standard error of the mean 
(SEM). The required concentration of 10 μM fumitremorgin C in the final assay protocol, as a 
reference value for maximal transporter inhibition, was determined via the performance of the 
H33342 and pheophorbide assay according to the standard protocol. 
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2. Biaryl Tariquidar-Related Derivatives as Potent and Selective 
BCRP Modulators* 
 
Starting from the lead structure 2 synthesized in our laboratory, and aiming at more stable and 
better soluble compounds, a new series of biaryl tariquidar derivatives was synthesized by solid 
phase and solution synthesis. The biaryl fragment was constructed via Suzuki coupling starting 
from resin bound 4-bromo-2-nitrobenzoic acid and 4-(hydroxymethyl)benzeneboronic acid for 
compounds 15a-h or methyl 2-amino-4-bromo benzoate and (4-(2-((tert-
butyldimethylsilyl)oxy)ethyl)phenyl)boronic acid for compounds 20a-d. Sequential steps of 
reduction, amide bond formation, deprotection, mesylation and nucleophilyc substitution led to 
the desired structures. Inhibition of ABCB1 and ABCG2 determined in the calcein-AM and the 
Hoechst 33342 microplate assay, respectively, showed that analogues 15b,g,h and 20c,d 
selectively inhibit the ABCG2 transporter at nanomolar concentrations with a maximal 
inhibitory effect over 90%, being compound 15g the most potent and selective ABCG2 
modulator with an IC50 value of 590 nM, and Imax 109% relative to FTC. Stability of compound 
15g was also evaluated in mouse plasma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________ 
* Patent and paper in preparation. All the synthesis and spectroscopical investigations (except compound 14) were 
done by Cristian Ochoa Puentes. Compound 14 was synthesized by Manuel Bause at the Institute of Organic 
Chemistry, University of Regensburg. Inhibition assays for ABCB1 and ABCG2 were performed by Stefanie Bauer 
at the Institute of Pharmacy, University of Regensburg. 
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2.1 Introduction 
 
The Breast Cancer Resistance Protein (BCRP, ABCG2), identified simultaneously by Doyle et 
al.1 Allikmets et al.2 and Miyake et al.3 is a member of the ABC transporter superfamily.4 The 
overexpression of this transporter is associated with the multidrug resistance phenomena which 
is one of the causes for failure in cancer chemotherapy.4 
 
As well as the P-glycoprotein, the most known and studied ABC transporter, ABCG2 has 
caught the attention of different research groups around the globe and several efforts have been 
focused on understanding the structure and function of this transporter together with its 
substrates. It is known that ABCG2 is a 72-kDa protein composed of 665 amino acids. It has an 
N-terminal ATP-binding domain (or nucleotide binding fold, NBF) and a C-terminal 
transmembrane domain (TMD), a structure half the size and in reverse configuration to most 
other ABC proteins comprising two NBFs and two TMDs.5,6 Like the other ABC transporters, 
ABCG2 uses the energy of ATP-hydrolysis to transport substrates across the cell membrane. 
However, little is known about its transport mechanism, in particular, how it recognizes and 
transports a broad variety of structurally and chemically unrelated compounds, including anti-
cancer drugs, thus conferring drug resistance to cancer cells. 
 
One approach to overcome BCRP mediated drug resistance involves the use of potent inhibitors 
of this transporter such as fumitremorgin C and its analogues Ko134 and Ko143,7-9 
novobiocin,10 camptothecins derivatives,11 flavonoids,12,13 Elacridar10 and Tariquidar and its 
analogues,14,15 some anti-HIV drugs,16 and some tyrosine kinase inhibitors17,18 (Fig 1). 
 
Figure 1. Structures of the main ABCG2 inhibitors. 
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Recently, we described the synthesis of a new class of potent and selective ABCG2 inhibitors 
derived from tariquidar (Figure 2).19,20 Compound 1, in which at the benzamide core, the 
hetarylcarboxamido residue was shifted to the meta-position and the two methoxy groups were 
replaced with a carboxylic acid methyl ester showed an IC50 value in the nanomolar range (59 ± 
11) and a maximal inhibitory effect of 63% (Hoechst 33342 assay).21 Interestingly, when a 
methoxy group on the tetrahydroisoquinoline core was replaced by a triethylenglycol chain an 
increase in potency was observed (IC50 130 ± 29, Imax. 88%). Compound 2 is among the most 
potent and selective ABCG2 modulator reported so far. 
 
 
Figure 2. Structure of selective and potent ABCG2 inhibitors. 
 
Although compounds 1 and 2 are potent and selective ABCG2 inhibitors, stability test 
performed in mouse plasma revealed that these compounds are hydrolyzed at the amide bond 
bearing the phenethyl tetrahydroisoquinoline fragment.21 Unfortunately, these results showed 
that the reported compounds lack drug-like properties. Encouraged by these results we decided 
to design and synthesize a new class of more stable and better soluble derivatives. Our design is 
based on a two aryl fragment connection, by a C-C bond, as alternative to have compounds 
enzimatically more stable. In addition, and based in our previous experience,20 we developed a 
solid phase synthesis protocol as a good alternative to have a small library of these derivatives. 
 
2.2 Results and Discussion 
 
As shown in Scheme 1, Wang resing was selected as solid support and 4-bromo-2-nitrobenzoic 
acid 3, was attached to the resin using EDC.HCl. Reduction of the nitro group with SnCl2·2H2O 
and acylation with quinoline-2 or quinoline-6-carbonyl chloride 6a,b (freshly prepared) led to 
the resin bound amides 7a,b. In the next step the biphenyl system was constructed by Suzuki 
coupling between 7a,b and commercially available 4-(hydroxymethyl)benzeneboronic acid. 
Biphenyl derivatives 8a,b were mesylated at the hydroxy group and substituted by the 
tetrahydroisoquinolines 10-14. Compound 14 was synthesized in similar manner than 1220 from 
1,2,3,4-tetrahydroisoquinoline-6,7-diol hydrobromide. Finally, cleavage of the resin with 
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TFA/DCM (1:1) and transformation of the obtained carboxylic acids into the methyl esters with 
trimethylsilyldiazomethane (TMSCHN2) led to the desired biphenyl tariquidar analogues 15a-h. 
 
 
Scheme 1. SPS of tariquidar derivatives. Reagents and conditions: (i) 4-bromo-2-nitrobenzoic 
acid 3, EDC.HCl, DMAP, DMF/DCM 1/1, rt, overnight; (ii) SnCl2·2H2O, DMF, 80 oC, 
overnight; (iii) quinolinecarbonyl chlorides 6a, b, DIPEA, DCM, rt, 12 h (twice); (iv) 4-
(hydroxymethyl)benzeneboronic acid, Pd(PPh3)4, K3PO4, DME, 80 oC, 21 h; (v) MsCl, DIPEA, 
DCM, rt, 6 h; (vi) tetrahydroisoquinolines 10 - 14, THF, 80 oC, 21 h; (vii) TFA/DCM (1:1), rt, 
30 min (twice); (viii) TMSCHN2, PhH/MeOH (1:1), rt, 1 h. 
 
As shown in Table 1, a set of 8 tariquidar analogues was obtained in low to acceptable overall 
yields, mainly due to incomplete coupling between 7a, b and the boronic acid as confirmed by 
analysis of by-products by NMR. All analogues bearing a tetrahydroisoquinoline with a 
triethylenglycol chain showed increased hydrophilic character and better solubility. 
 
ABCB1 and ABCG2 inhibitory activity of compounds 15a-h, as well as the reference 
compounds tariquidar and elacridar were investigated in a calcein-AM (ABCB1)22 and a 
Hoechst 33342 (ABCG2) microplate assay21 using ABCB1-overexpressing Kb-V1 and ABCG2-
overexpressing MCF-7/Topo cells. The data are summarized in Table 2. 
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Table 1. Biphenyl tariquidar derivatives synthesized by SPS and in solution. 
Compound n R1 R2 Het. Yield (%) 
15a 1 H H 2-Quinol. 51a 
15b 1 H H 6-Quinol. 27a 
15c 1 OCH3 OCH3 2-Quinol. 40a 
15d 1 OCH3 OCH3 6-Quinol. 23a 
15e 1 O(CH2CH2O)3CH3 OCH3 2-Quinol. 44a 
15f 1 O(CH2CH2O)3CH3 OCH3 6-Quinol. 23a 
15g 1 OCH3 O(CH2CH2O)3CH3 2-Quinol. 40a 
15h 1 O(CH2CH2O)3CH3 O(CH2CH2O)3CH3 2-Quinol. 41a 
20a 2 H H 2-Quinol. 14b 
20b 2 OCH3 OCH3 2-Quinol. 17b 
20c 2 OCH3 O(CH2CH2O)3CH3 2-Quinol. 12b 
20d 2 O(CH2CH2O)3CH3 O(CH2CH2O)3CH3 2-Quinol. 4b 
a Overall yield based on the loading of the resin. 
b Overall yield for compounds synthesized in solution. 
 
Table 2. Inhibition of ABC transporters by reference compounds and the tariquidar analogues 
15a–i, 20a–d determined in the calcein-AM (ABCB1) and Hoechst 33342 (ABCG2) microplate 
assay unless otherwise indicated 
Compd. ABCB1 ABCG2 IC50 (nM) IC50 (nM) Imaxa (%) 
Tariquidar 223 ± 8 526 ± 85 69c 
Elacridar 193 ± 18 127 ± 41 63c 
Ko143 Inactiveb 117 ± 53 103 ± 7c 
2 >50000 130 ± 29 88d 
15a n.d. 1460 85 
15b 4490 655 94 
15c n.d. 943 ± 79 87 
15d 10900 ± 1700 1540 ± 110 92 
15e n.d 1030 ± 139 114 
15f 18000 ± 1560 237 ± 65 67 
15g 1230 ± 105 591 ± 87 109 
15h n.d. 913 ± 144 101 
20a >100000 1100 90 
20b >150000 3215± 490 126 
20c 5420 ± 230 760 98 
20d 5990 ± 1220 581 ± 80 99 
a Relative to Fumitremorgin C (100%). b 1.6% inhibition at 10 
µM. c ref 21. d ref 20. n.d. = not determined 
 
Elacridar strongly inhibits both transporters without a preference to one of the two targets, 
whereas tariquidar was about equipotent with elacridar at ABCB1 but about four times less 
potent at ABCG2. The most potent ABCG2 inhibitor reported so far, Ko143,9 is inactive at 
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ABCB1 transporter and has an IC50 of 117 nM ± 53 with a maximal inhibitory effect of 103 nM 
± 7, relative to fumitremorgin C. 
Compounds 15b, 15d, 15f and 15g are inactive at ABCB1 transporter, were as compounds 15b, 
15c, 15f, 15g and 15h showed values in the nanomolar range for ABCG2 inhibition and are 
approximately 5, 7.5, 2, 5 and 7.2 fold higher than elacridar, the reference compound 2 and 
Ko143. However, 15b, 15g and 15h are superior to elacridar and 2 with respect to the maximal 
inhibitory effect: 94%, 109% and 101% versus 66% and 88%, being 15g and 15h as efficient as 
Ko143 (Figure 3). Compound 15g which is the best in this series also has an IC50 value 
comparable with tariquidar, but its efficience is higher at ABCG2 inhibition (109% vs 69%). 
 
In order to have a diverse library of compounds, we decided to synthesize a second series of 
derivatives leaving the methyl ester and the quinoline-2-carboxamido substituents in the 
structure which is a characteristic of the best inhibitors we have reported before including 
compound 15g.19,20 
Compounds 20a-d, in which the length of the linker between the tetrahydroisoquinoline moiety 
and the biphenyl motif was modified by adding a second methylene group, were synthesized in 
solution in similar fashion starting from methyl 2-amino-4-bromobenzoate 16 and (4-(2-((tert-
butyldimethylsilyl)oxy)ethyl)phenyl)boronic acid23 (Scheme 2, Table 1). 
 
Scheme 2. Solution synthesis of tariquidar analogues. Reagents and conditions: (i) methyl 2-
amino-4-bromobenzoate 15, (4-(2-((tert-butyldimethylsilyl)oxy)ethyl)phenyl)boronic acid, 
Pd(PPh3)4, K3PO4, THF, 80 oC, 15 h; (iii) quinoline-2-carbonyl chloride 6a, TEA, DCM, 40 oC, 
overnight; (iv) TBAF, THF, rt, 3 h; (iv) MsCl, TEA, DCM, rt, 5 h; (v) tetrahydroisoquinolines 
10, 11, 13 and 14, CH3CN, 80 oC, overnight. 
 
As shown in table 2, compounds 20a-d are also selective for the inhibition of the ABCG2 
transporter, but the insertion of an additional methylene group in the linker did not lead to a 
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more potent compound when compared to analogue 15g. These results suggest that the distance 
between the tetrahydroisoquinoline core and the biaryl moiety may influence the inhibitory 
activity of this class of analogues. Compounds 20c and 20d have higher IC50 values compared 
with all the reference compounds, but with respect to the maximal inhibitory effect, these 
compounds are superior to tariquidar, elaquidar and 2, and are comparable to Ko143 (Figure 3). 
Here is noteworthy to mention that the addition of one or two triethylen glycol chains at the 
tetrahydroisoquinoline core of the synthesized derivatives having a quinoline-2-carboxamido 
moiety increases the inhibitory activity over the transporter (compounds 15g, 15h, 20c and 
20d). 
concentration [µM]
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Figure 3. Concentration dependent inhibition of the ABCG2 transporter in MCF-7/Topo cells 
(Hoechst 33342 assay) by tariquidar (filled black circles), elacridar (filled black triangles) and 
the tariquidar analogues 1 (UR-ME22-1; filled red circles), 2 (UR-COP78; filled blue circles), 
15g (COPG228; filled green circles) and 20d (COPG258; filled pink circles). The maximal 
inhibition is expressed as % relative to the maximum inhibition of ABCG2 by fumitremorgin C 
(at a concentration of 10 µM). 
 
With respect to future in vivo studies, compound 15g was selected to evaluate its stability under 
physiological conditions.21 The stability test, performed in mouse plasma, revealed that this 
compound is more stable than compound 2, which is completely decomposed after 15 min (data 
not shown). Enzymatic degradation of the new compound started after 30 min, and after 24h 
around 60% of the compound still remains. HPLC/MS analysis showed that the methyl ester of 
the anthranilic ring is hydrolyzed affording the corresponding carboxylic acid derivative which 
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is not active in the inhibition of the ABCG2. This result shows that compound 15g might be 
used to perform further studies in vivo. 
 
2.3 Conclusion 
 
In conclusion, the solid phase synthesis herein presented is a straightforward method to 
conveniently obtain a small library of biaryl tariquidar related derivatives. A second set of 
compounds was also synthesized in solution following a similar procedure for the compounds 
obtained on solid phase. Compound 15g, which is the most active tariquidar analogue here 
obtained with a selective inhibitory activity over ABCG2, has a higher IC50 value compared to 
the most active inhibitor reported Ko143 (590 nM vs 117 nM ± 53), but has about the same 
maximal inhibitory effect (109% vs 103% ± 7 relative to fumitremorgin C). The structural 
characteristics of the compounds obtained here together with their activities and the improved 
stability may lead to a new class of active and more stable tariquidar derivatives. 
 
2.4 Experimental Section 
 
General. Wang resin was purchased from Fluka (100-200 mesh, 1.1 mmol/g, 1% 
divinylbenzene cross-linking). All other chemical reagents were obtained from either Aldrich, 
Acros, Merck, or Fluka and used without further purification. Manual solid-phase organic 
syntheses were carried out at 25 °C in polypropylene syringes equipped with a porous 
polypropylene disk at the bottom (purchased from Roland Vetter Laborbedarf OHG). Solid 
phase reaction at higher temperature was carried out in an eppendorf tube with a microcentifuge 
tube holder. Flash column chromatograph was performed with silica gel (Merck silica gel 60M 
40-63 μm); products were detected by TLC on alumina plates coated with silica gel (Merck 
silica gel 60 F254, thickness 0.2 mm) and visualized by UV light (λ ) 254 nm). Melting points 
were determined with an OptiMelt MPA100 and are uncorrected. NMR spectra were measured 
at 298 K on a Bruker Avance 300 or Bruker Avance 600 instruments. Chemical shifts are 
reported in δ (ppm) relative to external standards and coupling constants J are given in Hz. 
Abbreviations for the characterization of the signals: s ) singlet, d ) doublet, t ) triplet, m ) 
multiplet, bs ) broad singlet, dd ) double doublet. The relative numbers of protons is determined 
by integration. Mass spectra were recorded with Finnigan MAT TSQ 7000 (ESI) and Finnigan 
MAT 90 (HRMS), IR spectra with a Bio- Rad FT-IR-FTS 155 spectrometer. 
 
General procedure for SPS of tariquidar analogues 15. A polypropylene 5.0-ml fritted 
syringe was charged with 200 mg of Wang resin (0.9 mmol/g loading) and the resin was 
swollen in 3 mL of DCM/DMF (4/1) during 1 h. A mixture of 4-bromo-2-nitrobenzoic acid 
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(0.45 mmol, 2.5 equiv) and EDC.HCl (0.45 mmol, 2.5 equiv) in 2 mL of DCM/DMF (4/1) was 
added, the resin was cooled down and shaken for 5 min. then, DMAP (20% mol) was added and 
the resin was shaken at room temperature overnight. After washing the resin with DMF, MeOH 
and DCM (3X each), SnCl2.2H2O (1.8 mmol, 10 equiv) in DMF was added and the resin was 
heated at 80 oC overnight, then the resin was washed again with the same solvents and swollen 
in dry DCM. Quinoline-2(6)-carbonyl chloride (freshly prepared 0.9 mmol, 5 equiv) and DIPEA 
(0.9 mmol, 5 equiv) were added and the resin was shaken at room temperature during 12 h and 
washed three times with DCM, MeOH, DMF, MeOH and DMF (this coupling step was 
repeated). DME was added and the resin was swollen during 1 h. 4-
(Hydroxymethyl)benzeneboronic acid (0.54 mmol, 3 equiv), Pd(PPh3)4 (5% mol), and K3PO4, (2 
M sln. 0.54 mmol, 3 equiv) were added and the resin was heated at 80 oC during 21 h, then 
several washes with DMF, MeOH and DCM were done. Dry DCM was added and the resin was 
cooled down, then mesyl chloride (0.9 mmol, 5 equiv) and DIPEA (0.45 mmol, 2.5 equiv) were 
added and the resin was shaken at room temperature for 6 h. After several washes with DCM 
and THF, the resin was swollen in dry THF and the tetrahydroisoquinoline derivative (0.9 
mmol, 5 equiv) was added, after this, the resin was heated at 70 oC during 21 h. Finally, the 
resin was washed with DMF, MeOH and DCM and dry under vacuum. 
 
Cleavage. The resin was dried under vacuum and a mixture of TFA/DCM 1/1 was added (3 ml) 
and the resin was shaken for 30 min., the cleavage cocktail was collected and the content of the 
syringe was washed 2 times with fresh 50% TFA in DCM (this procedure was repeated). 
Combined washes were evaporated and residual oil was washed with fresh diethylether, the 
precipitated solid was filtered and dried. 
 
Esterification. The carboxylic acid derivative (1 equiv) was dissolved in 3 mL of a mixture 
PhH/MeOH 2/1 and trimethylsilyldiazomethane solution (2 M in diethyl ether) was added 
dropwise until no evolution of N2 was observed. The reaction was stirred during 1 h at room 
temperature. The solvent was evaporated and the solid was purified by flash chromatography 
(CHCl3/MeOH 95/5). 
 
Methyl 4'-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-3-(quinoline-2-carboxamido)-[1,1'-
biphenyl]-4-carboxylate 15a.  
 
Yield 51%, yellow solid, Rf = 0.25 (CHCl3/MeOH 95/5), mp. 154-156 oC dec. 1H-NMR 
(CDCl3, 300 MHz): δ= 13.33 (s 1H, NHCO), 9.37 (d, 4J=1.6 Hz, 1H, ArH), 8.41-8.33 (m, 3H, 
ArH), 8.16 (d, 3J=8.2 Hz, 1H, ArH), 7.89 (d, 3J=7.9 Hz, 1H, ArH), 7.82 (dt, 4J=1.1 Hz, 3J=8.2 
Hz, 1H, ArH), 7.71 (d, 3J=8.1 Hz, 2H, ArH), 7.65 (t, 3J=7.4 Hz, 1H, ArH), 7.49 (d, 3J=8.1 Hz, 
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2H, ArH), 7.39 (dd, 4J=1.8 Hz, 3J=8.3 Hz, 1H, ArH), 7.12-7.10 (m, 3H, ArH), 7.01-6.99 (m, 
1H, ArH), 4.07 (s, 3H, OCH3), 3.75 (s, 2H, CH2), 3.68 (s, 2H, CH2), 2.92 (t, 3J=5.7 Hz, 2H, 
CH2), 2.78 (t, 3J=5.6 Hz, 2H, CH2). 13C-NMR (CDCl3, 75 MHz) δ: 167.9 (C=O), 163.7 (C=O), 
150.1 (Cquat.), 146.7 (Cquat.), 146.6 (Cquat.), 141.2 (Cquat.), 138.8 (Cquat.), 138.6 (Cquat.), 
137.7 (+), 134.8 (Cquat.), 134.4 (Cquat.), 131.7 (+), 130.3 (+), 130.2 (+), 129.6 (+), 129.4 
(Cquat.), 128.7 (+), 128.2 (+), 127.6 (+.), 127.4 (+), 126.6 (+), 126.1 (+), 125.6 (+), 121.3 (+), 
119.0 (+), 118.9 (+), 115.1 (Cquat.), 62.4 (-), 56.1 (-), 52.4 (+), 50.6 (-), 29.1 (-). HRMS (EI-
MS) calcd. for C34H29N3O3 [M•+]: 527.2209; found: 527.2202. IR (KBr) [cm-1]: ν = 2958, 1681, 
1550, 1500. 
 
Methyl 4'-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-3-(quinoline-6-carboxamido)-[1,1'-
biphenyl]-4-carboxylate 15b.  
 
Yield 27%, yellow solid, Rf = 0.47 (CHCl3/MeOH 95/5), mp. 100-102 oC dec. 1H-NMR 
(CDCl3, 300 MHz): δ= 12.40 (s, 1H, NHCO), 9.36 (d, 4J=1.6 Hz, 1H, ArH), 9.06 (dd, 4J=1.6 
Hz, 3J=4.2 Hz, 1H, ArH), 8.65 (d, 4J=1.8 Hz, 1H, ArH), 8.44-8.38 (m, 2H, ArH), 8.29 (d, 3J=8.8 
Hz, 1H, ArH), 8.20 (d, 3J=8.3 Hz, 1H, ArH), 7.75 (d, 3J=8.1 Hz, 2H, ArH), 7.54 (d, 3J=8.1 Hz, 
2H, ArH), 7.53 (d, 3J=8.2 Hz, 1H, ArH), 7.45 (dd, 4J=1.8 Hz, 3J=8.3 Hz, 1H, ArH), 7.17-7.15 
(m, 3H, ArH), 7.06-7.04 (m, 1H, ArH), 4.06 (s, 3H, OCH3), 3.80 (s, 2H, CH2), 3.73 (s, 2H, 
CH2), 2.96 (t, 3J=5.7 Hz, 2H, CH2), 2.81 (t, 3J=5.6 Hz, 2H, CH2). 13C-NMR (CDCl3, 75 MHz) 
δ: 169.1 (C=O), 165.1 (C=O), 152.2 (+), 149.6 (Cquat.), 147.3 (Cquat.), 142.1 (Cquat.), 138.8 
(Cquat.), 138.5 (Cquat.), 137.4 (+), 134.7 (Cquat.), 134.3 (Cquat.), 132.7 (Cquat.), 131.5 (+), 
130.3 (+), 129.6 (+), 128.7 (+), 128.4 (+), 127.7 (Cquat.), 127.4 (+), 127.2 (+), 126.6 (+), 126.1 
(+), 125.6 (+), 121.9 (+), 121.3 (+), 118.8 (+), 113.8 (Cquat.), 62.3 (-), 56.1 (-), 52.6 (+), 50.6 (-
), 29.0 (-). HRMS (EI-MS) calcd. for C34H29N3O3 [M•+]: 527.2209; found: 527.2198. IR (KBr) 
[cm-1]: ν = 2966, 1674, 1566, 1500. 
 
Methyl 4'-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-3-(quinoline-2-
carboxamido)-[1,1'-biphenyl]-4-carboxylate 15c.  
 
Yield 40%, yellow solid, Rf = 0.28 (CHCl3/MeOH 95/5), mp. 162-164 oC dec. 1H-NMR 
(CDCl3, 600 MHz): δ= 13.33 (s, 1H, NHCO), 9.36 (d, 4J=1.7 Hz, 1H, ArH), 8.40-8.38 (m, 2H, 
ArH), 8.35 (d, 3J=8.4 Hz, 1H, ArH), 8.17 (d, 3J=8.2 Hz, 1H, ArH), 7.90 (dd, 4J=0.6 Hz, 3J=8.1 
Hz, 1H, ArH), 7.84-7.81 (m, 1H, ArH), 7.72 (d, 3J=8.1 Hz, 2H, ArH), 7.67-7.64 (m, 1H, ArH), 
7.50 (d, 3J=8.1 Hz, 2H, ArH), 7.40 (dd, 4J=1.8 Hz, 3J=8.2 Hz, 1H, ArH), 6.61 (s, 1H, ArH), 6.51 
(s, 1H, ArH), 4.08 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.74 (s, 2H, CH2), 
3.58 (s, 2H, CH2), 2.84 (t, 3J=5.7 Hz, 2H, CH2), 2.71 (t, 3J=5.9 Hz, 2H, CH2). 13C-NMR 
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(CDCl3, 151 MHz) δ: 167.9 (C=O), 163.7 (C=O), 150.1 (Cquat.), 147.5 (Cquat.), 147.2 
(Cquat.), 146.7 (Cquat.), 146.6 (Cquat.) 141.2 (Cquat.), 138.7 (Cquat.), 138.6 (Cquat.), 137.6 
(+), 131.7 (+), 130.2 (+), 130.1 (+), 129.6 (+), 129.3 (Cquat.), 128.2 (+), 127.6 (+.), 127.3 (+), 
126.6 (Cquat.), 126.1 (Cquat.), 121.3 (+), 119.0 (+), 118.8 (+), 115.1 (Cquat.), 114.4 (+), 109.5 
(+), 62.3 (-), 55.9 (+), 55.9 (+), 55.6 (-), 52.3 (+), 50.8 (-), 28.6 (-). HRMS (EI-MS) calcd. for 
C36H33N3O5 [M•+]: 587.2420; found: 587.2407. IR (KBr) [cm-1]: ν = 2962, 1681, 1608, 1516. 
 
Methyl 4'-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-3-(quinoline-6-
carboxamido)-[1,1'-biphenyl]-4-carboxylate 15d.  
 
Yield 23%, yellow solid, Rf = 0.54 (CHCl3/MeOH 95/5), mp. 120-122 oC dec. 1H-NMR 
(CDCl3, 600 MHz): δ= 12.35 (s, 1H, NHCO), 9.31 (d, 4J=1.8 Hz, 1H, ArH), 9.01 (dd, 4J=1.6 
Hz, 3J=4.1 Hz, 1H, ArH), 8.60 (d, 4J=1.9 Hz, 1H, ArH), 8.35 (dt, 4J=2.1 Hz, 3J=8.8 Hz, 2H, 
ArH), 8.25 (d, 3J=8.8 Hz, 1H, ArH), 8.16 (d, 3J=8.3 Hz, 1H, ArH), 7.71 (d, 3J=8.1 Hz, 2H, 
ArH), 7.55-7.49 (m, 3H, ArH), 7.40 (dd, 4J=1.8 Hz, 3J=8.2 Hz, 1H, ArH), 6.61 (s, 1H, ArH), 
6.51 (s, 1H, ArH), 4.01 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.75 (s, 2H, 
CH2), 3.59 (s, 2H, CH2), 2.84 (t, 3J=5.7 Hz, 2H, CH2), 2.77 (t, 3J=5.6 Hz, 2H, CH2). 13C-NMR 
(CDCl3, 151 MHz) δ: 169.1 (C=O), 165.0 (C=O), 152.2 (+), 149.5 (Cquat.), 147.5 (Cquat.), 
1447.3 (Cquat.), 147.2 (Cquat.), 142.1 (Cquat.), 138.5 (Cquat.), 137.4 (+), 132.7 (Cquat.), 131.4 
(+), 130.2 (+), 129.6 (+), 128.4 (+), 127.7 (Cquat.), 127.4 (+), 127.2 (+), 126.5 (Cquat.), 126.1 
(Cquat.), 121.9 (+), 121.3 (+), 118.8 (+), 115.4 (Cquat.), 113.8 (Cquat.), 111.4 (+),109.5 (+), 
62.3 (-), 55.9 (+), 55.6 (-), 52.5 (+), 50.8 (-), 28.6 (-). HRMS (EI-MS) calcd. for C36H33N3O5 
[M•+]: 587.2420; found: 587.2417. IR (KBr) [cm-1]: ν = 2958, 1674, 1566, 1500. 
 
Methyl 4'-((7-methoxy-6-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-
2(1H)-yl)methyl)-3-(quinoline-2-carboxamido)-[1,1'-biphenyl]-4-carboxylate 15e.  
 
Yield 44%, sticky yellow oil, Rf = 0.35 (CHCl3/MeOH 95/5). 1H-NMR (CDCl3, 600 MHz): δ= 
13.33 (s, 1H, NHCO), 9.36 (d, 4J=1.7 Hz, 1H, ArH), 8.39-8.33 (m, 3H, ArH), 8.15 (d, 3J=8.2 
Hz, 1H, ArH), 7.88 (d, 3J=8.2 Hz, 1H, ArH), 7.82-7.80 (m, 1H, ArH), 7.71 (d, 3J=8.1 Hz, 2H, 
ArH), 7.65-7.62 (m, 1H, ArH), 7.48 (d, 3J=8.1 Hz, 2H, ArH), 7.39 (dd, 4J=1.7 Hz, 3J=8.2 Hz, 
1H, ArH), 6.66 (s, 1H, ArH), 6.50 (s, 1H, ArH), 4.13 (t, 3J=5.4 Hz, 2H, CH2), 4.06 (s, 3H, 
OCH3), 3.85 (t, 3J=5.0 Hz, 2H, CH2), 3.78 (s, 3H, OCH3), 3.73-3.72 (m, 4H, 2 CH2), 3.67-3.63 
(m, 4H, 2 CH2), 3.56 (s, 2H, CH2), 3.54-3.53 (m, 2H, CH2), 3.36 (s, 3H, OCH3), 2.81 (t, 3J=5.6 
Hz, 2H, CH2), 2.74 (t, 3J=5.5 Hz, 2H, CH2). 13C-NMR (CDCl3, 151 MHz) δ: 167.8 (C=O), 
163.5 (C=O), 150.0 (Cquat.), 147.7 (Cquat.), 146.6 (Cquat.), 146.6 (Cquat.), 146.5 (Cquat.) 
141.1 (Cquat.), 138.6 (Cquat.), 138.5 (Cquat.), 137.6 (+), 131.6 (+), 130.2 (+), 130.1 (+), 129.5 
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(+), 129.3 (Cquat.), 128.1 (+), 127.5 (+), 127.3 (+), 127.3 (Cquat.), 126.1 (Cquat.), 121.2 (+), 
118.8 (+), 118.8 (+), 115.0 (Cquat.), 114.1 (+), 110.0 (+), 71.8 (-), 70.7 (-), 70.5 (-), 70.4 (-), 
69.5 (-), 68.6 (-), 62.3 (-), 58.9 (+), 55.9 (+), 55.6 (-), 52.3 (+), 50.7 (-), 28.5 (-). HRMS (EI-
MS) calcd. for C42H45N3O8 [M•+]: 719.3207; found: 719.3222. IR (KBr) [cm-1]: ν = 2960, 2918, 
1685, 1608, 1560, 1514. 
 
Methyl 4'-((7-methoxy-6-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-
2(1H)-yl)methyl)-3-(quinoline-6-carboxamido)-[1,1'-biphenyl]-4-carboxylate 15f.  
 
Yield 23%, sticky yellow oil, Rf = 0.25 (CHCl3/MeOH 95/5). 1H NMR (CDCl3, 300 MHz): δ= 
12.35 (s, 1H, NHCO), 9.31 (d, 4J=1.7 Hz, 1H, ArH), 9.01 (dd, 3J=4.2, 4J=1.7 Hz, 1H, ArH), 
8.59 (d, 4J=1.9 Hz, 1H, ArH), 8.39-8.31 (m, 2H, ArH), 8.25 (d, 3J=8.9 Hz, 1H, ArH), 8.15 (d, 
3J=8.4 Hz, 1H, ArH), 7.71 (d, 3J=8.2 Hz, 2H, ArH), 7.49 (d, 3J=8.2 Hz, 2H, ArH), 7.48 (d, 
J=8.2 Hz, 1H, ArH) 7.40 (dd, 3J=8.4, 4J=1.8 Hz, 1H, ArH), 6.67 (s, 1H, ArH), 6.50 (s, 1H, 
ArH), 4.14 (t, 3J=5.3 Hz, 2H, CH2), 4.00 (s, 3H, OCH3), 3.86 (t, 3J=5.3 Hz, 2H, CH2), 3.78 (s, 
3H, OCH3), 3.76-3.71 (m, 4H, 2 CH2), 3.69-3.63 (m, 4H, 2 CH2), 3.59-3.52 (m, 4H, 2 CH2), 
3.37 (s, 3H, OCH3), 2.82-2.76 (m, 4H, 2 CH2). 13C NMR (CDCl3, 75 MHz) δ: 168.1 (C=O), 
164.0 (C=O), 151.2 (+), 148.6 (Cquat.), 146.8 (Cquat.), 146.2 (Cquat.), 145.7 (Cquat.), 141.1 
(Cquat.), 137.9 (Cquat.), 137.4 (Cquat.), 136.3 (+), 131.6 (Cquat.), 130.4 (+), 129.3 (+), 128.6 
(+), 127.4 (+), 126.7 (Cquat.), 126.3 (+), 126.1 (+), 125.1 (Cquat.), 120.9 (+), 120.2 (+), 117.7 
(+), 113.1 (+), 112.7 (Cquat.), 109.0 (+), 70.9 (-), 69.7 (-), 69.6 (-), 69.5 (-), 68.6 (-), 67.6 (-), 
61.3 (-), 58.0 (+), 54.9 (+), 54.6 (-), 51.5 (+), 49.8 (-), 27.5 (+). HRMS (EI-MS) calcd. for 
C42H45N3O8 [M•+]: 719.3207; found: 719.3211. IR (KBr) [cm-1]: ν = 2931, 1672, 1612, 1566, 
1514. 
 
Methyl 4'-((6-methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-
2(1H)-yl)methyl)-3-(quinoline-2-carboxamido)-[1,1'-biphenyl]-4-carboxylate 15g.  
 
Yield 40%, sticky yellow oil, Rf = 0.16 (CHCl3/MeOH 95/5). 1H NMR (CDCl3, 300 MHz): δ= 
13.31 (s, 1H, NHCO), 9.32 (d, 4J=1.7 Hz, 1H, ArH), 8.34-8.29 (m, 3H, ArH), 8.14 (d, 3J=8.3 
Hz, 1H, ArH), 7.87 (d, 3J=8.1 Hz, 1H, ArH), 7.82-7.75 (m, 1H, ArH), 7.68 (d, 3J = 8.2 Hz, 2H, 
ArH), 7.65-7.58 (m, 1H, ArH), 7.46 (d, 3J=8.2 Hz, 2H, ArH), 7.37 (dd, 3J=8.3, 4J=1.8 Hz, 1H, 
ArH), 6.56 (s, 1H, ArH), 6.52 (s, 1H, ArH), 4.08 (t, 3J=5.2 Hz, 2H, CH2), 4.03 (s, 3H, OCH3), 
3.83-3.75 (m, 5H, OCH3, CH2), 3.68 (m, 4H, 2 CH2), 3.63-3.57 (m, 4H, 2 CH2), 3.53 (s, 2H, 
CH2), 3.48 (m, 2H, CH2), 3.31 (s, 3H, OCH3), 2.79 (m, 2H, CH2), 2.71 (m, 2H, CH2). 13C NMR 
(CDCl3, 75 MHz,) δ: 168.0 (C=O), 163.7 (C=O), 150.1 (Cquat.), 148.1 (Cquat.), 146.8 (Cquat.), 
146.6 (Cquat.), 146.4 (Cquat.), 141.2 (Cquat.), 138.7 (Cquat.), 138.6 (Cquat.), 137.7 (+), 131.7 
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(+), 130.3 (+), 130.2 (+), 129.6 (+), 129.4 (Cquat.), 128.2 (+), 127.6 (+), 127.4 (+), 126.9 
(Cquat.), 126.7 (Cquat.), 121.3 (+), 119.0 (+), 118.9 (+), 115.1 (Cquat.), 112.2 (+), 112.0 (+), 
71.96 (-), 70.86 (-), 70.66 (-), 70.56 (-), 69.66 (-), 68.66 (-), 62.36 (-), 59.0 (+), 56.0 (+), 55.76 (-
), 52.4 (+), 50.76 (-), 28.76 (-). HRMS (EI-MS) calcd. for C42H45N3NaO8 [M+Na]+: 742.3099; 
found: 742.3107. IR (KBr) [cm-1]: ν = 2926, 1612, 1517. 
 
Methyl 4'-((6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)methyl)-3-(quinoline-2-carboxamido)-[1,1'-biphenyl]-4-carboxylate 15h.  
 
Yield 41%, sticky light yellow oil, Rf = 0.3 (DCM/MeOH 100/1). 1H NMR (CDCl3, 300 MHz): 
δ= 13.31 (s, 1H, NHCO), 9.35 (d, 4J=1.6 Hz, 1H, ArH), 8.39-8.29 (m, 3H, ArH), 8.14 (d, 3J=8.3 
Hz, 1H, ArH), 7.87 (d, 3J=8.1 Hz, 1H, ArH), 7.83-7.76 (m, 1H, ArH), 7.70 (d, 3J=8.2 Hz, 2H, 
ArH), 7.65-7.58 (m, 1H, ArH), 7.47 (d, 3J=8.1 Hz, 2H, ArH), 7.38 (dd, 3J=8.3, 4J=1.7 Hz, 1H, 
ArH), 6.65 (s, 1H, ArH), 6.55 (s, 1H, ArH), 4.12-4.07 (m, 4H, 2 CH2), 4.04 (s, 3H, OCH3), 3.81 
(dd, 3J=9.9, 4J=4.7 Hz, 4H, 2 CH2), 3.75-3.69 (m, 6H, 3 CH2), 3.67-3.60 (m, 8H, 4 CH2), 3.55-
3.49 (m, 6H, 3 CH2), 3.36 (s, 3H, OCH3), 3.34 (s, 3H, OCH3), 2.80-2.72 (m, 4H, 2 CH2). 13C 
NMR (CDCl3, 75 MHz) δ 167.9 (C=O), 163.6 (C=O), 150.1 (Cquat.), 147.4 (Cquat.), 147.1 
(Cquat.), 146.7 (Cquat.), 146.6 (Cquat.), 141.2 (Cquat.), 138.8 (Cquat.), 138.6 (Cquat.), 137.6 
(+), 131.7 (+), 130.2 (+), 130.2 (+), 129.6 (+), 129.3, 128.2 (+), 127.7, 127.6 (+), 127.3 (+), 
127.2, 121.3 (+), 118.9 (+), 118.8 (+), 115.1 (+), 115.0 (Cquat.), 113.2 (+), 71.9 (-), 70.7 (-), 
70.6 (-), 70.5 (-), 69.7 (-), 69.7 (-), 69.0 (-), 62.4 (-), 59.0 (+), 55.7 (-), 52.4 (+), 50.7 (-), 28.7 (-
). HRMS (EI-MS) calcd. for C48H58N3O11 [M+H]+: 852.4066; found: 852.4072. IR (KBr) [cm-
1]: ν = 2875, 1685, 1500. 
 
Methyl 4'-(2-hydroxyethyl)-3-(quinoline-2-carboxamido)-[1,1'-biphenyl]-4-carboxylate 18.  
 
A mixture of methyl 2-amino-4-bromobenzoate 16 (3.24 g, 14.1 mmol), (4-(2-((tert-
butyldimethylsilyl)oxy)ethyl)phenyl)boronic acid (3.95 g, 14.1 mmol), Pd(PPh3)4 (808 mg, 0.7 
mmol, 5%mol) and K3PO4 (7.0 mL 2M solution, 14.1 mmol) in 25 mL of THF was stirred and 
heated at 80 oC for 15h. The solvent was evaporated and DCM was added. After washing with 
brine, the organic layer was separated and dried over MgSO4. The compound was purified by 
flash chromatograpy (PE:AcOEt 10:1) and the fraction containing the product (3.7 g) was 
collected and used for the next step. Quinoline-2-carbonyl chloride (1.83 g, 9.59 mmol) was 
added to a mixture of the biaryl derivative above obtained (3.7 g) and TEA (4.01 mL, 28.7 
mmol) in dry DCM. The mixture was heated at 40 oC and stirred overnight. 1N HCl was added 
and the organic phase separated, washed with 1N NaHCO3 and dried over MgSO4. The 
compound was purified by flash chromatograpy (PE:AcOEt 10:1) and the fraction containing 
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the product (4.07 g) was collected and used for the next step. TBAF (1.8 mL 1M solution in 
THF) was added to a cold solution of 17 (1.0 g) in 5 mL THF and the mixture was stirred at rt 
for 3 h. The solvent was evaporated, saturated NH4Cl was added and the compound extracted 
with DCM. The compound was purified by flash chromatograpy (PE:AcOEt 1.5:1, Rf = 0.20). 
Yield 27.2% over three steps, white solid, mp. 188-190 oC dec. 1H NMR (DMSO, 300 MHz): 
δ= 13.12 (s, 1H, NHCO), 9.23 (d, 4J=1.8 Hz, 1H, ArH), 8.65 (d, 3J=8.5 Hz, 1H, ArH), 8.29 (d, 
3J=8.5 Hz, 1H, ArH), 8.19 (d, 3J=8.4 Hz, 1H, ArH), 8.14-8.08 (m, 2H, ArH), 7.98-7.91 (m, 1H, 
ArH), 7.81-7.75 (m, 1H, ArH), 7.67 (d, 3J=8.2 Hz, 2H, ArH), 7.51 (dd, 3J=8.4, 4J=1.8 Hz, 1H, 
ArH), 7.40 (d, 3J=8.2 Hz, 2H, ArH), 4.75 (t, 3J=5.2 Hz, 1H, OH), 4.02 (s, 3H, OCH3), 3.72-3.66 
(m, 2H, CH2), 2.83 (t, 3J=6.9 Hz, 2H, CH2). 13C NMR (DMSO, 75 MHz) δ: 166.9 (C=O), 162.7 
(C=O), 149.2 (Cquat.), 145.6 (Cquat.), 140.3 (Cquat.), 138.2 (+), 136.3 (Cquat.), 131.6 (+), 
130.7 (+), 129.6 (+), 129.2 (+), 128.9 (Cquat.), 128.4 (+), 128.0 (+), 126.5 (+), 121.0 (+), 118.3 
(+), 117.4 (+), 114.5 (Cquat.), 61.9 (-), 52.4 (+), 38.5 (-). HRMS (EI-MS) calcd. for C26H23N2O4 
[M+H]+: 427.1652; found: 427.1662. IR (KBr) [cm-1]: ν = 3331, 3221, 2947, 1689, 1500, 1247. 
 
Methyl 4'-(2-((methylsulfonyl)oxy)ethyl)-3-(quinoline-2-carboxamido)-[1,1'-biphenyl]-4-
carboxylate 19.  
 
To a cold mixture of 18 (150 mg, 0.35 mmol) and TEA (0.12 mL, 0.7 mmol) in dry DCM, 
mesyl chloride (40.8 µL, 0.52 mmol) was added dropwise. The mixture was stirred at rt for 5h, 
saturated NaHCO3 solution was added and the organic layer was separated and dried over 
MgSO4. The compound was purified by flash chromatograpy (PE:AcOEt 1.5:1, Rf = 0.25). 
Yield 90%, white solid, mp. 184-186 oC dec. 1H NMR (CDCl3, 300 MHz,): δ= 13.33 (s, 1H, 
NHCO), 9.35 (d, 4J=1.7 Hz, 1H, ArH), 8.39-8.32 (m, 3H, ArH), 8.17 (d, 3J=8.3 Hz, 1H, ArH), 
7.90 (d, 3J=8.0 Hz, 1H, ArH), 7.86-7.79 (m, 1H, ArH), 7.72 (d, 3J=8.2 Hz, 2H, ArH), 7.69-7.62 
(m, 1H, ArH), 7.41-7.31 (m, 3H, ArH), 4.47 (t, 3J=6.8 Hz, 2H, CH2), 4.07 (s, 3H, OCH3), 3.12 
(t, 3J=6.8 Hz, 2H, CH2), 2.90 (s, 3H, OCH3). 13C NMR (CDCl3, 75 MHz) δ: 167.9 (C=O), 163.7 
(C=O), 150.1 (Cquat.), 146.6 (Cquat.), 146.3 (Cquat.), 141.2 (Cquat.), 138.6 (Cquat.), 137.7 (+), 
136.6 (Cquat.), 131.7 (+), 130.2 (+), 130.2 (+), 129.5 (+), 129.4 (Cquat.), 128.2 (+), 127.7 (+), 
127.6 (+), 121.2 (+), 118.8 (+), 115.2 (Cquat.), 70.0 (-), 52.4 (+), 37.4 (+), 35.3 (-). HRMS (EI-
MS) calcd. for C27H25N2O6S [M+H]+: 505.1428; found: 505.1442. IR (KBr) [cm-1]: ν = 3026, 
3221, 2929, 1697, 1672, 1500, 1251. 
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Methyl 4'-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-3-(quinoline-2-carboxamido)-[1,1'-
biphenyl]-4-carboxylate 20a.  
 
A mixture of 19 (700 mg, 1.38 mmol), 1,2,3,4-tetrahydroisoquinoline 10 (0.22 mL, 1.8 mmol) 
and DIPEA (0.48 mL, 2.76 mmol) in 25 mL of CH3CN was refluxed overnight. The solvent was 
evaporated, water was added and the compound was extracted with DCM. After purification by 
flash chromatograpy (CHCl3:MeOH 10:0.3, Rf = 0.23) 431 mg of a white solid was obtained. 
Yield 57%, mp. 98-100 oC dec. 1H NMR (CDCl3, 600 MHz): δ= 9.37 (d, 4J=1.8 Hz, 1H, ArH), 
8.37 (d, 3J=8.4 Hz, 1H, ArH), 8.32 (d, 3J=8.4 Hz, 1H, ArH), 8.28 (d, 3J=8.4 Hz, 1H, ArH), 8.12 
(d, 3J=8.2 Hz, 1H, ArH), 7.83 (d, 3J=8.1 Hz, 1H, ArH), 7.77 (t, 3J=7.6 Hz, 1H, ArH), 7.69 (d, 
3J=8.1 Hz, 2H, ArH), 7.59 (t, 3J=7.5 Hz, 1H, ArH), 7.36-7.33 (m, 3H, ArH), 7.16-7.10 (m, 3H, 
ArH), 7.06-7.04 (m, 1H, ArH), 4.03 (s, 3H, OCH3), 3.75 (s, 2H, CH2), 3.00-2.93 (m, 4H, 2 
CH2), 2.86-2.80 (m, 4H, 2 CH2). 13C NMR (CDCl3, 151 MHz) δ: 167.6 (C=O), 163.4 (C=O), 
149.8 (Cquat.), 146.4 (Cquat.), 146.3 (Cquat.), 141.0 (Cquat.), 140.5 (Cquat.), 137.4 (+), 137.2 
(Cquat.), 134.4 (Cquat.), 134.0 (Cquat.), 131.5 (+), 130.0 (+), 129.9 (+), 129.1 (+), 129.1 
(Cquat.), 128.5 (+), 127.9 (+), 127.4 (+), 127.4, 127.2 (+), 126.4 (+), 126.0 (+), 125.4 (+), 120.9 
(+), 118.6 (+), 118.5 (+), 114.7 (Cquat.), 59.8 (-), 55.8 (-), 52.1 (+), 50.7 (-), 33.4 (-), 28.9 (-). 
HRMS (EI-MS) calcd. for C35H31N3 [M+H]+: 542.2438; found: 542.2454. IR (KBr) [cm-1]: ν = 
2954, 1681, 1560, 1500, 1249. 
 
Methyl 4'-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-3-(quinoline-2-
carboxamido)-[1,1'-biphenyl]-4-carboxylate 20b.  
 
Compound 20b was obtained from compounds 19 and 11 following the same procedure 
described above. Yield 71%, white solid, mp. 126-128 oC dec., Rf = 0.25 (CHCl3:MeOH 
10:0.3). 1H NMR (CDCl3, 300 MHz): δ= 13.33 (s, 1H, NHCO), 9.35 (d, 4J=1.7 Hz, 1H, ArH), 
8.41-8.33 (m, 3H, ArH), 8.17 (d, 3J=8.3 Hz, 1H, ArH), 7.90 (d, 3J=8.1 Hz, 1H, ArH), 7.82 (ddd, 
3J=8.4, 3J=6.9, 4J=1.3 Hz, 1H, ArH), 7.73-7.62 (m, 3H, ArH), 7.39 (dd, 3J=8.4, 4J=1.8 Hz, 1H, 
ArH), 7.35 (d, 3J=8.2 Hz, 2H, ArH), 6.61 (s, 1H, ArH), 6.55 (s, 1H, ArH), 4.07 (s, 3H, OCH3), 
3.84 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.68 (s, 2H, CH2), 3.02-2.93 (m, 2H, CH2), 2.89-2.77 
(m, 6H, 3 CH2). 13C NMR (CDCl3, 151 MHz) δ: 167.8 (C=O), 163.6 (C=O), 150.0 (Cquat.), 
147.5 (Cquat.), 147.2 (Cquat.), 146.6 (Cquat.), 146.5 (Cquat.), 141.1 (Cquat.), 140.6 (Cquat.), 
137.6 (+), 137.5 (Cquat.), 131.6 (+), 130.2 (+), 130.1 (+), 129.3 (Cquat.), 129.2 (+), 128.1 (+), 
127.5 (+), 127.4 (+), 126.2 (Cquat.), 126.0 (Cquat.), 121.1 (+), 118.8 (+), 118.7 (+), 114.9 
(Cquat.), 111.3 (+), 109.4 (+), 59.8 (-), 55.8, 55.8, 55.5 (-), 52.3, 50.9 (-), 33.5 (-), 28.5 (-). 
HRMS (EI-MS) calcd. for C37H35N3NaO5 [M+Na]+: 624.2469; found: 624.2472. IR (KBr) [cm-
1]: ν = 2953, 1678, 1560, 1502, 1251, 771, 750. 
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Methyl 4'-(2-(6-methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquino 
lin-2(1H)-yl)ethyl)-3-(quinoline-2-carboxamido)-[1,1'-biphenyl]-4-carboxylate 20c.  
 
Compound 20c was obtained from compounds 19 and 13 following the same procedure 
described above. Yield 48%, white solid, mp. 109-111 oC dec., Rf = 0.27 (CHCl3:MeOH 
10:0.3). 1H NMR (CDCl3, 300 MHz): δ= 13.27 (s, 1H, NHCO), 9.32 (d, 4J=1.7 Hz, 1H, ArH), 
8.34-8.26 (m, 3H, ArH), 8.09 (d, 3J=8.3 Hz, 1H, ArH), 7.82 (d, 3J=8.2 Hz, 1H, ArH), 7.78-7.71 
(m, 1H, ArH), 7.65 (d, 3J=8.1 Hz, 2H, ArH), 7.60-7.53 (m, 1H, ArH), 7.36-7.27 (m, 3H, ArH), 
6.58 (s, 1H, ArH), 6.57 (s, 1H, ArH), 4.12 (t, 3J=5.2 Hz, 2H, CH2), 4.01 (s, 3H, OCH3), 3.83 (t, 
3J=4.9 Hz, 2H, CH2), 3.78 (s, 3H, OCH3), 3.73-3.69 (m, 2H, CH2), 3.67-3.60 (m, 6H, 3 CH2), 
3.51 (dd, 3J=5.9, 3J=3.4 Hz, 2H, CH2), 3.34 (s, 3H, OCH3), 2.96-2.90 (m, 2H, CH2), 2.86-2.72 
(m, 6H, 3 CH2). 13C NMR (CDCl3, 75 MHz) δ: 167.8 (C=O), 163.6 (C=O), 150.0 (Cquat.), 
148.2 (Cquat.), 146.6 (Cquat.), 146.5 (Cquat.), 146.4 (Cquat.), 141.1 (Cquat.), 140.7 (Cquat.), 
137.6 (+), 137.4 (Cquat.), 131.7 (+), 130.2 (+), 130.1 (+), 129.3 (Cquat.), 129.2 (+), 128.2 (+), 
127.6 (+), 127.4 (+), 126.8 (Cquat.), 126.4 (Cquat.), 121.1 (+), 118.8 (+), 118.7 (+), 114.9 
(Cquat.), 112.3 (+), 111.9 (+), 71.9 (-), 70.7 (-), 70.6 (-), 70.5 (-), 69.6 (-), 68.7 (-), 59.9 (-), 
59.0, 55.9, 55.6 (-), 52.3, 50.9 (-), 33.6 (-), 28.7 (-). HRMS (EI-MS) calcd. for C43H47N3NaO8 
[M+Na]+: 756.3255; found: 756.3258. IR (KBr) [cm-1]: ν = 3296, 2922, 1689, 1560, 1502, 
1251, 769. 
 
Methyl 4'-(2-(6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)ethyl)-3-(quinoline-2-carboxamido)-[1,1'-biphenyl]-4-carboxylate 20d.  
 
Compound 20d was obtained from compounds 19 and 14 following the same procedure 
described above. Yield 18%, sticky yellow oil solid, Rf = 0.25 (CHCl3:MeOH 100:1). 1H NMR 
(CDCl3, 600 MHz): δ= 13.32 (s, 1H, NHCO), 9.35 (d, 4J=1.8 Hz, 1H, ArH), 8.41-8.34 (m, 3H, 
ArH), 8.17 (d, 3J=8.3 Hz, 1H, ArH), 7.91 (d, 3J=7.9 Hz, 1H, ArH), 7.83 (ddd, 3J=8.3, 3J=6.9, 
4J=1.3 Hz, 1H, ArH), 7.69 (d, 3J=8.2 Hz, 2H, ArH), 7.67-7.64 (m, 1H, ArH), 7.40 (dd, 3J=8.3, 
4J=1.8 Hz, 1H, ArH), 7.35 (d, 3J=8.1 Hz, 2H, ArH), 6.66 (s, 1H, ArH), 6.61 (s, 1H, ArH), 4.15-
4.11 (m, 4H, 2 CH2), 4.07 (s, 3H, OCH3), 3.86-3.82 (m, 4H, 2 CH2), 3.74 (dd, 3J=5.8, 3J=3.8 
Hz, 4H, 2 CH2), 3.68-3.64 (m, 10H, 5 CH2), 3.55 (dd, 3J=5.6, 3J=3.9 Hz, 4H, 2 CH2), 3.37 (s, 
3H, OCH3), 3.37 (s, 3H, OCH3), 2.99-2.95 (m, 2H, CH2), 2.86-2.78 (m, 6H, 3 CH2). 13C NMR 
(CDCl3, 151 MHz) δ: 167.9, 163.6, 150.1, 147.5, 147.1, 146.7, 146.6, 141.1, 140.7, 137.6 (+), 
137.5, 131.6, 130.2 (+), 130.1 (+), 129.3, 129.2 (+), 128.2 (+), 127.6 (+), 127.4 (+), 127.1, 121.2 
(+), 118.8 (+), 118.8 (+), 115.0 (+), 115.0 (Cquat.), 113.3 (+), 71.9 (-), 70.7 (-), 70.6 (-), 70.5 (-
), 69.7 (-), 69.0 (-), 68.9 (-), 60.0 (-), 59.0 (+), 55.6 (-), 52.3 (+), 50.9 (-), 33.6 (-), 28.6 (-). 
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HRMS (EI-MS) calcd. for C49H59N3O11 [M]+2: 431.7069; found: 432.7075. IR (KBr) [cm-1]: ν = 
2872, 1683, 1502, 1103. 
 
Modulation of ABCB1 and ABCG2 was performed as decribed.20 
Stability Investigations in Mouse Plasma. Preparation of mouse plasma and determination of 
esterase activity: Blood of BL6 mice was collected by heart puncture in deep anesthesia using 
heparin-coated syringes. Samples were immediately centrifuged for 7 min at 7000 rpm 
(Eppendorf centrifuge 5415R, Eppendorf, Hamburg, Germany) and the supernatant was 
carefully removed. After pooling, the plasma was fractioned into small aliquots for long-term 
storage at -80 °C. The enzymatic activity of esterases in the plasma samples was measured 
spectrophotometrically. The coloured product o-nitrophenol, formed by enzymatic cleavage of 
the chromogenic substrate nitrophenyl butyrate was determined as a function of time. 
Absorbance was plotted against time, the linear slope at the beginning of the reaction was 
determined and used for the calculation of volume activity: 
 
஺ܸൌ
∆ܣ · ܸ
ݐ
ߝ · ݀ · ߥ  
 
The abbreviations of the present equation define the following parameters: VA=volume activity 
[U·mL-1] multiplied with 1000 for [U·L-1], ΔA=absorbance of o-nitrophenol at 414 nm, t=time 
[min], V=total volume [mL], εo-nitrophenol=3190 [L·mol-1·cm-1], d=path length [cm], ν=plasma 
volume [mL].  
The test compounds were dissolved in DMSO at a concentration of 3 mM. Subsequently, test 
compound stocks, mouse plasma, deproteinated plasma, culture medium and phosphate buffered 
saline were equilibrated on a Wealtec heat plate (Wealtec, Sparks, USA) to 37 °C for 
approximately 15 min. Thereafter, a 1:50 dilution of the substances with the corresponding 
medium was prepared in 1.5-mL polypropylene reaction vessels (Eppendorf, Hamburg, 
Germany). The samples were shortly vortexed and immediately incubated at 37 °C. After 
increasing periods of time, aliquots were taken, and the reaction was stopped by the addition of 
two parts of ice-cold acetonitrile. For quantitative precipitation of the denatured proteins, the 
samples were efficiently vortexed and stored at 4 °C for 30 min. Finally, samples were 
centrifuged for 5 min at 17000 g, using an Eppendorf MiniSpin plus centrifuge, and the 
supernatants were transferred into new plastic cups. For HPLC analysis the samples were 
further diluted (1:2) with acetonitrile and stored at -80 °C until the measurement. For HPLC 
analysis samples were unfrozen at room temperature and injected into the HPLC system 
(Waters, Eschborn, Germany). Analysis was accomplished by gradient elution with water 
containing TFA (0.05 %) and acetonitrile (0 min, 15 %; 25 min, 80 %; 26 min, 95 %; 36 min, 
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95 %; 37 min, 15 %; 45 min, 15 %), at a constant flow rate of 1.0 mL/min. The HPLC system 
was equipped with a Luna RP-18 (2), 3 μm, 150 mm x 4.6 mm column. Analysis was carried 
out via UV-detection at a wavelength of 210 nm.  
 
HPLC/MS analysis for the blank (mouse plasma, dotted lines) and for 15g (COPG228, solid 
line) after mouse plasma stability test. 
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3. Synthesis and Breast Cancer Resistance Protein (BCRP) Inhibitory 
Activity of New Multidrug Resistance Modulators Based on 
Tariquidar* 
 
A new class of potent and selective multidrug resistance modulators based on tariquidar is 
reported. The central core of the new compounds was synthesized via Sonogashira coupling and 
a palladium-copper mediated domino coupling-cyclization process. Sequential steps of 
acylation, deprotection, mesylation and nucleophylic substitution led to compounds 22a-h 
which were deprotected at the nitrogen of the indole core with TBAF. Compounds 22a-h and 
23a-h were evaluated for inhibition of the P-glycoprotein (ABCB1) and the Breast Cancer 
Resistance Protein (BRCP) determined in the calcein-AM and the Hoechst 33342 microplate 
assay, respectively. All compounds showed to be selective for ABCG2, however compounds 
23a-h are more active that their analogues 22a-h. The most promising compound is more potent 
that the most active ABCG2 inhibitor reported so far Ko143, and showed an IC50 value of 59 ± 
14 nM and a maximal inhibitory effect of 100%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________ 
* Patent and paper in preparation. All the synthesis and spectroscopical investigations (except compound 21) were 
done by Cristian Ochoa Puentes. Compound 21 was synthesized by Manuel Bause at the Institute of Organic 
Chemistry, University of Regensburg. Inhibition assays for ABCB1 and ABCG2 were performed by Stefanie Bauer 
at the Institute of Pharmacy, University of Regensburg 
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3.1 Introduction 
 
Cancer is one of the leading causes of death in the world. According with the International 
Agency for Research on Cancer (IARC), in 2008 about 12.7 million cancer cases and 7.6 
million cancer deaths were estimated to occurred worldwide1,2 and the number of cancer deaths 
is estimated to be 15.5 millions in 2030 due to population growth and adoption of cancer-
associated lifestyle like tobacco and alcohol use, physical inactivity and obesity. 
The increase in cancer incidence and mortality has motivated the development of prevention, 
screening and early detection programs as well as the development of new drugs and treatments 
to be used in chemotherapy. Although these strategies could reduce the mortality rates, a very 
important factor to be considered is the efficacy of the chemotherapy, which is influenced by 
different factors including the occurrence of drug-resistant tumor cells. The multi-drug 
resistance (MDR)3 is a phenomenon in which cancer cells develop resistance to a variety of non 
related chemotherapeutic drugs, and is known that altered cell membrane ABC transporters are 
involved in this resistance phenomenon. 
ABC transporters are large membrane-bound proteins with evolutionarily conserved structure-
function features.4 There are in total 48 known ABC transporters which are divided into seven 
distinct subfamilies of proteins, namely ABCA (12 members), ABCB (11 members), ABCC (12 
members), ABCD (4 members), ABCE (1 member), ABCF (3 members) and ABCG (5 
members).5 These proteins have the ability to transport a wide diversity of large hydrophobic or 
amphipatic molecules, various xenobiotics and endobiotics over biological barriers.6 However, 
in overexpressed membrane ABC transporters an increased drug efflux of chemotherapeutic 
agents is presented and thereby the intracellular drug level is reduced causing drug resistance.7 
 
From all the ABC transporters, P-glycoprotein (P-gp or ABCB1, ABCB subfamily), the 
multidrug resistance-associated proteins (MRPs, in the ABCC subfamily) and breast cancer 
resistance protein (BCRP or ABCG2, in the ABCG subfamily) are the best known extrusion 
pumps. These proteins have the same energy-dependent transport system which uses the energy 
of ATP hydrolysis as their energy source.7 
 
P-glycoprotein (ABCB1, P-gp), the first drug efflux pump found to contribute to multidrug 
resistance, is expressed in only a limited number of tissues with barrier function, including 
epithelia of the liver, kidney, small and large intestine and capillary endothelial cells in brain, 
ovary, and testis, and is able to pump out a broad range of cytotoxic drugs including 
anthracyclines, Vinca alkaloids, epipodophyllotoxins, and taxanes.8 The expression of the 
multidrug resistance-associated proteins (MRPs) is induced by cytotoxic drugs. Most of its 
members are involved in pharmacotherapy resistance and its preferred substrates are anionic 
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drugs (e.g. methotrexate) and neutral drugs conjugated to acidic ligands, such as glutathione 
(GSH), glucuronate, or sulfate.9 
Breast cancer resistance protein is a half transporter found in high levels in the placenta, liver, 
central nervous system, adrenal gland, prostate, testes, uterus, and breast, and in low levels in 
blood and blood brain barrier, gastrointestinal tract, lung, kidney and pancreas.10 The 
overexpression of this transporter confers resistance to a broad range of anticancer drugs like 
methotrexate, mitoxantrone, camptothecin derivatives, anthracyclines and flavopiridol.11 
 
One alternative to overcome the MDR in these transporters is to develop new compounds to be 
used in cancer treatment. However in some cases the new drugs also become substrates of the 
efflux pump, therefore the discovery of specific inhibitors of the drug-efflux activity is the most 
promising alternative to reverse the MDR phenomenon.9 P-glycoprotein inhibitors are well 
known due to the extensive research done with this transporter during the past two decades.12,13 
The first generation of P-gp inhibitors consists of drugs, not developed to reverse MDR, which 
have another pharmacological activity like verapamil, cyclosporine A and tamoxifen. The 
second generation of P-gp inhibitors is mainly composed of analogues of the first generation 
with improved potency, specificity and less toxicity, together with compounds with new 
structures. Some examples include dexverapamil, trans-flupentixol and valspodar. Finally, the 
third generation of P-gp inhibitors was developed with a more rational drug design approach 
and is expected to have a specific and potent interaction with the P-gp transporter without 
inhibiting other ABC family transporters.14 Biricodar (VX-710), tetrandrine, FG020326, S-
9788, elacridar (GF-120918), zosuquidar (LY-335979), laniquidar (R101933), tariquidar 
(XR9576, Figure 2)15 and its derivatives16 are some examples of these inhibitors (Figure 1). 
Based on the experience acquired with ABCB1, different approaches to develop ABCG2 
inhibitors have been explored. Fumitremorgin C was the first ABCG2 inhibitor described17 but 
its neurotoxic effects preclude its use in vivo, however some synthetic derivatives were 
obtained18 and its analogue Ko143 (Figure 1) was found to be nontoxic in vitro at useful 
concentrations and evinced no signs of toxicity in mice at high oral doses. This compound 
appears to be the most potent BCRP inhibitor known so far.19 Some other reported inhibitors 
include camptothecins derivatives,20 flavonoids,21,22 anti-HIV drugs,23 and tyrosine kinase 
inhibitors24,25 and also inhibitors of of P-gp or MRP1 such as elacridar, tariquidar (Figure 2) and 
biricodar (VX-710) (Figure 1). 
 
Recently, new ABCG2 inhibitors have been reported based on tariquidar.26,27 Several structural 
variations made on the basic structure led to one promising inhibitor in which no methoxy 
groups are attached to the benzamide core and the quinoline-3-carboxamide moiety was 
replaced by a 1-(4-nitrophenyl)urea fragment.27 
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Figure 1. Structures of zosuquidar (ABCB1 modulator), biricodar, elacridar (dual ABCB1 and 
ABCG2 modulators), Ko143 and lopinavir (ABCG2 modulators) 
 
During our studies on tariquidar based inhibitors16,28 we discovered that when the two methoxy 
groups attached to the benzamide were replaced by a carboxylic acid methyl ester and the 
hetarylcarboxamido residue was shifted to the meta-position a potent and highly selective 
ABCG2 modulator was obtained (UR-ME-22-1, Figure 2).29 In addition, the inclusion of a 
triethylenglycol ether group at the tetrahydroisoquinoline moiety, in order to increase the 
solubility, led to a compound (UR-COP78) comparable in potency to UR-ME-22-1 but 
considerably more efficient (max. inhibition 88% rel. to fumitremorgin C, 100%) (Figure 2).30 
Further stability studies performed in plasma mouse revealed that these compounds are not 
stable enough and the amide bond bearing the phenethyl tetrahydroisoquinoline fragment is 
hydrolyzed.31 These previous results prompted us to design, synthesize and evaluate the ABCG2 
inhibitory activity of a new class of tariquidar like derivatives. The design of the new 
compounds was based on the structural characteristics that lead to the best modulators UR-ME-
22-1 and UR-COP78 (dashed squares, Figure 2). In addition, we introduced an indole core 
linked to the anthranilamide fragment in order to improve the stability of the compounds (Figure 
2, target compounds). 
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Figure 2. Structures of tariquidar (ABCB1 preferring modulator), the selective ABCG2 
modulators UR-ME22-1 and UR-COP78 and the target compounds 
 
3.2 Results and Discussion 
 
Synthesis. As shown in Figure 2, the structure of the target compounds is composed from four 
fragments: the tetrahydroisoquinoline moiety (fragment A), the indole motif (fragment B), the 
methyl aminobenzoate moiety (fragment C) and the quinoline-2-carbonyl core (fragment D) 
(dashed ovals, Figure 2). First our synthetic efforts focussed on the indole core. There are 
different methodologies for the synthesis of indole derivatives;32-35 and we sought a strategy that 
would allow us to obtain the indole substituted at the position 2 with the methyl aminobenzoate 
core (fragments B and C) in a few sequential steps. A Sonogashira coupling followed by a 
palladium-copper mediated domino coupling-cyclization process36-39 was envisaged as good 
pathway to obtain this motif. 
According with our retrosynthetic approach (Scheme 1), an ortho-iodoaniline derivative with a 
suitable functional group that allow a further modification to attach the fragment A of the 
molecule, and a phenylacetylene derivative are the coupling partners needed to synthesize the 
desired indole. 
 
 
Scheme 1. Retrosynthetic approach for the synthesis of the target compounds. 
 
The ortho-iodoaniline derivative was obtained from ethyl 2-(4-amino-3-iodophenyl)acetate 140 
by sequential steps of reduction with BH3.THF, protection of the obtained amino alcohol 2 with 
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TBDMS-Cl and mesylation with MsCl to give 5. In order to have a set of diverse structures, 
compound 6 was synthesized in similar fashion starting from 441 (Scheme 2). 
 
 
 
Scheme 2. Synthesis of the ortho-iodoaniline derivatives 5 and 6. Reagents and conditions: (a) 
BH3.THF, THF, rt. (b) Imidazole, TBDMS-Cl, DCM, rt. (c) MsCl, Py, rt. 
 
Phenylacetylene derivative 9 was synthesized from commercially available methyl 2-amino-4-
bromobenzoate 7 and trimethylsilylacetylene under standard Sonogashira conditions. The 
trimethylsilyl group was removed with TBAF (Scheme 3). 
The so obtained aryl alkynes were converted into indoles 10 and 11 by reacting 9 with 5 or 6 in 
a palladium-copper mediated domino coupling-cyclization process (Scheme 3). 
 
 
 
Scheme 3. Synthesis of indoles 10 and 11. Reaction conditions: (a) Methyl 2-amino-4-
bromobenzoate 7, trimethylsilylacetylene, CuI, Pd(PPh3)2Cl2, THF/TEA 2/1, 60oC. (b) TBAF, 
THF, rt. (c) Pd(PPh3)2Cl2, CuI, DMF/TEA 2/1, 90oC. 
 
Next, fragment D of the target structure was attached to the indoles 10 and 11. Acylation of 10 
and 11 with freshly prepared quinoline-2-carbonyl chloride, obtained from commercially 
available quinoline-2-carboxylic acid, led to compounds 12 and 13 which were converted into 
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16 and 17 by deprotection and mesylation, in order to have a structure that allows the 
attachment of fragment A (Scheme 4). 
Finally, fragment A was coupled to the structure using commercially available 1,2,3,4-
tetrahydroisoquinoline 18, 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 19, 6-methoxy-7-(2-
(2-(2-methoxyethoxy)ethoxy)ethoxy)-1,2,3,4-tetrahydroisoquinoline 20 previously reported30 
and 6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-1,2,3,4-tetrahydroisoquinoline 2142 
synthesized analogously than 20 starting from 1,2,3,4-tetrahydroisoquinoline-6,7-diol (Scheme 
4). 
Several derivatives were prepared by reaction of compounds 22a-h with TBAF to remove the 
mesyl group at the nitrogen atom of the indole core affording compounds 23a-h (Scheme 4). 
 
 
Scheme 4. Synthesis of target compounds 22a-h and 23a-h. Reaction conditions: (a) Quinoline-
2-carbonyl chloride, TEA, DCM, 40oC. (b) TBAF, THF, rt. (c) MsCl, TEA, DCM, rt. (d) 
Tetrahydroisoquinolines 18-21, DIPEA, CH3CN, reflux. (e) TBAF, THF, rt. 
 
Inhibition of ABCB1 and ABCG2 transporters. The synthesized compounds 22a-h and 23a-
h together with the reference compounds Ko143, tariquidar and elacridar were investigated for 
their inhibition of ABCB1 and ABCG2 in a calcein-AM (ABCB1)43 and a Hoechst 33342 
(ABCG2) microplate assay31 using ABCB1-overexpressing Kb-V1 and ABCG2-overexpressing 
MCF-7/Topo cells (Table 1).  
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Table 1. Inhibition of ABCB1 and ABCG2 transporters by reference compounds (Ko143, 
tariquidar and elacridar) and the derivatives 22a–h, and 23a–h determined in the calcein-AM 
(ABCB1) and Hoechst 33342 (ABCG2) microplate assay unless otherwise indicated 
Compd ABCB1 ABCG2 
IC50 (nM) IC50 (nM) Imaxa (%) 
Ko143 inactiveb 117 ± 53 103 ± 7c 
Tariquidar 223 ± 8 526 ± 85 69c 
Elacridar 193 ± 18 127 ± 41 63c 
UR-COP78 >50000 130 ± 29 88d 
22a >150000 947 ± 121 45 
22b n.d. 2090 ± 270 22 
22c 2010 ± 510 992 ± 89 45 
22d n.d. 458 ± 35 63 
22e n.d. 504 ± 40 56 
22f n.d. 629 ± 26 38 
22g n.d. n.d. n.d. 
22h 1580 ± 80 1020 ± 70 50 
23a >150000 374 ± 27 103 
23b >100000 350 ± 35 99 
23c >100000 159 ± 24 99 
23d 7480 ± 790 412 ± 24 99 
23e n.d. 59 ± 14 100 
23f 1620 ± 230 140 ± 33 99 
23g n.d. n.d. n.d. 
23h n.d. 136 ± 48 107 
a Relative to Fumitremorgin C (100%). b 1.6% inhibition at 10 µM. 
c ref 31. d ref 30. n.d = not determined 
 
All tested compounds showed no inhibitory activity over ABCB1 transporter, whereas the 
ABCG2 inhibitory activity is in the nanomolar range (except compound 22b and 22h). In the 
first series of compounds, in which a mesyl group is attached at the nitrogen of the indole core, 
two derivatives (22d, 22e) have similar IC50 values compared to tariquidar but are slightly less 
effective (63% and 56% vs 69%) 
 
The second set of compounds, with an unprotected N-H group at the indole core, is more 
effective that the analogues having the mesyl group at the same position. This result suggests 
that the unprotected N-H group is fundamental for the activity. Compounds 23a-f and 23h are 
more potent and efficient than tariquidar (lower IC50 values and higher maximal inhibitory 
effect) at ABCG2 inhibition. With respect to elacridar and UR-COP78, analogues 23a,b and 
23d have IC50 values approximately 2.8 and 3.2 fold higher, but the maximal inhibitory effect is 
superior (103% and 99% vs 63% and 88%). Compounds 23c, 23f and 23h have IC50 values in 
the same range but are more efficient (Imax of 99%, 100% and 107%, respectively) (Figure 3). 
Compared to the most potent and selective ABCG2 inhibitor reported so far Ko143,19 
compounds 23a,b and 23d have IC50 values 3 and 3.5 fold higher and a comparable maximal 
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inhibitory effect. More interesting, analogues 23c,f and 23h have about the same IC50 values and 
maximal inhibitory effect. 
The most potent and promising compound, however, is 23e, which has an improved potency 
compared to Ko143,(59 ± 14 nM vs 117 ± 53 nM) and a very close maximal inhibitory effect 
(100% vs 103%). 
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Figure 3. Concentration dependent inhibition of the ABCG2 transporter in MCF-7/Topo cells 
(Hoechst 33342 assay) by tariquidar (filled black circles), elacridar (filled black triangles) and 
the tariquidar analogues UR-COP78 (filled red circles), 23f (COPG251; filled blue circles), 23h 
(COPG260; filled green circles), 23c (COPG268; filled pink circles) and 23e (COPG269; filled 
gray circles). The maximal inhibition is expressed as % relative to the maximum inhibition of 
ABCG2 by fumitremorgin C (at a concentration of 10 µM). 
 
In order to evaluate the biological stability of the synthesized analogues, compound 23f, was 
selected for a stability test in mouse plasma.31 In this test, the compound and mouse plasma 
were incubated at 37 °C and after increasing periods of time, aliquots were taken, the reaction 
was stopped and the protein was removed. Analysis of the sample by HPLC showed that the 
compound is stable after one hour and after 24 hours around 50% of the compound is 
degradated. HPLC/MS analysis confirmed that the fragments obtained correspond to the 
enzymatic hydrolysis of the methyl ester located at the anthranilic ring.  
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3.3 Conclusion 
 
A new class of potent and selective multidrug resistance modulators derived from tariquidar was 
synthesized via Sonogashira coupling and a palladium-copper mediated domino coupling-
cyclization process. All tested compounds showed no inhibitory activity over ABCB1 
transporter, whereas the ABCG2 inhibitory activity is in the nanomolar range, except for 
compound 22b and 22h. 
The most potent and promising compound, 23e, has a lower IC50 value and a very close 
maximal inhibitory effect (59 ± 33 nM, Imax 100%) compared to the most potent and selective 
ABCG2 inhibitor reported so far Ko143, (117 ± 53, Imax 103 ± 7%). 
The selectivity, the increased activity and the biological stability of derivatives 23e,f and 23h, 
show that these compounds are good candidates for in vivo studies in order to overcome drug 
resistance of tumor cells associated to ABCG2 transporters. 
 
3.4 Experimental Section 
 
General. Commercial reagents and starting materials were purchased from Aldrich, Fluka, or 
Apollo Scientific and used without further purification. Compounds 1, 4 and PdCl2(PPh3)2 were 
prepared by reported methods. Flash chromatography was performed on silica gel (Merck silica 
gel Si 60 40-63 μm); products were detected by TLC on alumina plates coated with silica gel 
(Merck silica gel 60 F254, thickness 0.2 mm) and visualized by UV light (λ ) 254 nm). Melting 
points were determined with an OptiMelt MPA100 apparatus and are uncorrected. NMR spectra 
were recorded with Bruker Avance 300 (1H: 300.1 MHz; 13C: 75.5 MHz; T = 300 K), Bruker 
Avance 400 (1H: 400.1 MHz; 13C: 100.6 MHz; T = 300 K), and Bruker Avance 600 (1H: 600.1 
MHz; 13C: 150.1 MHz; T = 300 K) instruments. Chemical shifts are reported in δ/ppm relative 
to external standards and coupling constants J are given in Hz. Abbreviations for the 
characterization of the signals: s = singlet, d = doublet, t = triplet, m = multiplet, bs = broad 
singlet, dd = double doublet. The relative numbers of protons is determined by integration. Error 
of reported values: chemical shift 0.01 ppm (1H NMR), 0.1 ppm (13C NMR), coupling constant 
0.1 Hz. The used solvent for each spectrum is reported. Mass spectra were recorded with 
Finnigan MAT TSQ 7000 (ESI) and Finnigan MAT 90 (HRMS), and the IR spectra with a Bio-
Rad FT-IR-FTS 155 spectrometer. 
 
2-(4-Amino-3-iodophenyl)ethanol 2.  
 
Ethyl 2-(4-amino-3-iodophenyl)acetate 140 (100 mg, 0.32 mmol) was dissolved in dry THF, the 
solution was cooled in an ice bath and BH3.THF complex (0.97 mL, 0.97 mmol, 3 equiv) was 
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added dropwise. After the addition, the reaction was stirred at rt during 3 h and quenched with 
MeOH, diluted with water and extracted with AcOEt. The organic layer was washed with brine 
and dried over MgSO4. After evaporating the solvent, the compound was purified by 
recrystalization from PE:AcOEt 1:1. Yield 77%, white solid, mp. 81.4-82.0oC. 1H NMR 
(MeOD, 300 MHz): δ= 7.47 (d, 4J=1.9 Hz, 1H, ArH), 6.98 (dd, 3J=8.1, 4J=2.0 Hz, 1H, ArH), 
6.73 (d, 3J=8.1 Hz, 1H, ArH), 3.65 (t, 3J=7.0 Hz, 2H, CH2), 2.64 (t, 3J=7.0 Hz, 2H, CH2). 13C 
NMR (MeOD, 75 MHz): δ= 147.4 (Cquat,), 140.1 (+), 131.6 (Cquat,), 131.0 (+), 116.1 (+), 84.6 
(Cquat,), 64.3 (–), 38.8 (–). HRMS (EI-MS) calcd. for C8H10INO [MH]+: 262.9807; found: 
262.9809. IR (KBr) [cm-1]: ν = 3372, 3267, 2947, 2860, 1601, 1495, 665, 584. 
 
4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-2-iodoaniline 3.  
 
Imidazole (140 mg, 2.09 mmol, 1.1 equiv) was added to a mixture of 2-(4-amino-3-
iodophenyl)ethanol 2 (500 mg, 1.9 mmol, 1 equiv) and TBDMS -Cl (310 mg, 2.09 mmol, 1.1 
equiv) in 10 mL of dry DCM. The reaction was stirred at rt for 4 h, water was added and the 
organic phase was separated, wahed with brine and dried over MgSO4. After evaporating the 
solvent, the compound was purified by flash chromatography (PE:AcOEt 10:1, Rf = 0.22). Yield 
99%, light yellow solid, mp. 81.4-82.0oC. 1H NMR (CDCl3, 300 MHz): δ= 7.51 (d, 4J=1.7 Hz, 
1H, ArH), 6.98 (dd, 3J=8.1, 4J=1.8 Hz, 1H, ArH), 6.67 (d, 3J=8.1 Hz, 1H, ArH), 3.98 (s, 2H, 
NH2), 3.73 (t, 3J=6.9 Hz, 2H, CH2), 2.67 (t, 3J=6.9 Hz, 2H, CH2), 0.89 (s, 9H, 3 CH3), -0.00 (s, 
6H, 2 CH3). 13C NMR (CDCl3, 75 MHz): δ= 144.9 (Cquat,), 139.3 (+), 131.0 (Cquat,), 130.1 (+), 
114.5 (+), 84.1 (Cquat,), 64.5 (–), 38.0 (–), 25.9 (+), 18.3 (Cquat,), -5.3 (+). HRMS (EI-MS) calcd. 
for C14H25INOSi [M+H]+: 378.0745; found: 378.0750. IR (KBr) [cm-1]: ν = 3448, 3207, 2951, 
2856, 1616, 1498, 665. 
 
General procedure for the preparation of the methanesulfonamides 5 and 6. 
Methanesulfonyl chloride (0.36 mmol) was added dropwise to a solution of the aromatic amines 
3 or 441 (0.36 mmol) in 5 mL of pyridine at 0oC. After the addition, the reaction was stirred at 
room temperature overnight. Water and AcOEt were added and the organic phase separated, 
washed with 1 N HCl, 1 N NaHCO3 and dried over MgSO4. After evaporating the solvent, the 
compound was recristalized from PE:DCM 1:1 (compound 5) or used without any further 
purification (compound 6). 
 
N-(4-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-2-iodophenyl)methanesulfonamide 5.  
 
Yield 83%, viscous orange oil. 1H NMR (CDCl3, 300 MHz): δ= 7.75 (d, 4J=1.8 Hz, 1H, ArH), 
7.58 (d, 3J=8.3 Hz, 1H, ArH), 7.25 (dd, 3J=8.3, 4J=1.5 Hz, 1H, ArH), 6.62 (s, 1H, NH), 3.82 (t, 
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3J=6.4 Hz, 2H, CH2), 3.01 (s, 3H, CH3), 2.78 (t, 3J=6.4 Hz, 2H, CH2), 0.89 (s, 9H, 3 CH3), -0.00 
(s, 6H, 2 CH3). 13C NMR (CDCl3, 75 MHz) δ 140.0 (+), 139.5 (Cquat,), 135.6 (Cquat,), 130.7 (+), 
122.8 (+), 92.5 (Cquat,), 63.7 (–), 39.9 (+), 38.1 (–), 25.8 (+), 18.2 (Cquat,), -5.4 (+). HRMS (EI-
MS) calcd. for C15H27INO3SSi [M+H]+: 456.0520; found: 456.0513. IR (KBr) [cm-1]: ν =2926, 
2856, 1332, 1161, 632. 
 
N-(4-(((tert-Butyldimethylsilyl)oxy)methyl)-2-iodophenyl)methanesulfonamide 6.  
 
Yield 80%, white solid, mp. 100.3-101.8oC, 1H NMR (CDCl3, 300 MHz): δ= 7.81-7.78 (m, 1H, 
ArH), 7.59 (d, 3J=8.3 Hz, 1H, ArH), 7.31 (dd, 3J=8.4, 4J=1.6 Hz, 1H, ArH), 6.57 (s, 1H, NH), 
4.67 (s, 2H, CH2), 2.99 (s, 3H, CH3), 0.94 (s, 9H, 3 CH3), 0.11 (s, 6H, 2 CH3). 13C NMR 
(CDCl3, 75 MHz) δ 141.1 (Cquat,), 136.8 (+), 136.1 (Cquat,), 127.5 (+), 122.6 (+), 92.4 (Cquat,), 
63.4 (–), 40.0 (+), 25.9 (+), 18.4 (Cquat,), -5.2 (+). HRMS (EI-MS) calcd. for C14H24INO3SSi 
[MH]+: 441.0291; found: 441.0290. IR (KBr) [cm-1]: ν = 3273, 2953, 1327, 1149, 1089, 775. 
 
Methyl 2-amino-4-((trimethylsilyl)ethynyl)benzoate 8  
 
A mixture of methyl 2-amino-4-bromobenzoate 7 (100 mg, 0.43 mmol), trimethylsilylacetylene 
(73µL, 0.52 mmol, 1.2 equiv.), CuI (8.1 mg, 430 µmol, 10% mol) and Pd(PPh3)2Cl2 (15 mg, 
21.5 µmol, 5%mol) in 5 mL of THF/TEA 2/1 was stirred and heated at 60 oC for 6 h. Water and 
DCM were added, the organic layer separated and washed with 1N HCl, 1N NaHCO3, brine and 
dried over MgSO4. The solvent was evaporated and the compound was purified by flash 
chromatography PE:AcOEt 10:1. Yield 73%, Yellow solid, mp. 69-73.1oC, Rf = 0.27. 1H NMR 
(CDCl3, 300 MHz): δ= 7.72 (d, 3J=8.3 Hz, 1H, ArH), 6.73 (d, 4J=1.4 Hz, 1H, ArH), 6.67 (dd, 
3J=8.3, 4J=1.5 Hz, 1H, ArH), 5.68 (s, 2H, NH2), 3.80 (s, 3H, OCH3), 0.20 (s, 9H, 3 CH3). 13C 
NMR (CDCl3, 75 MHz): δ= 168.2 (C=O,), 150.1 (Cquat,), 131.2 (+), 128.6 (Cquat,), 119.9 (+), 
119.7 (+), 110.6 (Cquat,), 104.5 (Cquat,), 96.5 (Cquat,), 51.7 (+), -0.01 (+). MS (CI-MS NH3): m/z 
(%)= 247.1 (75) [MH]+˙. IR (KBr) [cm-1]: ν = 3460, 3354, 2949, 2160, 1689, 1244, 837, 758. 
 
Methyl 2-amino-4-ethynylbenzoate 9.  
 
A solution of methyl 2-amino-4-((trimethylsilyl)ethynyl)benzoate 8 (77 mg, 0.31 mmol) in 5 
mL THF was stirred and cooled in an ice bath. TBAF (0.31 mL, 0.31 mmol, 1M in THF) was 
added and the reaction was stirred for 10 min. The solvent was evaporated, saturated NH4Cl 
solution was added and the compound was extracted with DCM. The organic layer was 
separated and dried over MgSO4. The solvent was evaporated and the compound was purified 
by flash chromatography PE:AcOEt 10:1. Yield 74%, Yellow solid, mp. 75.1-76.8oC, Rf = 0.22. 
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1H NMR (CDCl3, 300 MHz): δ= 7.82 (d, 3J=8.3 Hz, 1H, ArH), 6.81 (d, 4J=1.5 Hz, 1H, ArH), 
6.76 (dd, 3J=8.2, 4J=1.5 Hz, 1H, ArH), 5.77 (s, 2H, NH2), 3.88 (s, 3H, OCH3), 3.16 (s, 1H). 13C 
NMR (CDCl3, 75 MHz): δ= 168.0 (C=O), 149.9 (Cquat,), 131.2 (+), 127.5 (Cquat,), 120.0 (+), 
119.7 (+), 110.8 (Cquat,), 83.0 (Cquat,), 79.0 (+), 51.6 (+). MS (EI-MS): m/z (%)= 175.1 (100) 
[MH]+˙. IR (KBr) [cm-1]: ν = 3479, 3375, 3244, 2949, 1689, 1244, 1099, 769. 
 
General procedure for the synthesis of compounds 10 and 11.  
 
A mixture of methyl 2-amino-4-ethynylbenzoate 9 (0.57 mmol), Methanesulfonamides 5 or 6 
(0.57 mmol), CuI (10.8 mg, 57 µmol, 10% mol) and Pd(PPh3)2Cl2 (20 mg, 28.5 µmol, 5%mol) 
in 5 mL of DMF/TEA 2/1 was stirred and heated at 90oC for 24 h. Water was added and the 
compound was extracted with AcOEt. The organic layer was dried over MgSO4 and the solvent 
evaporated. The compound was purified by flash chromatography PE:AcOEt 10:3. 
 
Methyl 2-amino-4-(5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-(methylsulfonyl)-1H-indol-2-
yl)benzoate 10.  
 
Yield 54%, Yellow solid, mp. 132-134oC, Rf = 0.36. 1H NMR (CDCl3, 300 MHz): δ= 8.01 (d, 
3J=8.5 Hz, 1H, ArH), 7.90 (d, 3J=8.1 Hz, 1H, ArH), 7.44 (d, 4J=1.0 Hz, 1H, ArH), 7.26 (dd, 
3J=8.9, 4J=1.9 Hz, 1H, ArH), 6.91-6.84 (m, 2H, ArH), 6.73 (s, 1H, ArH), 5.83 (bs, 2H, NH2), 
3.91-3.83 (m, 5H, OCH3, CH2), 2.94 (t, 3J=6.9 Hz, 2H, CH2), 2.70 (s, 3H, SO2CH3), 0.89 (s, 9H, 
3 CH3), 0.00 (s, 6H, 2 CH3). 13C NMR (CDCl3, 75 MHz) δ: 168.3 (C=O), 149.7 (Cquat,), 141.4 
(Cquat,), 137.5 (Cquat,), 137.0 (Cquat,), 136.0 (Cquat,), 130.5 (+), 130.4 (Cquat,), 126.9 (+), 121.5 (+), 
118.1 (+), 117.9 (+), 115.6 (+), 113.8 (+), 110.7 (Cquat,), 64.6 (–), 51.6 (+), 39.3 (–), 38.7 (+), 
25.9 (+), 18.3 (Cquat,), -5.3 (+). HRMS (EI-MS) calcd. for C25H35N2O5SSi [M+H]+: 503.2030; 
found: 503.2035. IR (KBr) [cm-1]: ν = 3495, 3379, 2951, 2854, 1689, 773. 
 
Methyl 2-amino-4-(5-(((tert-butyldimethylsilyl)oxy)methyl)-1-(methylsulfonyl)-1H-indol-2-
yl)benzoate 11.  
 
Yield 69%, Yellow solid, mp. 112-114.8oC, Rf = 0.29. 1H NMR (CDCl3, 300 MHz): δ= 8.03 (d, 
3J=8.6 Hz, 1H, ArH), 7.87 (d, 3J=8.2 Hz, 1H, ArH), 7.54 (d, 4J=0.8 Hz, 1H, ArH), 7.31 (dd, 
3J=8.6, 4J=1.6 Hz, 1H, ArH), 6.87-6.80 (m, 2H, ArH), 6.73 (s, 1H, ArH), 5.49 (bs, 2H, NH2), 
4.83 (s, 2H, CH2), 3.86 (s, 3H, OCH3), 2.69 (s, 3H, SO2CH3), 0.95 (s, 9H, 3 OCH3), 0.12 (s, 6H, 
2 CH3). 13C NMR (CDCl3, 75 MHz) δ 168.3 (C=O), 149.6 (Cquat,), 141.5 (Cquat,), 138.2 (Cquat,), 
137.5 (Cquat,), 137.4 (Cquat,), 130.5 (+), 130.3 (Cquat,), 123.9 (+), 118.6 (+), 118.2 (+), 117.9 (+), 
115.7 (+), 113.9 (+), 110.7, 64.8 (–), 51.6 (+), 38.9 (+), 26.0 (+), 18.4 (Cquat,), -5.1 (+). MS (EI-
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MS): m/z (%)= 530 (100) [M+NH4]+, 489 (10) [MH]+. IR (KBr) [cm-1]: ν = 3496, 3381, 2953, 
2858, 1678 775. 
 
General procedure for the preparation of compounds 12 and 13. To a mixture of 10 or 11 
(0.38 mmol) and TEA (1.66 mmol, 3 equiv.) in dry DCM, quinoline-2-carbonyl chloride (0.45 
mmol, 1.2 equiv.) was added. The mixture was stirred and heated at 40oC overnight. 1N HCl 
was added and the compound was extracted with DCM, washed with 1N NaHCO3, brine and 
dried over MgSO4. The solvent was evaporated and the compound was purified by flash 
chromatography PE:AcOEt 10:3. 
 
Methyl 4-(5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-1-(methylsulfonyl)-1H-indol-2-yl)-2-
(quinoline-2-carboxamido)benzoate 12.  
 
Yield 92%, Yellow solid, mp. 81-83oC, Rf = 0.45. 1H NMR (CDCl3, 300 MHz): δ= 13.39 (s, 
1H, NHCO), 9.30 (d, 4J=1.6 Hz, 1H, ArH), 8.38-8.33 (m, 3H, ArH), 8.17 (d, 3J=8.3 Hz, 1H, 
ArH), 8.02 (d, 3J=8.5 Hz, 1H, ArH), 7.90 (d, 3J=8.2 Hz, 1H, ArH), 7.83 (ddd, 3J=8.4, 3J=6.9, 
4J=1.4 Hz, 1H, ArH), 7.69-7.62 (m, 1H, ArH), 7.46 (d, 4J=1.1 Hz, 1H, ArH), 7.41 (dd, 3J=8.3, 
4J=1.7 Hz, 1H, ArH), 7.27 (dd, 3J=8.5, 4J=1.7 Hz, 1H, ArH), 6.89 (s, 1H, ArH), 4.08 (s, 3H, 
OCH3), 3.88 (t, 3J=6.8 Hz, 2H, CH2), 2.95 (t, 3J=6.8 Hz, 2H, CH2), 2.84 (s, 3H, SO2CH3), 0.89 
(s, 9H, 3 CH3), 0.00 (s, 6H, 2 CH3). 13C NMR (CDCl3, 75 MHz): δ 167.7 (C=O), 163.8 (C=O), 
149.9 (Cquat,), 146.6 (Cquat,), 141.0 (Cquat,), 140.4 (Cquat,), 138.0 (Cquat,), 137.7 (+), 137.1 (Cquat,), 
136.0 (Cquat,), 130.4 (Cquat,), 130.3 (+), 130.3 (+), 130.2 (+), 129.4 (Cquat,), 128.3 (+), 127.6 (+), 
127.1 (+), 125.3 (+), 121.6 (+), 120.6 (+), 118.8 (+), 116.1 (Cquat,), 115.5 (+), 114.5 (+), 64.6 (–), 
52.5 (+), 39.3 (–), 39.2 (+), 25.9 (+), 18.3 (Cquat,), -5.3 (+). HRMS (EI-MS) calcd. for 
C35H40N3O6SSi [M+H]+: 658.2402; found: 658.2402. IR (KBr) [cm-1]: ν = 2953, 2856, 1685, 
771. 
 
Methyl 4-(5-(((tert-butyldimethylsilyl)oxy)methyl)-1-(methylsulfonyl)-1H-indol-2-yl)-2-
(quinoline-2-carboxamido)benzoate 13.  
 
Yield 76%, Yellow solid, mp. 165-167oC, Rf = 0.50. 1H NMR (CDCl3, 300 MHz): δ= 13.34 (s, 
1H, NHCO), 9.25 (d, 4J=1.6 Hz, 1H, ArH), 8.34-8.29 (m, 3H, ArH), 8.13 (d, 3J=8.3 Hz, 1H, 
ArH), 8.01 (d, 3J=8.6 Hz, 1H, ArH), 7.87 (d, 3J=8.1 Hz, 1H, ArH), 7.79 (ddd, 3J=8.4, 3J=6.9, 
4J=1.3 Hz, 1H, ArH), 7.65-7.59 (m, 1H, ArH), 7.54 (s, 1H, ArH), 7.37 (dd, 3J=8.3, 4J=1.7 Hz, 
1H, ArH), 7.31 (dd, 3J=8.6, 4J=1.4 Hz, 1H, ArH), 6.87 (s, 1H, ArH), 4.82 (s, 2H, CH2), 4.03 (s, 
3H, OCH3), 2.81 (s, 3H, SO2CH3), 0.93 (s, 9H, 3 CH3), 0.09 (s, 6H, 2 CH3). 13C NMR (CDCl3, 
75 MHz) δ: 167.7 (C=O), 163.8 (C=O), 149.9 (Cquat,), 146.6 (Cquat,), 141.1 (Cquat,), 140.4 (Cquat,), 
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138.2 (Cquat,), 137.9 (Cquat,), 137.7 (+), 137.5 (Cquat,), 130.3 (+), 130.3 (+), 130.2 (+), 129.4 
(Cquat,), 128.3 (+), 127.6 (+), 125.3 (+), 124.0 (+), 120.6 (+), 118.8 (+), 118.7 (+), 116.2 (Cquat,), 
115.6 (+), 114.7 (+), 64.9 (–), 52.5 (+), 39.4 (+), 26.0 (+), 18.4 (Cquat,), -5.1 (+). HRMS (EI-MS) 
calcd. for C34H37N3NaO6SSi [M+Na]+: 666.2065; found: 666.2066. IR (KBr) [cm-1]: ν = 2949, 
2852, 1705, 1676, 767. 
 
Synthesis of compounds 14 and 15. General procedure. A solution of 12 or 13 (0.15 mmol) 
in 5 mL THF was stirred and cooled in an ice bath. TBAF (0.15 mmol, 1M in THF) was added 
and the reaction was stirred for 10 min. The solvent was evaporated, saturated NH4Cl solution 
was added and the compound was extracted with DCM. The organic layer was separated and 
dried over MgSO4. The solvent was evaporated and the compound was purified by flash 
chromatography PE:AcOEt 1:1.5 
 
Methyl 4-(5-(2-hydroxyethyl)-1-(methylsulfonyl)-1H-indol-2-yl)-2-(quinoline-2-carbox 
amido)benzoate 14.  
 
Yield 61%, Yellow solid, mp. 198-200oC, Rf = 0.32. 1H NMR (CDCl3, 300 MHz): δ= 13.38 (s, 
1H, NHCO), 9.28 (d, 4J=1.6 Hz, 1H, ArH), 8.39-8.32 (m, 3H, ArH), 8.17 (d, 3J=8.3 Hz, 1H, 
ArH), 8.03 (d, 3J=8.5 Hz, 1H, ArH), 7.91 (d, 3J=8.1 Hz, 1H, ArH), 7.83 (ddd, 3J=8.4, 3J=7.0, 
4J=1.3 Hz, 1H, ArH), 7.70-7.62 (m, 1H, ArH), 7.47 (s, 1H, ArH), 7.39 (dd, 3J=8.3, 4J=1.7 Hz, 
1H, ArH), 7.29-7.24 (m, 1H, ArH), 6.86 (s, 1H, ArH), 4.08 (s, 3H, OCH3), 3.93 (t, 3J=6.5 Hz, 
2H, CH2), 2.99 (t, 3J=6.5 Hz, 2H, CH2), 2.89 (s, 3H, SO2CH3). 13C NMR (CDCl3, 75 MHz) δ: 
167.7 (C=O), 163.8 (C=O), 149.9 (Cquat,), 146.6 (Cquat,), 141.1 (Cquat,), 140.3 (Cquat,), 137.9 
(Cquat,), 137.7 (+), 137.1 (Cquat,), 135.1 (Cquat,), 130.6 (Cquat,), 130.4 (+), 130.3 (+), 130.2 (+), 
129.4 (Cquat,), 128.3 (+), 127.6 (+), 126.6 (+), 125.3 (+), 121.5 (+), 120.7 (+), 118.8 (+), 116.2 
(Cquat,), 115.8 (+), 114.2 (+), 63.8 (–), 52.5 (+), 39.7 (+), 39.0 (–). HRMS (EI-MS) calcd. for 
C29H26N3O6S [M+H]+: 544.1537; found: 544.1541. IR (KBr) [cm-1]: ν = 2937, 2883, 1683, 769. 
 
Methyl 4-(5-(hydroxymethyl)-1-(methylsulfonyl)-1H-indol-2-yl)-2-(quinoline-2-carbox 
amido)benzoate 15.  
 
Yield 73%, Yellow solid, mp. 172.6-174oC, Rf = 0.25. 1H NMR (DMSO, 300 MHz): δ= 13.12 
(s, 1H, NHCO), 9.12 (d, 4J=1.6 Hz, 1H, ArH), 8.62 (d, 3J=8.5 Hz, 1H, ArH), 8.25 (d, 3J=8.5 Hz, 
1H, ArH), 8.18 (d, 3J=8.4 Hz, 1H, ArH), 8.09 (m, 2H, ArH), 7.92 (m, 2H, ArH), 7.75 (td, 
3J=7.1, 4J=0.8 Hz, 1H, ArH), 7.67 (s, 1H, ArH), 7.43 (td, 3J=8.3, 4J=1.5 Hz, 2H, ArH), 7.05 (s, 
1H, ArH), 5.32 (s, 1H, OH), 4.64 (s, 2H, CH2), 4.03 (s, 3H, OCH3), 3.22 (s, 3H, SO2CH3). 13C 
NMR (75 MHz, DMSO) δ: 166.8 (C=O), 162.7 (C=O), 149.1 (Cquat,), 145.6 (Cquat,), 140.0 
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(Cquat,), 139.0 (Cquat,), 138.7 (Cquat,), 138.3 (+), 137.8 (Cquat,), 136.6 (Cquat,), 130.7 (+), 130.3 (+), 
129.5 (Cquat,), 129.2 (+), 128.9 (Cquat,), 128.5 (+), 128.0 (+), 124.3 (+), 124.1 (+), 120.5 (+), 
119.0 (+), 118.4 (+), 115.6 (Cquat,), 114.7 (+), 113.6 (+), 62.6 (–), 52.6 (+), 40.1 (+). HRMS (EI-
MS) calcd. for C28H24N3O6S [M+H]+: 530.1380; found: 530.1382. IR (KBr) [cm-1]: ν = 3267, 
1681, 1249, 765. 
 
Synthesis of compounds 16 and 17. General procedure. A mixture of 14 or 15 (0.18 mmol) 
and TEA (0.47 mmol, 2.5 equiv.) in 10 mL of dry DCM was stirred and cooled in an ice bath. 
Mesyl chloride (0.18 mmol) was added dropwise and the reaction was stirred at rt overnight. 
Water was added, the organic layer separated and washed with 1N HCl, 1N NaHCO3, brine and 
dried over MgSO4. The solvent was evaporated and the compound was purified by flash 
chromatography (Ethyl ether:PE 10:1). Compound 17 was used in the next step without any 
further purification. 
 
Methyl 4-(1-(methylsulfonyl)-5-(2-((methylsulfonyl)oxy)ethyl)-1H-indol-2-yl)-2-(quinoline-
2-carboxamido)benzoate 16.  
 
Yield 81%, Yellow solid, mp. 220-222oC, Rf = 0.40. 1H NMR (CDCl3, 300 MHz)= δ: 13.39 (s, 
1H, NHCO), 9.28 (d, 4J=1.6 Hz, 1H, ArH), 8.40-8.32 (m, 3H, ArH), 8.18 (d, 3J=8.3 Hz, 1H, 
ArH), 8.06 (d, 3J=8.6 Hz, 1H, ArH), 7.92 (d, 3J=8.2 Hz, 1H, ArH), 7.84 (ddd, 3J=8.4, 3J=7.0, 
4J=1.3 Hz, 1H, ArH), 7.71-7.64 (m, 1H, ArH), 7.49 (d, 4J=1.2 Hz, 1H, ArH), 7.39 (dd, 3J=8.3, 
4J=1.7 Hz, 1H, ArH), 7.27 (dd, 3J=8.6, 4J=1.7, 1H, ArH), 6.86 (s, 1H, ArH), 4.49 (t, 3J=6.8 Hz, 
2H, CH2), 4.09 (s, 3H, OCH3), 3.19 (t, 3J=6.8 Hz, 2H, CH2), 2.93 (s, 3H, SO2CH3), 2.92 (s, 3H, 
SO2CH3). 13C NMR (CDCl3, 75 MHz) δ: 167.7 (C=O), 163.8 (C=O), 149.9 (Cquat,), 146.6 
(Cquat,), 141.3 (Cquat,), 140.4 (Cquat,), 137.7 (Cquat,), 137.7 (+), 137.3 (Cquat,), 132.8 (Cquat,), 130.5 
(Cquat,), 130.5 (+), 130.3 (+), 130.2 (+), 129.4 (Cquat,), 128.3 (+), 127.6 (+), 126.4 (+), 125.2 (+), 
121.6 (+), 120.8 (+), 118.8 (+), 116.3 (Cquat,), 115.9 (+), 113.8 (+), 70.2 (–), 52.5 (+), 40.0 (+), 
37.5 (+), 35.5 (–). HRMS (EI-MS) calcd. for C30H28N3O8S2 [M+H]+: 622.1312; found: 
622.1315. IR (KBr) [cm-1]: ν = 2949, 1683, 769. 
 
General procedure for the synthesis of indol derivatives 22a-h. A mixture 16 or 17 
(56µmol), DIPEA (67µmol, 1.2 equiv.) and the tetrahydroisoquinolines 18-21 in CH3CN was 
refluxed overnight. The solvent was evaporated, 1N HCl was added and the compound was 
extracted with AcOEt. The organic layer was washed with 1N NaHCO3, brine and dried over 
MgSO4. The solvent was evaporated and the compound was purified by flash chromatography. 
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Methyl 4-(5-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-1-(methylsulfonyl)-1H-indol-2-yl)-
2-(quinoline-2-carboxamido)benzoate 22a.  
 
Yield 62%, yellow solid, mp. 121-123 oC, Rf = 0.21 (DCM/MeOH 100/3). 1H NMR (CDCl3, 
600 MHz): δ= 13.38 (s, 1H, NHCO), 9.29 (d, 4J=1.6 Hz, 1H, ArH), 8.38-8.34 (m, 3H, ArH), 
8.17 (d, 3J=8.2 Hz, 1H, ArH), 8.02 (d, 3J=8.5 Hz, 1H, ArH), 7.91 (d, 3J=7.7 Hz, 1H, ArH), 7.85-
7.82 (m, 1H, ArH), 7.67-7.65 (m, 1H, ArH), 7.49 (d, 4J=0.9 Hz, 1H, ArH), 7.40 (dd, 3J=8.2, 
4J=1.7 Hz, 1H, ArH), 7.30 (dd, 3J=8.5, 4J=1.6 Hz, 1H, ArH), 7.16-7.10 (m, 3H, ArH), 7.07-7.04 
(m, 1H, ArH), 6.87 (s, 1H, ArH), 4.08 (s, 3H, OCH3), 3.77 (s, 2H, CH2), 3.05 (dd, 3J=9.5, 
3J=6.6 Hz, 2H, CH2), 2.96 (t, 3J=5.8 Hz, 2H, CH2), 2.88 (s, 3H, SO2CH3), 2.86-284 (m, 4H, 2 
CH2). 13C NMR (CDCl3, 151 MHz) δ: 167.7 (C=O), 163.7 (C=O), 149.9 (Cquat.), 146.6 
(Cquat.), 140.9 (Cquat.), 140.3 (Cquat.), 137.9 (Cquat.), 137.6 (+), 137.0 (Cquat.), 136.9 
(Cquat.), 134.2 (Cquat.), 130.5 (+), 130.3 (+), 130.3 (+), 130.2 (Cquat.), 129.3 (Cquat.), 128.6 
(+), 128.2 (+), 127.6 (+), 126.5 (+), 126.5 (+), 126.1 (+), 125.6 (+), 125.3 (+), 121.0 (+), 120.6 
(Cquat.), 118.7 (+), 116.1 (Cquat.), 115.6 (+), 114.3 (+), 77.2  (–), 77.0  (–), 76.7  (–), 60.4  (–), 
56.1  (–), 52.4 (+), 50.9  (–), 39.5 (+), 33.7 (–), 29.0 (–). HRMS (EI-MS) calcd. for 
C38H35N4O5S [M+H]+: 659.2323; found: 659.2329. IR (KBr) [cm-1]: ν = 2931, 1685, 1519, 773. 
 
Methyl 4-(5-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-(methylsulfonyl)-1H-indol-2-yl)-
2-(quinoline-2-carboxamido)benzoate 22b.  
 
Yield 79%, yellow solid, mp. 135-137 oC, Rf = 0.23 (DCM/MeOH 100/4). 1H NMR (CDCl3, 
600 MHz): δ= 13.37 (s, 1H, NHCO), 9.29 (d, 4J=1.6 Hz, 1H, ArH), 8.37-8.34 (m, 3H, ArH), 
8.18 (d, 3J=8.2 Hz, 1H, ArH), 8.06 (d, 3J=8.5 Hz, 1H, ArH), 7.91 (d, 3J=8.1 Hz, 1H, ArH), 7.83 
(ddd, 3J=8.3, 3J=6.9, 4J=1.3 Hz, 1H, ArH), 7.68-7.64 (m, 2H, ArH), 7.47 (dd, 3J=8.6, 4J=1.6 Hz, 
1H, ArH), 7.40 (dd, 3J=8.2, 4J=1.7 Hz, 1H, ArH), 7.15-7.09 (m, 3H, ArH), 7.00 (d, 3J=6.9 Hz, 
1H, ArH), 6.88 (s, 1H, ArH), 4.08 (s, 3H, OCH3), 3.82 (s, 2H, CH2), 3.70 (s, 2H, CH2), 2.96-
2.92 (m, 5H, SO2CH3, CH2), 2.81 (t, 3J = 5.9 Hz, 2H, CH2). 13C NMR (CDCl3, 151 MHz) δ: 
167.6 (C=O), 163.7 (C=O), 149.8 (Cquat.), 146.5 (Cquat.), 140.9 (Cquat.), 140.3 (Cquat.), 
137.9 (Cquat.), 137.6 (+), 137.5 (Cquat.), 134.8 (Cquat.), 134.6 (Cquat.), 134.2 (Cquat.), 130.3 
(+), 130.2 (+), 130.2 (Cquat.), 130.2 (+), 129.3 (Cquat.), 128.6 (+), 128.2 (+), 127.6 (+), 126.7 
(+), 126.5 (+), 126.1 (+), 125.5 (+), 125.2 (+), 121.6 (+), 120.7 (+), 118.7 (+), 116.1 (Cquat.), 
115.4 (+), 114.1 (+), 62.4 (–), 56.0  (–), 52.4 (+), 50.6  (–), 39.8 (+), 29.0  (–). HRMS (EI-MS) 
calcd. for C37H33N4O5S [M+H]+: 645.2166; found: 645.2161. IR (KBr) [cm-1]: ν = 1683, 1504, 
775. 
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Methyl 4-(5-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-1-(methylsulfonyl) -
1H-indol-2-yl)-2-(quinoline-2-carboxamido)benzoate 22c. Yield 86%, yellow solid, mp. 124-
126 oC, Rf = 0.24 (DCM/MeOH 100/4). 1H NMR (CDCl3, 300 MHz): δ= 13.38 (s, 1H, NHCO), 
9.28 (d, 4J=1.5 Hz, 1H, ArH), 8.40-8.31 (m, 3H, ArH), 8.17 (d, 3J=8.3 Hz, 1H, ArH), 8.02 (d, 
3J=8.5 Hz, 1H, ArH), 7.91 (d, 3J=8.1 Hz, 1H, ArH), 7.86-7.80 (m, 1H, ArH), 7.68-7.63 (m, 1H, 
ArH), 7.48 (s, 1H, ArH), 7.40 (dd, 3J=8.3, 4J=1.6 Hz, 1H, ArH), 7.29 (dd, 3J=8.6, 4J=1.5 Hz, 
1H, ArH), 6.87 (s, 1H, ArH), 6.62 (s, 1H, ArH), 6.56 (s, 1H, ArH), 4.08 (s, 3H, OCH3), 3.85 (s, 
3H, OCH3), 3.84 (s, 3H, OCH3), 3.70 (s, 2H, CH2), 3.04 (dd, 3J=9.7, 3J=6.0 Hz, 2H, CH2), 2.88-
2.82 (m, 9H, SO2CH3, 6 CH2).13C NMR (75 MHz, CDCl3) δ: 167.7 (C=O), 163.8 (C=O), 149.9 
(Cquat.), 147.5 (Cquat.), 147.2 (Cquat.), 146.6 (Cquat.), 141.0 (Cquat.), 140.4 (Cquat.), 137.9 
(Cquat.), 137.7 (Cquat.), 137.0 (+), 136.9 (Cquat.), 130.5 (Cquat.), 130.4 (+), 130.3 (+), 130.2 
(+), 129.4 (Cquat.), 128.3 (+), 127.6 (+), 126.6 (+), 126.3 (Cquat.), 126.1 (Cquat.), 125.3 (+), 
121.1 (+), 120.6 (+), 118.8 (+), 116.2 (Cquat.), 115.7 (+), 114.3 (+), 111.3 (+), 109.4 (+), 60.3 
(–)55.9 (+), 55.9 (+), 55.7 (–), 52.5 (+), 51.0 (–), 39.6 (+), 33.8 (–), 28.6 (–). HRMS (EI-MS) 
calcd. for C40H39N4O7S [M+H]+: 719.2534; found: 719.2532. IR (KBr) [cm-1]: ν = 2931, 1683, 
1518, 773. 
 
Methyl 4-(5-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-(methylsulfonyl) -
1H-indol-2-yl)-2-(quinoline-2-carboxamido)benzoate 22d.  
 
Yield 52%, light yellow solid, mp. 140-142 oC, Rf = 0.29 (CHCl3/MeOH 100/3). 1H NMR 
(CDCl3, 600 MHz): δ= 13.38 (s, 1H, NHCO), 9.28 (d, 4J=1.5 Hz, 1H, ArH), 8.39-8.32 (m, 3H, 
ArH), 8.18 (d, 3J=8.2 Hz, 1H, ArH), 8.06 (d, 3J=8.5 Hz, 1H, ArH), 7.91 (d, 3J=7.9 Hz, 1H, 
ArH), 7.86-7.81 (m, 1H, ArH), 7.69-7.64 (m, 2H, ArH), 7.46 (dd, 3J=8.5, 4J=1.1 Hz, 1H, ArH), 
7.40 (dd, 3J=8.2, 4J=1.6 Hz, 1H, ArH), 6.87 (s, 1H, ArH), 6.61 (s, 1H, ArH), 6.50 (s, 1H, ArH), 
4.08 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.83-3.80 (m, 5H, OCH3, CH2), 3.61 (s, 2H, CH2), 2.94 
(s, 3H, SO2CH3), 2.88-2.84 (m, 2H, CH2), 2.83-2.79 (m, 2H, CH2). 13C NMR (CDCl3, 151 
MHz) δ: 167.7 (C=O), 163.8 (C=O), 149.9 (Cquat.), 147.5 (Cquat.), 147.2 (Cquat.), 146.6 
(Cquat.), 140.9 (Cquat.), 140.3 (Cquat.), 137.9 (Cquat.), 137.6 (+), 137.5 (Cquat.), 130.4 (+), 
130.3 (+), 130.2 (Cquat.), 130.2 (+), 129.3 (Cquat.), 128.3 (+), 127.6 (+), 126.8 (+), 126.0 
(Cquat.), 125.2 (+), 121.7 (+), 120.7 (+), 118.7 (+), 116.2 (Cquat.), 115.5 (+), 114.1 (+), 111.4 
(+), 109.4 (+), 62.4 (–), 55.8 (+), 52.4 (+), 50.7 (–), 39.9 (+), 29.6 (–), 28.5 (–). HRMS (EI-MS) 
calcd. for C39H37N4O7S [M+H]+: 705.2377; found: 705.2376. IR (KBr) [cm-1]: ν = 1687, 1518, 
769. 
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Methyl 4-(5-(2-(6-methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroiso 
quinolin-2(1H)-yl)ethyl)-1-(methylsulfonyl)-1H-indol-2-yl)-2-(quinoline-2-carboxamido) 
benzoate 22e.  
 
Yield 82%, yellow solid, mp. 93-96 oC, Rf = 0.22 (DCM/MeOH 100/4). 1H NMR (CDCl3, 600 
MHz): δ= 13.36 (s, 1H, NHCO), 9.27 (d, 4J=1.6 Hz, 1H, ArH), 8.35-8.33 (m, 3H, ArH), 8.16 (d, 
3J=8.2 Hz, 1H, ArH), 8.01 (d, 3J=8.5 Hz, 1H, ArH), 7.90 (d, 3J=7.4 Hz, 1H, ArH), 7.83-7.81 (m, 
1H, ArH), 7.67-7.64 (m, 1H, ArH), 7.48 (d, 4J=0.6 Hz, 1H, ArH), 7.39 (dd, 3J=8.2, 4J=1.7 Hz, 
1H, ArH), 7.29 (dd, 3J = 8.6, 4J=1.6 Hz, 1H, ArH), 6.86 (s, 1H, ArH), 6.61 (s, 2H, ArH), 4.13 (t, 
3J=5.0 Hz, 2H, CH2), 4.07 (s, 3H, OCH3), 3.85 (t, 3J=5.3 Hz, 2H, CH2), 3.81 (s, 3H, OCH3), 
3.73 (m, 2H, CH2), 3.69-3.63 (m, 6H, 3 CH2), 3.55-3.53 (m, 2H, CH2), 3.37 (s, 3H, OCH3), 
3.06-3.03 (m, 2H, CH2), 2.89-2.84 (m, 9H, SO2CH3, 3 CH2). 13C NMR (CDCl3, 151 MHz) δ: 
167.7 (C=O), 163.7 (C=O), 149.8 (Cquat.), 148.2 (Cquat.), 146.5 (Cquat.), 146.4 (Cquat.), 
140.9 (Cquat.), 140.3 (Cquat.), 137.9 (Cquat.), 137.6 (+), 136.9 (Cquat.), 136.7 (Cquat.), 130.4 
(+), 130.3 (+), 130.2 (+), 130.2 (Cquat.), 129.3 (Cquat.), 128.2 (+), 127.6 (+), 126.7 (Cquat.), 
126.5 (+), 125.2 (+), 121.0 (+), 120.6 (+), 118.7 (+), 116.1 (Cquat.), 115.6 (+), 114.2 (+), 112.2 
(+), 111.9 (+), 71.8 (–), 70.7 (–), 70.5 (–), 70.4 (–), 69.6 (–), 68.6 (–), 60.1 (–), 58.9 (+), 55.9 
(+), 55.4 (–), 52.4 (+), 50.8 (–), 39.5 (+), 33.5 (–), 28.4 (–). HRMS (EI-MS) calcd. for 
C46H51N4O10S [M+H]+: 851.3320; found: 851.3326. IR (KBr) [cm-1]: ν = 2922, 1685, 1518, 
771. 
 
Methyl 4-(5-((6-methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquino 
lin-2(1H)-yl)methyl)-1-(methylsulfonyl)-1H-indol-2-yl)-2-(quinoline-2-carboxamido) 
benzoate 22f.  
 
Yield 63%, yellow solid, mp. 115-117 oC, Rf = 0.16 (DCM/MeOH 100/3). 1H NMR (CDCl3, 
600 MHz): δ= 13.35 (s, 1H, NHCO), 9.28 (d, 4J=1.7 Hz, 1H, ArH), 8.36-8.31 (m, 3H, ArH), 
8.16 (d, 3J=8.2 Hz, 1H, ArH), 8.05 (d, 3J=8.6 Hz, 1H, ArH), 7.88 (d, 3J=8.2 Hz, 1H, ArH), 7.81 
(ddd, 3J=8.4, 3J=6.9, 4J=1.3 Hz, 1H, ArH), 7.66-7.62 (m, 2H, ArH), 7.44 (dd, 3J=8.6, 4J=1.5 Hz, 
1H, ArH), 7.39 (dd, 3J=8.2, 4J=1.7 Hz, 1H, ArH), 6.86 (s, 1H, ArH), 6.60 (s, 1H, ArH), 6.55 (s, 
1H, ArH), 4.10 (t, 3J=5.4 Hz, 2H, CH2), 4.06 (s, 3H, OCH3), 3.83 (t, 3J=5.1 Hz, 2H, CH2), 3.80 
(s, 3H, OCH3), 3.78 (s, 2H, CH2), 3.71 (dd, 3J=5.9, 3J=3.7 Hz, 2H, CH2), 3.66-3.61 (m, 4H, 2 
CH2), 3.57 (s, 2H, CH2), 3.54-3.51 (m, 2H, CH2), 3.35 (s, 3H, OCH3), 2.93 (s, 3H, SO2CH3), 
2.83 (t, 3J=5.6 Hz, 2H, CH2), 2.76 (t, 3J=5.7 Hz, 2H, CH2). 13C NMR (CDCl3, 151 MHz) δ: 
167.6 (C=O), 163.6 (C=O), 149.8 (Cquat.), 148.1 (Cquat.), 146.5 (Cquat.), 146.3 (Cquat.), 
140.8 (Cquat.), 140.2 (Cquat.), 137.8 (Cquat.), 137.5 (+), 137.4 (Cquat.), 134.8 (Cquat.), 130.3 
(+), 130.2 (+), 130.1 (Cquat.), 130.1 (+), 129.2 (Cquat.), 128.2 (+), 127.5 (+), 126.8 (Cquat.), 
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126.7 (+), 126.5 (Cquat.), 125.1 (+), 121.5 (+), 120.6 (+), 118.6 (+), 116.1 (Cquat.), 115.3 (+), 
114.1 (+), 112.2 (+), 111.9 (+), 71.8 (–), 70.6 (–), 70.5 (–), 70.4 (–), 69.5 (–), 68.6 (–), 62.4 (–), 
58.9 (+), 55.9 (+), 55.5 (–), 52.4 (+), 50.6 (–), 39.7 (+), 28.6 (–). HRMS (EI-MS) calcd. for 
C45H49N4O10S [M+H]+: 837.3164; found: 837.3174. IR (KBr) [cm-1]: ν = 2931, 1681, 1518, 
767. 
 
Methyl 4-(5-(2-(6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-
2(1H)-yl)ethyl)-1-(methylsulfonyl)-1H-indol-2-yl)-2-(quinoline-2-carboxamido)benzoate 
22g.  
 
Yield 38%, sticky yellow solid, Rf = 0.27 (DCM/MeOH 100/5). 1H NMR (CDCl3, 300 MHz): 
δ= 13.35 (s, 1H, NHCO), 9.26 (d, 4J=1.6 Hz, 1H, ArH), 8.35-8.29 (m, 3H, ArH), 8.14 (d, 3J=8.3 
Hz, 1H, ArH), 8.00 (d, 3J=8.6 Hz, 1H, ArH), 7.88 (d, 3J=8.2 Hz, 1H, ArH), 7.80 (ddd, 3J=8.4, 
3J=7.0, 4J=1.3 Hz, 1H, ArH), 7.67-7.59 (m, 1H, ArH), 7.46 (s, 1H, ArH), 7.37 (dd, 3J=8.3, 
4J=1.7 Hz, 1H, ArH), 7.30-7.25 (m, 1H, ArH), 6.85 (s, 1H, ArH), 6.65 (s, 1H, ArH), 6.60 (s, 1H, 
ArH), 4.11 (t, 3J=5.0 Hz, 4H, 2 CH2), 4.05 (s, 3H, OCH3), 3.82 (t, 3J=5.1 Hz, 4H, 2 CH2), 3.75-
3.70 (m, 4H, 2 CH2), 3.66-3.62 (m, 10H, 5 CH2), 3.53 (dd, 3J=5.9, 3J=3.3 Hz, 4H, 2 CH2), 3.36 
(s, 6H, 2 OCH3), 3.03-2.98 (m, 2H, CH2), 2.86 (s, 3H, SO2CH3), 2.88-2.75 (m, 6H, 3 CH2). 13C 
NMR (CDCl3, 75 MHz) δ: 167.7 (C=O), 163.7 (C=O), 149.9 (Cquat.), 147.5 (Cquat.), 147.1 
(Cquat.), 146.6 (Cquat.), 141.0 (Cquat.), 140.3 (Cquat.), 137.9 (Cquat.), 137.7 (+), 137.0 
(Cquat.), 136.9 (Cquat.), 130.5 (Cquat.), 130.4 (+), 130.3 (+), 130.2 (+), 129.3 (Cquat.), 128.3 
(+), 127.6 (+), 127.5 (+), 127.2 (Cquat.), 126.5 (+), 125.2 (+), 121.1 (+), 120.6 (+), 118.8 (+), 
116.1 (Cquat.), 115.6 (+), 115.0 (+), 114.3 (+), 113.3 (+), 71.9 (–), 70.7 (–), 70.6 (–), 70.5 (–), 
69.7 (–), 69.1 (–), 69.0 (–), 60.4 (–), 59.0 (+), 55.7 (–), 52.5 (+), 51.0 (–), 39.5 (+), 33.8 (–), 28.6 
(–). HRMS (EI-MS) calcd. for C52H63N4O13S [M+H]+: 983.4107; found: 983.4109. IR (KBr) 
[cm-1]: ν = 2926, 2879, 1683, 1518. 
 
Methyl 4-(5-((6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)methyl)-1-(methylsulfonyl)-1H-indol-2-yl)-2-(quinoline-2-carboxamido) benzoate 22h.  
 
Yield 80%, sticky yellow solid, Rf = 0.27 (CHCl3/MeOH 100/4). 1H NMR (CDCl3, 300 MHz): 
δ= 13.37 (s, 1H, NHCO), 9.28 (d, 4J=1.6 Hz, 1H, ArH), 8.38-8.32 (m, 3H, ArH), 8.17 (d, 3J=8.3 
Hz, 1H, ArH), 8.05 (d, 3J=8.6 Hz, 1H, ArH), 7.90 (d, 3J=8.2 Hz, 1H, ArH), 7.82 (ddd, 3J=8.4, 
3J=6.9, 4J=1.3 Hz, 1H, ArH), 7.67-7.62 (m, 2H, ArH), 7.44 (dd, 3J=8.6, 4J=1.5 Hz, 1H, ArH), 
7.39 (dd, 3J=8.3, 4J=1.7 Hz, 1H, ArH), 6.87 (s, 1H, ArH), 6.66 (s, 1H, ArH), 6.55 (s, 1H, ArH), 
4.15-4.05 (m, 7H, OCH3, 2 CH2), 3.86-3.76 (m, 6H, 3 CH2), 3.75-3.69 (m, 4H, 2 CH2), 3.68-
3.61 (m, 8H, 4 CH2), 3.56-3.51 (m, 6H, 3 CH2), 3.36 (s, 3H, OCH3), 3.35 (s, 3H, OCH3), 2.93 
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(s, 3H, SO2CH3), 2.81-2.75 (m, 4H, 2 CH2). 13C NMR (CDCl3, 75 MHz) δ: 167.7 (C=O), 163.8 
(C=O), 149.9 (Cquat.), 147.5 (Cquat.), 147.1 (Cquat.), 146.6 (Cquat.), 140.9 (Cquat.), 140.3 
(Cquat.), 138.0 (Cquat.), 137.7 (+), 137.5 (Cquat.), 135.0 (Cquat.), 130.4 (+), 130.3 (+), 130.3 
(Cquat.), 130.2 (+), 129.4 (Cquat.), 128.3 (+), 127.6 (+), 127.2 (Cquat.), 126.8 (+), 125.2 (+), 
121.6 (+), 120.7 (+), 118.8 (+), 116.2 (Cquat.), 115.5 (+), 115.1 (+), 114.2 (+), 113.2 (+), 71.9 (-
), 70.7 (–), 70.6 (–), 70.5 (–), 69.7 (–), 69.7 (–), 69.0 (–), 69.0 (–), 62.6 (–), 59.0 (+), 55.7 (–), 
52.5 (+), 50.7 (–), 39.8 (+), 28.6 (–). HRMS (EI-MS) calcd. for C51H61N4O13S [M+H]+: 
969.395; found: 969.3954. IR (KBr) [cm-1]: ν = 2877, 1685, 1518, 769. 
 
General procedure for the synthesis of indol derivatives 23a-h. A solution of 22a (0.15 
mmol) in 5 mL THF was stirred and cooled in an ice bath. TBAF (0.15 mmol, 1M in THF) was 
added and the reaction was stirred for 72 h at room temperature. The solvent was evaporated, 
saturated NH4Cl solution was added and the compound was extracted with DCM. The organic 
layer was separated and dried over MgSO4. The solvent was evaporated and the compound was 
purified by flash chromatography. 
 
Methyl 4-(5-(2-(3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-1H-indol-2-yl)-2-(quinoline-2-
carboxamido)benzoate 23a.  
 
Yield 57%, yellow solid, mp. 116-118 oC Rf = 0.29 (DCM/MeOH 100/4). 1H NMR (CDCl3, 5% 
MeOD, 300 MHz): δ= 13.39 (s, 1H, NHCO), 9.99 (s, 1H, NH), 9.19 (d, 4J=1.5 Hz, 1H, ArH), 
8.36-8.29 (m, 3H, ArH), 8.10 (d, 3J=8.4 Hz, 1H, ArH), 7.89 (d, 3J=8.2 Hz, 1H, ArH), 7.81 (ddd, 
3J=8.4, 3J=7.0, 4J=1.3 Hz, 1H, ArH), 7.67-7.61 (m, 1H, ArH), 7.51 (dd, 3J=8.4, 4J=1.7 Hz, 1H, 
ArH), 7.46 (s, 1H, ArH), 7.42-7.31 (m, 2H, ArH), 7.13-7.02 (m, 4H, ArH), 6.92 (s, 1H, ArH), 
4.05 (s, 3H, OCH3), 3.79 (s, 2H, CH2), 3.06-2.93 (m, 4H, 2 CH2), 2.91-2.76 (m, 4H, 2 CH2). 13C 
NMR (CDCl3, 5% MeOD, 75 MHz) δ: 167.7 (C=O), 163.9 (C=O), 149.9 (Cquat.), 146.6 
(Cquat.), 141.4 (Cquat.), 137.8 (Cquat.), 137.7 (+), 136.6 (Cquat.), 136.1 (Cquat.), 134.2 
(Cquat.), 132.2 (Cquat.), 131.9 (+), 130.2 (+), 129.4 (Cquat.), 128.6 (+), 128.3 (+), 128.0 
(Cquat.), 127.6 (+), 127.2 (Cquat.), 126.6 (+), 126.1 (+), 125.6 (+), 124.5 (+), 120.5 (+), 119.6 
(+), 118.8 (+), 115.6 (+), 114.8 (Cquat.), 111.2 (+), 101.9 (+), 56.1 (–), 52.4 (+), 51.0 (–), 40.3 
(–), 34.0 (–), 28.3 (–). HRMS (EI-MS) calcd. for C37H33N4O3 [M+H]+: 581.2547; found: 
581.2545. IR (KBr) [cm-1]: ν = 1681, 1519, 771, 740. 
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Methyl 4-(5-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-indol-2-yl)-2-(quinoline-2-
carboxamido)benzoate 23b.  
 
Yield 34%, yellow solid, mp. 204-206 oC Rf = 0.20 (CHCl3/MeOH 100/4). 1H NMR (CDCl3, 
300 MHz): δ= 13.40 (s, 1H, NHCO), 9.36 (d, 4J=1.6 Hz, 1H, ArH), 8.95 (s, 1H, NH), 8.39-8.30 
(m, 3H, ArH), 8.13 (d, 3J=8.3 Hz, 1H, ArH), 7.91 (d, 3J=8.1 Hz, 1H, ArH), 7.82 (ddd, 3J=8.4, 
3J=6.9, 4J=1.3 Hz, 1H, ArH), 7.70-7.64 (m, 1H, ArH), 7.63 (s, 1H, ArH), 7.48 (dd, 3J=8.4, 
4J=1.7 Hz, 1H, ArH), 7.39 (d, 3J=8.3 Hz, 1H, ArH), 7.29 (dd, 3J=8.3, 4J=1.3 Hz, 1H, ArH), 
7.10-7.07 (m, 3H, ArH), 7.02-6.94 (m, 2H, ArH), 4.07 (s, 3H, OCH3), 3.79 (s, 2H, CH2), 3.69 
(s, 2H, CH2), 2.92 (t, 3J=5.5 Hz, 2H, CH2), 2.80 (t, 3J=5.7 Hz, 2H, CH2). 13C NMR (75 MHz, 
CDCl3) δ 167.7 (C=O), 163.9 (C=O), 146.6 (Cquat.), 137.7 (+), 136.8 (Cquat.), 136.6 (Cquat.), 
134.9 (Cquat.), 134.4 (Cquat.), 131.9 (+), 131.6 (Cquat.), 130.2 (+), 129.4 (Cquat.), 129.3 
(Cquat.), 128.9 (Cquat.), 128.7 (+), 128.3 (+), 127.6 (+), 126.6 (+), 126.0 (+), 125.5 (+), 125.0 
(+), 121.5 (+), 119.7 (+), 118.8 (+), 115.7 (+), 114.9 (+), 111.1 (+), 102.1 (+), 63.2 (–), 56.0 (–), 
52.4 (+), 50.5 (–), 29.1 (–). HRMS (EI-MS) calcd. for C36H31N4O3 [M+H]+: 567.2391; found: 
567.240. IR (KBr) [cm-1]: ν = 3408, 1683, 1514, 773. 
 
Methyl 4-(5-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)-1H-indol-2-yl)-2-
(quinoline-2-carboxamido)benzoate 23c.  
 
Yield 70%, yellow solid, mp. 118-120 oC Rf = 0.24 (DCM/MeOH 100/4). 1H NMR (CDCl3, 5% 
MeOD, 300 MHz): δ= 13.35 (s, 1H, NHCO), 10.18 (s, 1H, NH), 9.14 (d, 4J=1.4 Hz, 1H, ArH), 
8.30-8.27 (m, 3H, ArH), 8.06 (d, 3J=8.4 Hz, 1H, ArH), 7.85 (d, 3J=8.1 Hz, 1H, ArH), 7.81-7.75 
(m, 1H, ArH), 7.61 (t, 3J=7.5 Hz, 1H, ArH), 7.51-7.43 (m, 2H, ArH), 7.36 (d, 3J=8.3 Hz, 1H, 
ArH), 7.07 (dd, 3J=8.3, 4J=1.2 Hz, 1H, ArH), 6.90 (s, 1H, ArH), 6.59 (s, 1H, ArH), 6.54 (s, 1H, 
ArH), 4.02 (s, 3H, OCH3), 3.82 (s, 6H, 2 OCH3), 3.70 (s, 2H, CH2), 3.00 (dd, 3J=10.6, 3J=5.4 
Hz, 2H, CH2), 2.85-2.80 (m, 6H, 3 CH2). 13C NMR (CDCl3, 5% MeOD, 75 MHz) δ 167.6 
(C=O), 163.7 (C=O), 149.6 (Cquat.), 147.5 (Cquat.), 147.2 (Cquat.), 146.5 (Cquat.), 140.8 
(Cquat.), 138.1 (Cquat.), 137.6 (+), 136.6 (Cquat.), 136.3 (Cquat.), 131.8 (+), 131.5 (Cquat.), 
130.2 (+), 130.2 (+), 129.3 (Cquat.), 129.1 (Cquat.), 128.3 (+), 127.6 (+), 126.1 (Cquat.), 125.9 
(Cquat.), 124.2 (+), 120.3 (+), 120.0 (+), 118.7 (+), 115.5 (+), 114.7 (Cquat.), 111.3 (+), 111.3 
(+), 109.4 (+), 101.4 (+), 60.8 (–), 55.9 (+), 55.8 (+), 55.5 (–), 52.4 (+), 50.9 (–), 33.8 (–), 28.3 
(–). HRMS (EI-MS) calcd. for C39H37N4O5 [M+H]+: 641.2758; found: 641.2763. IR (KBr) [cm-
1]: ν = 3520, 1668, 1518, 775. 
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Methyl 4-(5-((6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1H-indol-2-yl)-2-
(quinoline-2-carboxamido)benzoate 23d.  
 
Yield 75%, yellow solid, mp. 168-170 oC Rf = 0.23 (CHCl3/MeOH 100/5). 1H NMR (CDCl3, 
300 MHz): δ= 13.31 (s, 1H, NHCO), 9.31 (d, 4J=1.6 Hz, 1H, ArH), 9.13 (s, 1H, NH), 8.30-8.25 
(m, 3H, ArH), 8.04 (d, 3J=8.4 Hz, 1H, ArH), 7.84 (d, 3J=8.1 Hz, 1H, ArH), 7.80-7.73 (m, 1H, 
ArH), 7.64-7.57 (m, 2H, ArH), 7.39 (dd, 3J=8.4, 4J=1.6 Hz, 1H, ArH), 7.32 (d, 3J=8.3 Hz, 1H, 
ArH), 7.25 (dd, 3J=8.4, 4J=1.2 Hz, 1H, ArH), 6.92 (d, 4J=1.5 Hz, 1H, ArH), 6.58 (s, 1H, ArH), 
6.47 (s, 1H, ArH), 4.03 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.76 (s, 2H, 
CH2), 3.57 (s, 2H, CH2), 2.81 (m, 4H, 2 CH2). 13C NMR (CDCl3, 75 MHz) δ: 167.6 (C=O), 
163.8 (C=O), 149.8 (Cquat.), 147.4 (Cquat.), 147.1 (Cquat.), 146.5 (Cquat.), 141.3 (Cquat.), 
137.7 (Cquat.), 137.6 (+), 136.8 (Cquat.), 136.7 (Cquat.), 131.8 (+), 130.2 (+), 130.1 (+), 130.0 
(Cquat.), 129.3 (Cquat.), 128.9 (Cquat.), 128.2 (+), 127.6 (+), 126.8 (Cquat.), 126.3 (Cquat.), 
124.9 (+), 121.5 (+), 119.6 (+), 118.7 (+), 115.7 (+), 114.8 (Cquat.), 111.4 (+), 111.2 (+), 109.5 
(+), 102.0 (+), 63.2 (–), 55.9 (+), 55.8 (+), 55.6 (–), 52.4 (+), 50.7 (–), 28.7 (–). HRMS (EI-MS) 
calcd. for C38H35N4O5 [M+H]+: 627.2602; found: 627.2608. IR (KBr) [cm-1]: ν = 3408, 1683, 
1516, 771. 
 
Methyl 4-(5-(2-(6-methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydro isoquino 
lin-2(1H)-yl)ethyl)-1H-indol-2-yl)-2-(quinoline-2-carboxamido)benzoate 23e.  
 
Yield 65%, yellow solid, mp. 128-130 oC Rf = 0.20 (DCM/MeOH 100/5). 1H NMR (CDCl3, 5% 
MeOD, 300 MHz): δ= 13.35 (s, 1H, NHCO), 9.96 (s, 1H, NH), 9.18 (d, 4J=1.2 Hz, 1H, ArH), 
8.30-8.27 (m, 3H, ArH), 8.06 (d, 3J=8.4 Hz, 1H, ArH), 7.86 (d, 3J=8.2 Hz, 1H, ArH), 7.82-7.75 
(m, 1H, ArH), 7.62 (t, 3J=7.5 Hz, 1H, ArH), 7.48-7.44 (m, 2H, ArH), 7.35 (d, 3J=8.3 Hz, 1H, 
ArH), 7.07 (dd, 3J=8.3, 4J=1.2 Hz, 1H, ArH), 6.90 (s, 1H, ArH), 6.59 (s, 2H, ArH), 4.12 (t, 
3J=5.2 Hz, 2H, CH2), 4.03 (s, 3H, OCH3), 3.85 (t, 3J=5.1 Hz, 2H, CH2), 3.80 (s, 3H, OCH3), 
3.74-3.70 (m, 2H, CH2), 3.67-3.62 (m, 6H, 3 CH2), 3.54 (dd, 3J=5.8, 3J=3.3 Hz, 2H, CH2), 3.36 
(s, 3H, OCH3), 2.99 (dd, 3J=10.5, 3J=5.4 Hz, 2H, CH2), 2.82 (dd, 3J=9.9, 3J=6.0 Hz, 6H, 3 CH2). 
13C NMR (CDCl3, 5% MeOD, 75 MHz,) δ: 167.7 (C=O), 163.8 (C=O), 149.7 (Cquat.), 148.1 
(Cquat.), 146.5 (Cquat.), 146.4 (Cquat.), 141.0 (Cquat.), 138.1 (Cquat.), 137.6 (+), 136.7 
(Cquat.), 136.4 (Cquat.), 131.8 (+), 131.7 (Cquat.), 130.2 (+), 129.3 (Cquat.), 129.1 (Cquat.), 
128.3 (+), 127.6 (+), 126.8 (Cquat.), 126.4 (Cquat.), 124.2 (+), 120.3 (+), 119.9 (+), 118.7 (+), 
115.6 (+), 114.7 (Cquat.), 112.2 (+), 111.9 (+), 111.4 (+), 101.5 (+), 71.9 (–), 70.7 (–), 70.6 (–), 
70.5 (–), 69.6 (–), 68.6 (–), 60.9 (–), 59.0 (+), 55.9 (+), 55.6 (–), 52.4 (+), 51.0 (–), 33.9 (–), 28.5 
(–). HRMS (EI-MS) calcd. for C45H49N4O8 [M+H]+: 773.3545; found: 773.3544. IR (KBr) [cm-
1]: ν = 3533, 2916, 2833, 1681, 1516, 771. 
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Methyl 4-(5-((6-methoxy-7-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoqui 
nolin-2(1H)-yl)methyl)-1H-indol-2-yl)-2-(quinoline-2-carboxamido)benzoate 23f.  
 
Yield 18%, light yellow solid, mp. 110-112 oC Rf = 0.15 (CHCl3/MeOH 100/4). 1H NMR 
(CDCl3, 600 MHz): δ= 13.34 (s, 1H, NHCO), 9.32 (d, 4J=1.7 Hz, 1H, ArH), 9.18 (s, 1H, NH), 
8.31-8.29 (m, 3H, ArH), 8.08 (d, 3J=8.3 Hz, 1H, ArH), 7.87 (d, 3J=8.1 Hz, 1H, ArH), 7.79 (ddd, 
3J=8.3, 3J=6.9, 4J=1.3 Hz, 1H, ArH), 7.65-7.61 (m, 1H, ArH), 7.59 (s, 1H, ArH), 7.44 (dd, 
3J=8.3, 4J=1.7 Hz, 1H, ArH), 7.36 (d, 3J=8.3 Hz, 1H, ArH), 7.27-7.25 (m, 1H, ArH), 6.95 (d, 
4J=1.5 Hz, 1H, ArH), 6.58 (s, 1H, ArH), 6.52 (s, 1H, ArH), 4.07 (t, 3J=5.4 Hz, 2H, CH2), 4.05 
(s, 3H, OCH3), 3.81 (t, 3J=5.1 Hz, 2H, CH2), 3.79 (s, 3H, OCH3), 3.76 (s, 2H, CH2), 3.70 (dd, 
3J=5.9, 3J=3.7 Hz, 2H, CH2), 3.65-3.61 (m, 4H, 2 CH2), 3.56 (s, 2H, CH2), 3.53-3.50 (m, 2H, 
CH2), 3.35 (s, 3H, OCH3), 2.82 (t, 3J=5.5 Hz, 2H, CH2), 2.76 (t, 3J=5.6 Hz, 2H, CH2). 13C NMR 
(CDCl3, 151 MHz) δ: 167.6 (C=O), 163.7 (C=O), 149.8 (Cquat.), 148.0 (Cquat.), 146.5 
(Cquat.), 146.3 (Cquat.), 141.2 (Cquat.), 137.7 (Cquat.), 137.6 (+), 136.8 (Cquat.), 136.6 
(Cquat.), 131.8 (+), 130.1 (+), 130.1 (+), 129.9 (Cquat.), 129.3 (Cquat.), 128.8 (Cquat.), 128.2 
(+), 127.5 (+), 127.0 (Cquat.), 126.8 (Cquat.), 124.8 (+), 121.4 (+), 119.5 (+), 118.7 (+), 115.7 
(+), 114.7 (Cquat.), 112.2 (+), 111.9 (+), 111.1 (+), 101.9 (+), 71.8 (–), 70.7 (–), 70.5 (–), 70.4 
(–), 69.5 (–), 68.5 (–), 63.1 (–), 58.9 (+), 55.9 (+), 55.5 (–), 52.3 (+), 50.5 (–), 28.6 (–). HRMS 
(EI-MS) calcd. for C44H47N4O8 [M+H]+: 759.3394; found: 759.3408. IR (KBr) [cm-1]: ν = 2900, 
2875, 1681, 1516, 771. 
 
Methyl 4-(5-(2-(6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-
2(1H)-yl)ethyl)-1H-indol-2-yl)-2-(quinoline-2-carboxamido)benzoate 23g.  
 
Yield 53%, sticky light yellow oil, Rf = 0.23 (DCM/MeOH 100/5). 1H NMR (CDCl3, 300 
MHz): δ= 13.33 (s, 1H, NHCO), 9.31 (d, 4J=1.5 Hz, 1H, ArH), 9.25 (s, 1H, NH), 8.33-8.26 (m, 
3H, ArH), 8.07 (d, 3J=8.4 Hz, 1H, ArH), 7.87 (d, 3J=8.1 Hz, 1H, ArH), 7.82-7.75 (m, 1H, ArH), 
7.66-7.59 (m, 1H, ArH), 7.46-7.43 (m, 2H, ArH), 7.33 (d, 3J=8.3 Hz, 1H, ArH), 7.07 (dd, 
3J=8.4, 4J=1.3 Hz, 1H, ArH), 6.92 (s, 1H, ArH), 6.63 (s, 1H, ArH), 6.58 (s, 1H, ArH), 4.11 (t, 
3J=5.0 Hz, 4H, 2 CH2), 4.04 (s, 3H, OCH3), 3.82 (t, 3J=5.1 Hz, 4H, 2 CH2), 3.75-3.70 (m, 4H, 2 
CH2), 3.69-3.61 (m, 10H, 5 CH2), 3.54 (dd, 3J=5.9, 3J=3.3 Hz, 4H, 2 CH2), 3.36 (s, 3H, OCH3), 
3.36 (s, 3H, OCH3), 2.99 (dd, 3J=10.1, 3J=5.6 Hz, 2H, CH2), 2.83-2.77 (m, 6H, 3 CH2). 13C 
NMR (CDCl3, 75 MHz) δ 167.7 (C=O), 163.8 (C=O), 149.8 (Cquat.), 147.4 (Cquat.), 147.0 
(Cquat.), 146.5 (Cquat.), 141.3 (Cquat.), 137.9 (Cquat.), 137.6 (+), 136.6 (Cquat.), 136.2 
(Cquat.), 132.0 (Cquat.), 131.8 (+), 130.2 (+), 129.3 (Cquat.), 129.2 (Cquat.), 128.2 (+), 127.6 
(+), 127.2 (Cquat.), 124.3 (+), 120.4 (+), 119.5 (+), 118.7 (+), 115.7 (+), 114.9 (+), 114.7 
(Cquat.), 113.2 (+), 111.3 (+), 101.7 (+), 71.9 (–), 70.7 (–), 70.6 (–), 70.5 (–), 69.7 (–), 69.0 (–), 
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68.9 (–), 61.0 (–), 59.0 (+), 55.7 (–), 52.4 (+), 51.0 (–), 34.1 (–), 28.6 (–). HRMS (EI-MS) 
calcd. for C51H61N4O11 [M+H]+: 905.4331; found: 905.4333. IR (KBr) [cm-1]: ν = 2870, 1683, 
1516, 771. 
 
Methyl 4-(5-((6,7-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-3,4-dihydroisoquinolin-2(1H)-
yl)methyl)-1H-indol-2-yl)-2-(quinoline-2-carboxamido)benzoate 23h.  
 
Yield 55%, light yellow oil, Rf = 0.18 (CHCl3/MeOH 100/6). 1H NMR (CDCl3, 300 MHz): δ= 
13.37 (s, 1H, NHCO), 9.34 (d, 4J=1.5 Hz, 1H, ArH), 9.15 (s, 1H, NH), 8.36-8.28 (m, 3H, ArH), 
8.11 (d, 3J=8.4 Hz, 1H, ArH), 7.89 (d, 3J=8.1 Hz, 1H, ArH), 7.84-7.76 (m, 1H, ArH), 7.66-7.59 
(m, 2H, ArH), 7.48 (dd, 3J=8.4, 4J=1.5 Hz, 1H, ArH), 7.38 (d, 3J=8.3 Hz, 1H, ArH), 7.26 (dd, 
3J=8.3, 4J=1.1 Hz, 1H, ArH), 6.96 (s, 1H, ArH), 6.63 (s, 1H, ArH), 6.51 (s, 1H, ArH), 4.12-4.05 
(m, 5H, OCH3, CH2), 3.82-3.60 (m, 20H, 10 CH2), 3.55-3.49 (m, 6H, 3 CH2), 3.36 (s, 3H, 
OCH3), 3.34 (s, 3H, OCH3), 2.82-2.71 (m, 4H, 2 CH2). 13C NMR (CDCl3, 75 MHz) δ: 167.7 
(C=O), 163.8 (C=O), 149.9 (Cquat.), 147.3 (Cquat.), 147.0 (Cquat.), 146.6 (Cquat.), 141.4 
(Cquat.), 137.8 (Cquat.), 137.7 (+), 136.8 (Cquat.), 136.7 (Cquat.), 131.9 (+), 130.2 (+), 130.0 
(+), 129.4 (Cquat.), 128.9 (Cquat.), 128.3 (+), 127.9 (Cquat.), 127.6 (+), 127.3 (Cquat.), 124.9 
(+), 121.4 (+), 119.6 (+), 118.8 (+), 115.7 (+), 115.1 (+), 114.8 (Cquat.), 113.1 (+), 111.2 (+), 
102.0 (+), 77.2 (–), 71.9 (–), 70.7 (–), 70.7 (–), 70.6 (–), 70.6 (–), 70.5 (–), 70.5 (–), 69.7 (–), 
69.7 (–), 68.9 (–), 63.2 (–), 59.0 (+), 55.6 (–), 52.4 (+), 50.6 (–), 28.6 (–). HRMS (EI-MS) 
calcd. for C50H59N4O11 [M+H]+: 891.4175; found: 891.4178. IR (KBr) [cm-1]: ν = 2872, 1685, 
1516, 771. 
 
Drugs and chemicals used for analysis. 
A Milli-Q system (Millipore, Eschborn, Germany) was used for the purification of water in 
aqueous drug solutions. All chemicals used were of analytical grade, if not otherwise 
mentioned. Hoechst 33342 (Invitrogen, Karlsruhe, Germany) was dissolved in sterile water to 
produce a 0.8 mM working solution. Test compounds were dissolved in DMSO (Merck, 
Darmstadt, Germany) at a concentration of 10 mM. All stocks were stored at -20 °C. Topotecan 
(Sigma, Munich,Germany) was diluted in 70 % ethanol to a concentration of 0.1 mM and stored 
at 4 °C. PBS (phosphate buffered saline) was made of 8.0 g/L NaCl, 1.0 g/L Na2HPO4·2 H2O, 
0.20 g/L KCl, 0.20 g/L KH2PO4 and 0.15 g/L NaH2PO4·H2O. The pH-value was adjusted to 7.3 
- 7.4 by using a 1 M NaOH or HCl solution. Phosphate buffered saline with calcium and 
magnesium was made by dissolving 0.2 g/L KCl, 0.2 g/L KH2PO4, 8.0 g/L NaCl, 1.15 g/L 
Na2HPO4·2 H2O in water followed by adding 0.132 g/L of CaCl2·2 H2O and 0.10 g/L of 
MgCl2·6 H2O. Adjusting the pH-value to 7.3 was performed by the dropwise addition of a 1 M 
NaOH solution. Fumitremorgin C (FTC, Merck, Darmstadt, Germany) was also dissolved in 
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DMSO and diluted to a concentration of 1 mM. A solution of 4 % (m/m) of paraformaldeyde 
(Merck, Darmstadt, Germany) in PBS was made by stirring 1.5 g of paraformaldehyde per 50 g 
total solution while heating on a magnetic stirrer for approximately 30 min. Tariquidar (free 
base) was synthesized according to the literature with slight modifications.43 Elacridar was 
kindly provided by GlaxoSmith-Kline (Research Triangle Park, NC). Calcein-AM, purchased 
from Biotrend (Cologne, Germany), was dissolved in DMSO (Merck, Darmstadt, Germany) to 
achieve a final concentration of 100 µM. 
 
Cell lines and culture condition. 
Kb-V1 cells, an ABCB1 overexpressing subclone of KB cells (ATCC CCL-17), were 
maintained in Dulbecco’s modified Eagle’s medium (Sigma, Deisenhofen, Germany) 
supplemented with 10% FCS (Biochrom, Berlin, Germany) and 270 ng/mL vinblastine. 
MCF-7/Topo cells, an ABCG2 overexpressing subclone of MCF-7 breast cancer 
adenocarcinoma cells (ATTC HTB-22) were obtained by passaging the MCF-7 cells with 
increasing concentrations of topotecan in the culture medium to a maximum concentration of 
0.50 μM. Having reached the final concentration of topotecan, the cells were passaged after 
trypsinization using 0.05% trypsin/0.02% EDTA (PAA Laboratories, Pasching, Austria) every 
3-5 days. The treated cells showed sufficient quantities of the ABCG2 transporter after three 
passages in Eagle’s minimum essential medium (Sigma, Deisenhofen, Germany) containing L-
glutamine, 2.2 g/L NaHCO3 (Merck, Darmstadt, Germany), 0.11 g/L sodium pyruvate (Serva, 
Heidelberg, Germany), 10% fetal calf serum (Biochrom, Berlin, Germany), and topotecan at a 
concentration of 0.50 μM.  
 
Modulation of ABCB1 (P-gp) by the flow cytometric calcein-AM assay and ABCG2 by 
Hoechst 33342 assay. 
These assay were performed as described before.30 
 
Stability Investigations in Mouse Plasma. 
These assay were performed as described before.31 
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4. Summary 
 
Three different classes of selective ABCG2 modulator (BCRP, breast cancer resistance protein) 
derived from the lead structure tariquidar have been prepared in this thesis.  
 
In chapters one and two the solid phase synthesis approach was used to obtain new derivatives 
of the lead structure and two different methodologies were developed. A very simple, effective 
and straightforward method of synthesis using Wang resing as solid support was developed in 
chapter one. A small library of new tariquidar derivatives was obtained in very good yields, 
improving thus the solution synthesis previously reported. Some of the new compounds bearing 
a triethylenglycol chain at the tetrahydroisoquinoline core proved to be better soluble in 
comparison to the other analogs. The inhibitory activity against ABCB1 and ABCG2 
transporters were evaluated for all the compounds synthesized. During this work it was 
discovered that the methyl esters bearing both, a triethylene glycol ether and a quinoline-2-
carboxamido substituent, showed selectivity for ABCG2 over ABCB1 and are superior 
compared to the lead structure with respect to the maximal inhibitory effect. These compounds 
are among the most potent and selective ABCG2 modulators reported so far and might be useful 
to reverse the multidrug phenomenon in cancer cells. 
 
The second chapter, in which Wang resing was also used as solid support, describes a 
methodology more elaborated for the synthesis of new tariquidar-like derivatives. In order to 
obtain more stable compounds, the amide bond between the amino anthranilic ring and the 
tetrahydroisoquinolineethylphenylamine moiety was replaced and the two fragments of the 
molecule were linked by a C-C bond using Suzuki coupling. A set of eight compounds were 
obtained using the solid phase methodology, and four compounds were synthesized in solution. 
ABCB1 and ABCG2 inhibitory activity of the analogues were determined in the calcein-AM 
and the Hoechst 33342 microplate assay, respectively, and its result showed that all tested 
compounds are selective to ABCG2. The most potent compound in this series has an IC50 value 
of 591± 87 nM, and Imax 109% relative to FTC. Stability test, performed in mouse plasma, 
revealed that the enzymatic degradation of this derivative starts after 30 min, but after 24 h, 
around 60% of the compound still remains intact. The structural characteristics of the 
compounds here obtained together with their activity may contribute to design a new class of 
active and more stable tariquidar derivatives. 
 
The last chapter describes the synthesis of another class of ABCG2 inhibitors bearing an indole 
core unit. The modifications were done to overcome stability problems and to improve the 
solubility of the compounds. In the new compounds, that share structural characteristics of the 
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best inhibitors previously synthesized, an indole fragment was introduced as central core in 
order to increase the stability of the compound. The indole fragment was synthesized by a 
Sonogashira coupling followed by palladium catalyzed cyclization to the heterocycle. The 
mesyl group at the nitrogen of the indole was removed and the selectivity and inhibitory activity 
of the compounds for ABCG2 was determined. The most potent and promising compound has a 
lower IC50 value (59 ± 14 nM) and a very close maximal inhibitory effect (Imax 100%) compared 
to the most potent and selective ABCG2 reported so far Ko143, (117 ± 53 nM, Imax 103 ± 7%). 
The selectivity, the increased activity and the biological stability of some analogues render these 
compounds good candidates for in vivo studies in order to overcome drug resistance of tumor 
cells associated to ABCG2 transporters. 
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5. Zusammenfassung 
 
In dieser Arbeit wurden ausgehend von Tariquidar (Leitstruktur) drei verschiedene Klassen von 
ABCG2 selektiven Modulatoren (BCRP, breast cancer resistance protein) erhalten. 
 
Kapitel 1 und 2 beschreiben die Entwicklung von zwei verschiedenen Methoden an 
Festphasensystemen, welche anschließend zur Synthese von neuen Derivaten der Leitstruktur 
eingesetzt wurden. Kapitel 1 beschäftigt sich mit einer sehr einfachen, effektiven und 
geradlinigen Synthesestrategie  unter Verwendung von Wang Harz als Festphasenmaterial. Mit 
dieser Strategie wurde eine kleine Bibliothek von Tariquidar analogen Verbindungen in sehr 
guten Ausbeuten hergestellt , was eine Optimierung gegenüber der Synthese in Lösung darstellt. 
Die Einführung einer Triethylenglykol-Kette an der Tetrahydroisochinolin-Einheit einiger der 
neuen Verbindungen führte zu einer deutlichen Verbesserung der Löslichkeit im Vergleich zu 
den nicht substituierten Derivaten. Für alle dargestellten Verbindungen wurde die Aktivität für 
die Hemmung des ABCB1- und ABCG2-Transporter ermittelt. Während diesen 
Untersuchungen stellte sich heraus, dass die Verbindungen mit Methylester, welche sowohl eine 
Triethylenglykol-Kette als auch einen Chinolin-2-carboxamid Substituenten tragen, eine 
Selektivität für den ABCG2- gegenüber den ABCB1-Transporter aufweisen. Des Weiteren sind 
diese im Hinblick auf den maximalen inhibitorischen Effekt der Leitstruktur überlegen. Diese 
Verbindungen zählen zu den wirksamsten und selektivsten bekannten ABCG2- Modulatoren 
und könnten zur Behandlung von  multiwirkstoffresistenten Krebszellen beitragen.  
 
Kapitel 2 beschreibt eine sorgfältig ausgearbeitete Methode, die ebenfalls auf dem Einsatz von 
Wang Harz als Festphase basiert und zur Synthese von neuen Tariquidar-ähnlichen 
Verbindungen geeignet ist. Um die Stabilität der Verbindungen gegenüber enzymatischer 
Hydrolyse zu erhöhen, wurde die Amidbindung zwischen der dreifach substituierten 
aromatischen Teilstruktur und der Tetraisochinolin-ethylphenylamin Einheit mittels einer 
Suzuki Kupplung durch eine direkte C-C–Verknüpfung der beiden Fragmente ersetzt. Der 
Einsatz der festphasengestützten Synthese führte zu einer Serie von acht verschiedenen 
Verbindungen, sowie eine konventionelle Synthese in Lösung zu weiteren vier Derivaten. 
Anschließend wurden alle Verbindungen mit Hilfe eines Calcein-AM-Assays bzw. eines 
Hoechst 33342 Microplate Assays auf ihre Aktivität als ABCB1- und ABCG2-Inbihitor 
untersucht. Alle Derivate zeigten im Test eine Selektivität für den ABCG2-Transporter, wobei 
die wirksamste Verbindung dieser Serie einen IC50 Wert von 591± 87 nM und eine maximale 
Inhibition Imax von 109% relativ zu FTC erreichte. Weitergehende Studien zur Stabilität dieser 
Verbindung gegenüber enzymatischer Zersetzung in Mäuseplasma zeigten zum einen den 
Beginn des Abbaus nach bereits 30 min und zum anderen, dass nach 24 Std. noch 60% der 
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Verbindung intakt vorhanden waren. Die strukturellen Eigenschaften der Tariquidar-ähnlichen 
Verbindungen zusammen mit ihrer Aktivität könnten zum Design einer neuen Klasse von 
stabileren und aktiven Derivaten beitragen.  
 
Das letzte Kapitel der Arbeit handelt von der Synthese einer weiteren Klasse von ABCG2-
Inhibitoren, welche als Modifikation eine zentrale Indol-Einheit zur Verbesserung der 
Löslichkeit und zur Reduzierung des Stabilitätsproblems beinhalten. Diese neuen Verbindungen 
vereinen strukturelle Eigenschaften der aktivsten Inhibitoren aus Kapitel 1 und 2 mit einem 
zentralen Indol-Fragment zur Erhöhung der Stabilität gegenüber enzymatischer Zersetzung. Die 
Synthesestrategie zum Aufbau der Indol-Einheit besteht aus einer Sonogashira Kupplung 
gefolgt von einer weiteren Palladium katalysierten Reaktion zur Zyklisierung. Nach dem 
Entfernen der Mesyl-Schutzgruppe am Indol-Stickstoff wurde wiederum die Selektivität und 
Aktivität als Inhibitor für den ABCG2-Transporter bestimmt. Die vielversprechendste und 
wirksamste Verbindung aus dieser Serie besitzt einen besseren IC50 Wert von 59 ± 14 nM und 
einen nahezu maximalen inhibitorischen Effekt Imax von 100% im Vergleich zum bekannten, 
wirksamsten und selektivsten ABCG2-Inhibitor Ko143 (117 ± 53 nM, Imax 103 ± 7%). 
Die erhöhte Aktivität und Selektivität sowie die erhöhte biologische Stabilität von einigen 
Derivaten machen diese zu guten Kandidaten für in vivo Studien um das Problem von 
multiwirkstoffresistenten Tumorzellen, welche in Verbindung mit ABCG2-Transporter 
auftreten, zu überwinden. 
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6. Abbreviations 
 
 
ABC   ATP binding cassette 
ABCB1 ABC transporter B1, 
pgylocoprotein 170 
ABCG2 ABC transporter G2, 
breast cancer resistance 
protein 
ATP  Adenosine triphosphate 
BBB  Blood brain barrier 
BCRP Breast cancer resistance 
protein 
(Boc)2O   t-Butyloxycarbonyl 
Calcein-AM Calcein-
acetoxymethylester 
Calcd  Calculated 
CI  Chemical ionization 
DCC Dicyclohexylcarbo 
diimide 
DCM  Dichloromethane 
DEPT Distortionless 
enhancement by 
polarization transfer 
DIPEA  Diisopropylethylamine 
DMAP  Dimethylaminopyridine 
DME  1,2-Dimethoxyethan 
DMF  Dimethylformamide 
DMSO  Dimethylsulfoxide 
EDC N-(3-Dimethylamino 
propyl)-N′-ethylcarbo 
diimide 
Et2O Diethylether 
EMEM Eagels minimum 
essential medium 
eq  Equivalent 
EI-MS Electron-impact 
ionization mass 
spectrometry 
ESI Electronspray 
ionisation 
EtOAc  Ethyl acetate 
EtOH  Ethanol 
FCS  Fetal calf serum 
FTC  Fumitremorgin C 
FT  Fourier transformed 
GHS  Glutathione 
HBTU (2-(1H-Benzotriazole-
1-yl)-1,1,3,3-
tetramethyluronium 
hexafluorophosphate) 
HIV Human 
immunodeficiency 
virus 
HOAt (1-Hydroxy-7-
azabenzotriazole). 
HOBt  1-Hydroxy 
benzotriazole 
HPLC High pressure liquid 
chromatography 
HR-MS High resolution mass 
spectrometry 
5-HT  5-Hydroxytryptamin 
IARC International agency for 
research on cancer 
IC50 Half maximal 
inhibitory concentration 
Imax Maximal inhibitory 
effect 
IR  Infrared spectroscopy 
J   Coupling constant 
6. Abbreviations 
 
 
73 
MCF-7/Topo Topotecan resistant 
human breast cancer 
cells 
MDR  Multidrug resistance 
MRPs Multidrug resistance-
associated proteins 
Me  Methyl 
MeOH  Methanol 
MF  Molecular formula 
Mp  Melting point 
MS  Mass spectrometry 
MsCl  Mesyl chloride 
MW  Molecular weight 
NBF Nucleotide binding fold 
NMR Nuclear magnetic 
resonance 
PBS Phosphate buffered 
saline 
PE  Petrol ether (hexanes) 
PET Proton emission 
tomography 
P-gp  P-glycoprotein 
PhH  Benzene 
Rf  Retention factor 
RP  Reversed phase 
rt Room temperature 
SEM Standard error of the 
mean 
SPS Solis phase synthesis 
TBAF Tetrabutylammonium 
fluoride 
TBDMS-Cl tert-Butyldimethylsilyl 
chloride 
TES triethylsilane 
TFA  Trifluorous acetic acid 
THF  Tetrahydrofuran 
TLC Thin layer 
chromatography 
TMD Transmembrane 
domain 
TMSCHN2 trimethylsilyl 
diazomethane 
Topo  Topotecan 
tr   Retention time 
UV  Ultraviolett 
Vis  Visible 
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